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Abstract 
Sustaining proliferative signalling is one of the hallmarks of cancer. Cancer cells 
universally have high demands for nutrients to support their rapid proliferation. 
Studies presented in this thesis are focused on mTORC1 and MAPK/ERK signalling 
pathways, both of which promote cell growth and proliferation and are frequently 
found over-active in a wide range of cancer types, and their role in response to amino 
acid deprivation. mTORC1 activation requires GTP-bound Rheb and Rag GTPase-
mediated lysosomal translocation. TSC2 inhibits mTORC1 by deactivating Rheb and 
it also undergoes lysosomal translocation. GCN2, a kinase that senses amino acid 
deficiency, has been identified as a novel regulator of mTORC1 signalling 
potentially by promoting the lysosomal translocation of TSC2, which inhibits 
mTORC1 additionally by preventing RagA from associating with lysosomes. We 
demonstrate that Rheb not only activates the catalytic activity of mTORC1 but also 
lysosomal translocation of both mTORC1 and TSC2. Therefore, these data suggest 
an alternative model of mTORC1 inhibition by amino acid deprivation. In addition, 
we demonstrate that the MAPK/ERK cascade contributes to ferroptosis, an oxidative 
non-apoptotic cell death, in response to deprivation of the amino acid cystine, via 
downregulating GPX4 and upregulating NOX4, enzymes known to scavenge and 
produce lipid ROS respectively. Based on this, amino acid cystine has been 
identified as a synthetic lethal target in NSCLC cells expressing an activated EGFR 
mutant, and pharmacological depletion of intracellular cystine using an engineered 
cystine-degrading enzyme efficiently suppresses tumour growth in a NSCLC 
xenograft model. These data therefore provide an approach that can be potentially 
exploited for cancer therapeutics.  
 
 
 
 
 
 
 
Final word count: 42144  
3 
 
 
Acknowledgements 
First and foremost, I would like to express my sincere gratitude to my supervisor Dr 
Nikolina Vlatković for the continuous support of my PhD study, for her patience, 
motivation, and immense knowledge. It was a great honour to have her as my 
supervisor after my previous supervisor Dr Richard Lamb left the University in May 
2016. Her valuable guidance helped me in all the time of writing of this thesis. Her 
advice on both research as well as on my career have been priceless. I could not have 
imagined having a better supervisor for my PhD study. I would also like to thank my 
co-supervisor Prof Mark Boyd and my previous supervisor Dr Richard Lamb for 
their insightful comments and constructive suggestions, which were determinant for 
the accomplishment of the work presented in this thesis. I would specially like to 
thank Dr Ioannis Poursaitidis, my colleague and also my friend, for being a “big 
brother” to me both in the lab and in life, who had always encouraging words and 
was always ready to help me. I also want to thank Drs Carlos Rubbi, Shankar 
Varadarajan and Rebecca Lamond for their kind help and support with experiments.  
 
I gratefully acknowledge the financial support for my PhD study from the North 
West Cancer Research Committee and the Institute of Translational Medicine. 
 
A special thanks to my family, my parents and my sister for their unconditional 
support, encouragement and love, without which I would not have come this far. I 
would also like to thank my close friends for their unconditional friendship, support 
and patience throughout these years.  
 
 
 
  
4 
 
 
Declaration  
This thesis is a result of my own work performed during the course of studies in the 
Department of Molecular and Clinical Cancer Medicine, Institute of Translational 
Medicine, University of Liverpool, between November 2014 and July 2018. All 
work described was performed by me unless clearly indicated. The thesis was 
written wholly by me under the valued guidance of my supervisor Dr Nikolina 
Vlatković.  
5 
 
 
List of Contents 
Abstract ....................................................................................................................... 2 
Acknowledgements ..................................................................................................... 3 
Declaration .................................................................................................................. 4 
List of Contents .......................................................................................................... 5 
List of Figures and Tables ......................................................................................... 9 
List of Abbreviations ............................................................................................... 12 
List of Publications ................................................................................................... 18 
Chapter 1- Introduction .......................................................................................... 20 
1.1 Role of oncogenic signalling pathways in cancer development ....................... 20 
1.2 The PI3K/Akt signalling pathway .................................................................... 23 
1.2.1 RTKs are a group of transmembrane receptors ......................................... 24 
1.2.2 Aberrant activation of EGFR in cancer ..................................................... 25 
1.2.3 The small G protein RAS .......................................................................... 26 
1.2.4 Activation of the PI3K/Akt signalling pathway ........................................ 27 
1.3 The MAPK/ERK cascade ................................................................................. 29 
1.3.1 The serine/threonine kinase RAF .............................................................. 29 
1.3.2 MEK and ERK ........................................................................................... 29 
1.4 The mTOR signalling pathways ....................................................................... 31 
1.4.1 mTORC1 and mTORC2 possess multiple subunits .................................. 32 
1.4.2 Downstream of the mTOR signalling network .......................................... 35 
1.4.3 Upstream of mTORC1 signalling network ................................................ 39 
1.4.4 GCN2 senses amino acid deficiency and represses protein synthesis ....... 47 
1.4.5 MAP4K3 senses amino acid sufficiency and activates mTORC1 ............. 48 
1.5 Role of tumour suppressor p53 in cancer development ................................... 50 
1.6 Role of programmed cell death (PCD) in cancer development ........................ 53 
6 
 
 
1.6.1 Apoptosis ................................................................................................... 54 
1.6.2 Ferroptosis is an oxidative non-apoptotic form of cell death .................... 58 
1.7 Synthetic lethality is a promising approach for cancer therapeutics ................ 63 
1.8 Project strategies and aims ............................................................................... 64 
Chapter 2 - Materials and Methods ....................................................................... 68 
2.1 Materials ........................................................................................................... 68 
2.1.1 Chemicals................................................................................................... 68 
2.1.2 Antibodies .................................................................................................. 70 
2.1.3 Molecular cloning enzymes ....................................................................... 73 
2.1.4 Antibiotics .................................................................................................. 73 
2.1.5 Kinase inhibitors ........................................................................................ 73 
2.1.6 Small interfering RNA (siRNA) ................................................................ 74 
2.1.7 Primers ....................................................................................................... 74 
2.1.8 Plasmid constructs ..................................................................................... 74 
2.1.9 Cell lines .................................................................................................... 74 
2.1.10 Media ....................................................................................................... 75 
2.1.11 Solutions .................................................................................................. 76 
2.1.12 Buffers ..................................................................................................... 77 
2.1.13 Gel electrophoresis systems ..................................................................... 78 
2.2 Methods ............................................................................................................ 78 
2.2.1 Bacterial culture ......................................................................................... 78 
2.2.2 Molecular cloning ...................................................................................... 79 
2.2.3 Cell culture ................................................................................................. 80 
2.2.4 Media switch treatments ............................................................................ 80 
2.2.5 Transient vector transfection ..................................................................... 81 
2.2.6 Bradford assay ........................................................................................... 81 
2.2.7 Western blotting ......................................................................................... 82 
7 
 
 
2.2.8 Immunoprecipitation (IP) .......................................................................... 82 
2.2.9 S6K1 reporter assay ................................................................................... 83 
2.2.10. In vitro kinase assay ................................................................................ 83 
2.2.11 Immunofluorescence (IF) ........................................................................ 84 
2.2.12 Intracellular amino acid extraction .......................................................... 84 
2.2.13 Cell viability assay ................................................................................... 84 
2.2.14 Flow cytometry (FACS analysis) ............................................................ 85 
2.2.15 Statistical analysis .................................................................................... 85 
Chapter 3-Results ..................................................................................................... 87 
3.1 Mechanisms involved in amino acid regulation of mTORC1 .......................... 87 
3.1.1 GCN2 inhibits mTORC1 potentially by regulating TSC2 lysosomal 
translocation ........................................................................................................ 87 
3.1.2 RagA and Rheb promotes TSC2 lysosomal translocation ....................... 102 
3.1.3 TSC2 preferentially binds RagC .............................................................. 104 
3.1.4 Rheb does not associate with lysosomes ................................................. 105 
3.1.5 Rheb promotes lysosomal localization of mTOR and RagC ................... 108 
3.1.6 Rheb promotes the association of RagA and lysosomes ......................... 111 
3.2. MAP4K3 is an activator of mTORC1 ........................................................... 115 
3.2.1. PLD1 is a downstream effector of MAP4K3.......................................... 115 
3.2.2. mTORC1 activation and lysosomal translocation are independent of 
PLD1 ................................................................................................................. 118 
3.2.3 Characterization of cancer-associated MAP4K3 mutations .................... 122 
3.3 MAPK/ERK promotes ferroptosis in response to cystine deprivation ........... 126 
3.3.1 Cystine deprivation selectively kills EGFR delE746-A750 HME cells .. 127 
3.3.2 Cystine deprivation induces ferroptosis in EGFR delE746-A750 HME 
cells ................................................................................................................... 129 
8 
 
 
3.3.3 Active MAPK/ERK cascade promotes cystine deprivation-induced cell 
death .................................................................................................................. 130 
3.3.4 Active MAPK/ERK cascade promotes lipid ROS independently of 
glutathione ........................................................................................................ 134 
3.3.5 The MAPK/ERK cascade promotes lipid ROS by regulating GPX4 and 
NOX4 ................................................................................................................ 135 
3.3.6 Cystine deprivation inhibits the viability of three NSCLC cell lines. ..... 142 
3.3.7 Pharmacological depletion of intracellular cystine inhibits the growth of 
NCI-NHI1650 cells engrafted tumour .............................................................. 146 
3.4 P53 is activated by amino acid deprivation .................................................... 151 
Chapter 4-Discussion ............................................................................................. 158 
4.1 Mechanisms of mTORC1 inactivation following amino acid depletion ........ 159 
4.1.1 GCN2 is a novel inhibitor of mTORC1 ...................................................... 159 
4.1.2. Alternative model of mTORC1 regulation by TSC/Rheb axis .................. 160 
4.2. The MAPK/ERK cascade promotes cell death in response to cystine 
deprivation ............................................................................................................ 165 
Appendix - Supplementary Tables and Figures .................................................. 172 
Appendix 1. Sites of point mutations in human MAP4K3 sequence. .................. 172 
Appendix 2. Primers for MAP4K3 mutagenesis and sequencing ........................ 175 
Appendix 3. PCR conditions for mutagenesis of human MAP4K3 ..................... 177 
Appendix 4. Rheb promotes the co-localization of mTOR and RagC with 
lysosomes. ............................................................................................................ 178 
Appendix 5. Inhibition of the MAPK/ERK cascade by the specific inhibitors.... 180 
Appendix 6. Publication ....................................................................................... 181 
Reference................................................................................................................ 202 
  
9 
 
 
List of Figures and Tables  
Figure 1. Overview of the hallmarks of cancer. ......................................................... 21 
Figure 2. Crosstalk between PI3K/Akt, MAPK/ERK and mTORC1 pathways. ....... 23 
Figure 3. Schematic representation of RTK structure. ............................................... 24 
Figure 4. Regulation of GTPase by GEF and GAP. .................................................. 26 
Figure 5. Schematic representation of the PI3K/Akt pathway. .................................. 28 
Figure 6. Activation of the MAPK/ERK cascade. ..................................................... 31 
Figure 7. Linear schematic representation of mTOR structure. ................................. 32 
Figure 8. mTORC1 and mTORC2 subunits. .............................................................. 34 
Figure 9. Regulation of mTORC1 and mTORC2 by their subunits. ......................... 35 
Figure 10. The mTOR signalling network. ................................................................ 38 
Figure 11. TSC/Rheb regulates mTORC1 activity. ................................................... 41 
Figure 12. A currently proposed model of mTORC1 regulation by amino acids. ..... 46 
Figure 13. Proposed activators and inhibitors of mTORC1 in response to amino acids.
 .................................................................................................................................... 46 
Figure 14. GCN2 senses amino acid deficiency and inhibits protein synthesis......... 48 
Figure 15. Linear schematic representation of MAP4K3 structure. .......................... 49 
Figure 16. MAP4K3 is a putative tumour suppressor and promoter. ........................ 50 
Figure 17. Overview of p53 in cellular responses...................................................... 51 
Figure 18. Crosstalk between p53 and PI3K/Akt and mTORC1 pathways. .............. 52 
Figure 19. Main forms of cell death. .......................................................................... 53 
Figure 20. Structural and functional classification of the Bcl-2 proteins. ................. 55 
Figure 21. Extrinsic and intrinsic apoptotic pathways. .............................................. 57 
Figure 22. The GSH/GPX4 antioxidant system. ........................................................ 60 
Figure 23. Ferroptosis is an iron-dependent oxidative non-apoptotic cell death. ...... 62 
Figure 24. Schematic representation of synthetic lethality. ....................................... 64 
Figure 25. Image-based screening for regulators of TSC2 subcellular distribution. . 89 
Figure 26. GCN2 promotes TSC2 lysosomal translocation upon amino acid removal.
 .................................................................................................................................... 92 
Figure 27. GCN2 senses amino acid deficiency and inhibits mTORC1 activation. .. 94 
Figure 28. GCN2 activity is required for TSC2 translocation to lysosomes. ............ 98 
10 
 
 
Figure 29. GCN2 regulates TSC2 lysosomal translocation independently of eIF2α.
 .................................................................................................................................. 101 
Figure 30. GCN2 does not interact with TSC2. ....................................................... 102 
Figure 31. Rheb and RagA promote TSC2 translocation to lysosomes. .................. 104 
Figure 32. TSC2 preferentially interacts with RagC. ............................................... 105 
Figure 33. Rheb does not associate with lysosomes. ............................................... 107 
Figure 34. mTOR and RagC localize with lysosomes in a Rheb-dependent 
mechanism................................................................................................................ 111 
Figure 35. Interaction of RagA with LAMTOR1 requires Rheb. ............................ 112 
Figure 36. TSC2 promotes dissociation of RagA from lysosomes in response to 
amino acid deprivation. ............................................................................................ 114 
Figure 37. PLD1 is a potential substrate of MAP4K3. ............................................ 117 
Figure 38. MAP4K3 stimulates phosphorylation of PLD1-Thr147. ....................... 118 
Figure 39. Amino acids activate mTORC1 in a PLD1-independent mechanism. ... 119 
Figure 40. mTOR translocates to lysosomes in a PLD1-independent mechanism. . 121 
Figure 41. Linear schematic representation of MAP4K3 structure and mutations. . 122 
Figure 42. Analysis of mTORC1 activation by MAP4K3 mutants. ........................ 123 
Figure 43. In vitro kinase assay of Flag-purified MAP4K3. ................................... 125 
Figure 44. Investigation of MAP4K3 subcellular distribution................................. 126 
Figure 45. Cystine deprivation selectively kills EGFR delE746-A750 HME cells. 129 
Figure 46. Inhibitors of MAPK/ERK and PI3K/Akt pathways. .............................. 131 
Figure 47. MAPK/ERK promotes cell death in response to cystine deprivation. ... 133 
Figure 48. Analysis of the intracellular amino acids in EGFR delE746-A750 and WT 
HME cells. ............................................................................................................... 135 
Figure 49. Hypothesized mechanisms of lipid ROS regulation by MAPK/ERK. ... 136 
Figure 50. Analysis of GPX1 and GPX4 expression in HME cell lines. ................. 138 
Figure 51. MAPK/ERK cascade downregulates GPX4 expression. ........................ 139 
Figure 52. Inhibition of the MAPK/ERK cascade upregulates GPX4. .................... 140 
Figure 53. GPX2 is not expressed in WT or EGFR delE746-A750 HME cells. ..... 141 
Figure 54. MAPK/ERK cascade upregulates NOX4 expression. ............................ 142 
Figure 55. Cystine deprivation induces cell death in three NSCLC cell lines. ........ 144 
Figure 56. Analysis of GPX4 and NOX4 expression in a panel of NSCLC cell lines.
 .................................................................................................................................. 146 
11 
 
 
Figure 57. Cystine/cysteine-degrading enzyme AECase induces cell death in NCI-
NHI1650 NSCLC cells. ........................................................................................... 148 
Figure 58. Cystine/cysteine-degrading enzyme AECase inhibits the growth of NCI-
NHI1650 cells engrafted tumour. ............................................................................. 150 
Figure 59. P53 does not seem to inhibit mTORC1 activity in HCT116 cells. ......... 152 
Figure 60. Amino acid deprivation seems to activate p53. ...................................... 153 
Figure 61. Activation of p53 in response to amino acid deprivation. ...................... 154 
Figure 62. A time-course of p53 activation following amino acid deprivation or 
replenishment in HCT116 cells. ............................................................................... 155 
Figure 63. Inhibition of mTORC1 by rapamycin induced an increase in p53 overall 
levels and activity. .................................................................................................... 156 
Figure 64. A suggested model of mTORC1 regulation by TSC/Rheb in response to 
amino acid deprivation ............................................................................................. 165 
Figure 65. MAPK/ERK cascade promotes cell death in response to cystine 
deprivation................................................................................................................ 169 
Figure 66. Schematic representation of cystine/cysteine as a synthetic lethal target of 
EGFR delE746-A750 mutation. ............................................................................... 170 
 
Table 1. Morphological changes during different types of cell death........................ 53 
Table 2. Kinase inhibitors .......................................................................................... 73 
Table 3. NSCLC cell lines ......................................................................................... 75 
Table 4. Homemade ECL reagent 1 recipe ................................................................ 76 
Table 5. Homemade ECL reagent 2 recipe ................................................................ 76 
Table 6. Jośe buffer recipe ......................................................................................... 77 
Table 7. Transfection conditions for IP...................................................................... 83 
 
 
 
 
 
 
 
 
12 
 
 
List of Abbreviations 
AGC    protein kinase A/protein kinase G/protein kinase C  
AIF   apoptosis-inducing factor 
AML    acute myeloid leukaemia 
AMP    adenosine monophosphate  
AMPK   AMP-activated protein kinase  
Apaf1   apoptotic protease activating factor 1 
APS    ammonium persulfate  
Atg13   autophagy-related gene 13 
ASS1   argininosuccinate synthetase 1 
ATF4   activating transcription factor 4 
ATM    ataxia-telangiectasia mutated 
ATP   adenosine triphosphate 
BH domain  Bcl-2 homology domain   
BSA    albumin from bovine serum 
BSO    buthionine sulfoximine  
BRCA1  breast cancer 1 
BRCA2  breast cancer 2 
CAD    caspase-activated DNase  
CNH    citron homology  
COX2   cyclooxygenase-2 
CST   Cell Signaling Technology 
CRC   colorectal cancer 
DA   DFG motif to AFG 
delE746-A750   deletion of Leu-Arg-Glu at positions 747 to 749 
Deptor   DEP-domain-containing mTOR-interacting protein 
d.FBS    dialysed FBS  
DFO   deferoxamine  
DISC   death-inducing signalling complex 
DMEM  Dulbecco's modified Eagle's medium 
DMSO   dimethylsulfoxide 
DNA    deoxyribonucleic acid 
13 
 
 
dNTP    deoxynucleotide 
DPBS    Dulbecco’s PBS  
DTT   dithiothreitol 
DsRed   red fluorescent protein 
4E-BP1  eIF-4E-binding protein 1 
ECL    enhanced chemilumescent 
eEF2K   eukaryotic elongation factor 2 kinase 
EF3   Elongation factor 3  
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor 
eIF2   eukaryotic initiation factor 2 
EIF2AK4  eIF2 alpha kinase 4 gene  
eIF4B   eukaryotic translation initiation factor 4B 
eIF4E   eukaryotic initiation factor 4E 
Endo G  endonuclease G  
ER    endoplasmic reticulum 
ERK   extracellular-signal-regulated kinase 
FACS    fluorescence-activated cell sorting  
FADD   Fas-associating protein with death domain  
Fas   first apoptosis signal receptor 
FasL   Fas ligand  
FBS   fetal bovine serum  
FGF   fibroblast growth factor 
Fip200   focal adhesion kinase family-interacting protein of 200kDa 
FKBP    FK506-binding protein 
FRAP   FKBP-rapamycin-associated protein  
GAP   GTPase activating protein 
GATOR  GAP activity toward Rags complexes 
GCK    germinal-center kinase 
GCN2   general control nonderepressible 2  
GDP   guanosine diphosphate  
GEF   guanine nucleotide exchange factor  
GFP   green fluorescent protein 
14 
 
 
GLK    GCK)-like kinase 
β-GP   β-Glycerophosphate disodium salt hydrate 
G protein   guanine nucleotide-binding protein  
GPX   glutathione peroxidase 
Grb2   growth factor receptor-bound protein 2  
GSH    reduced glutathione 
GSSG   oxidized glutathione 
GST   glutathione S-transferase 
GTP   guanosine triphosphate  
HA   haemagglutinin 
HBXIP  C7orf59 and hepatitis B X-interacting protein  
HEK    human embryonic kidney 
HIF1α    hypoxia-inducible factor 1-alpha 
HisRS    histidyl-tRNA synthetases 
HME   human mammary epithelial  
HO•   hydroxyl radicals 
H2O2   hydrogen peroxide 
HPLC   high-performance liquid chromatography 
HRP    horseradish peroxidase 
HtrA2   high temperature requirement protein A2 
ICAD   inhibitor of CAD 
IF   immunofluorescence 
IP    Immunoprecipitation 
IRS1   insulin receptor substrate 1 
JACoP   Just Another Colocalisation Plugin  
JNK   c-Jun amino-terminal kinase 
LAMP2  lysosomal associated membrane protein 2 
LAMTOR  MAPK and mTOR activator 
LB   lysogeny broth  
LC-MS   liquid chromatography-mass spectrometry  
LDS    Lithium dodecyl sulfate  
LiCl    lithium chloride  
L-O•   lipid free radicals 
15 
 
 
LOOH   lipid peroxides  
MAPK   mitogen-activated protein kinase 
MAP4K3  Mitogen-activated protein kinase kinase kinase kinase 3 
MBP    myelin basic protein 
β-ME    β-Mercaptoethanol 
MEF    mouse embryonic fibroblasts  
MEM   minimum essential medium 
MDCK  Madin-Darby Canine Kidney  
MDM2  mouse double minute 2 homolog  
mLST8  mammalian lethal with Sec13 protein 8 
MP1   MAPK binding partner 1 
mSin1   mammalian stress-activated protein kinase interacting protein 
mTOR   mechanistic target of rapamycin 
mTORC1  mTOR complex 1 
mTORC2  mTOR complex 2 
MBP    myelin basic protein 
NaCl   sodium chloride 
NEB    New England BioLabs  
NF-kB   nuclear factor kappa-light-chain-enhancer of activated B cells  
NOX    NADPH oxidases 
NSCLC  non-small cell lung cancer 
O2   oxygen 
O2
•−   superoxide anions 
O.A.   okadaic acid potassium salt  
PA    phosphatidic acid  
PARP   poly(ADP-ribose) polymerase 
PBS   phosphate buffered saline  
PCD    programmed cell death 
PCR    polymerase chain reaction 
Pen strep  penicillin streptomycin 
PEST   proline, glutamic acid, serine, and threonine 
PDGF   platelet-derived growth factor 
PDI    protein disulfide isomerase 
16 
 
 
PDK1   3-phosphoinositide-dependent protein kinase-1 
PFA    paraformaldehyde 
PH domain  pleckstrin-homology domain 
PKB   protein kinase B 
PKC   protein kinase C 
PI3K   phosphatidylinositol-4,5-bisphosphate 3-kinase 
PIKK   PI3K-related kinase 
PIP2   phosphatidylinositol (4,5)-bisphosphate  
PIP3   phosphatidylinositol (3,4,5)-trisphosphate 
PLD1   phospholipase D 1 
PR core   proline-rich core  
PRAS40  proline-rich Akt substrate 40kDa 
Protor1/2  protein observed with Rictor-1 or 2 
PTEN   phosphatase and tensin homolog 
PUFA    polyunsaturated fatty acid 
PVDF   polyvinylidene difluoride 
Rag   Ras-related small GTPase  
Raptor   regulatory-associated protein of mTOR 
Rictor    rapamycin-insensitive companion of mTOR 
ROS   reactive oxygen species  
RSK   p90 ribosomal S6 kinase 
RTK   receptor tyrosine kinases 
SD   standard deviation  
SDS   sodium dodecyl sulfate 
SDS-PAGE   SDS-polyacrylamide gel electrophoresis  
SH2 domain   Src homology 2 domain  
siRNA   small interfering RNA  
Smac   second mitochondria-derived activator of caspase 
S6K1   p70S6 Kinase 1 
SOS   son of sevenless 
SREBP   sterol responsive element binding protein 
TBC1D7  Tre2-Bub2-CDC16 (TBC) 1 domain family member 7 
Tel2   telomere maintenance 2 
17 
 
 
TFR    transferrin receptor 
TKD   tyrosine kinase domain 
TNF    tumour necrosis factor  
TSC   tuberous sclerosis complex 
Tti1   Tel2-interacting protein 1 
Ulk1   unc-51-like kinase 1 
UV   ultraviolet 
v-ATPase  vacuolar H+-ATPase 
VEGF   vascular endothelial growth factor 
WB   western blotting  
  
18 
 
 
List of Publications 
 
*Poursaitidis, I., *Wang, X. (co-first author), Crighton, T., Labuschagne, C., Mason, 
D., Cramer, S.L., Triplett, K., Roy, R., Pardo, O.E., Seckl, M.J., Rowlinson, S.W., 
Stone, E., Lamb, R.F. (2017) “Oncogene-Selective Sensitivity to Synchronous Cell 
Death following Modulation of the Amino Acid Nutrient Cystine.” Cell Rep. 18(11): 
p. 2547-2556. 
 
*These authors contributed equally to this publication by generating figures and 
providing results about the inhibitor and siRNA treatment, viability assays, FACS 
analyses, immunoblotting experiments, intracellular metabolites extraction, NSCLC 
experiments and analysis of tumour tissue samples.   
 
  
19 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
                                           Introduction   
20 
 
 
Chapter 1- Introduction 
1.1 Role of oncogenic signalling pathways in cancer development  
The latest data (1 February 2018) from World Health Organization (WHO, 
http://www.who.int/en/news-room/fact-sheets/detail/cancer) suggest that cancer is 
the second leading cause of death worldwide (8.8 million deaths in 2015), with lung 
cancer being the most prevalent cause of cancer death (1.69 million deaths). Cancer 
is a group of diseases involving abnormal cell growth with the potential of 
metastasis. Many cancers form solid tumours (abnormal masses of tissue) with 
malignancy that can invade nearby and distant tissue, such as lung, liver and breast 
cancers, whilst hematologic cancers, such as leukaemia, generally do not form solid 
tumours and they affect the circulation and immune systems.  
 
Cancer cells differ from normal cells in a variety of ways that allow them to grow 
without restraint and become invasive (reviewed in reference [1]) (Figure 1). 
Sustaining proliferative signalling is one of the most fundamental traits of cancer 
cells. Production and release of growth-promoting signals, which are mainly 
conveyed by growth factors that stimulate cell growth and cell cycle progression, are 
under precise control in normal tissues to ensure a homeostasis of cell number and 
thus maintenance of normal tissue architecture and function. These signals, however, 
become deregulated in cancer cells and endow them with unrestrained growth and 
division. Growth factors, such as insulin and epidermal growth factor (EGF), bind to 
their corresponding transmembrane receptor tyrosine kinases (RTKs), which 
transduce the signals to the branched downstream intracellular signalling pathways 
that promote cell growth, division and survival [2, 3]. Cancer cells, by upregulating 
the activity of these signalling pathways, become capable of proliferating in a 
sustained manner. Such hyperactive growth-promoting signals in cancer cells can 
result from ligand-dependent and –independent mechanisms. The former includes 
enhanced production and release of growth factor ligands and the elevated 
expression of RTKs that render cancer cells hyper-responsive to the ligands. 
Alternatively, constitutive activation of RTKs and the downstream signalling 
components, due to structural alterations, may facilitate the ligand-independent 
proliferation and growth in cancer cells. For example, activation of EGF receptor 
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(EGFR) oncogene, either by overexpression or mutation, has been implicated in a 
number of cancers including a large proportion of non-small cell lung cancer 
(NSCLC) cases [4-6]. Likewise, activating mutations in RAS and RAF oncogenes 
are prevalent in about 30% and 8% of all human cancers respectively [7, 8]. Such 
alterations render the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt 
(also known as protein kinase B), mitogen-activated protein kinase 
(MAPK)/extracellular-signal-regulated kinase (ERK) and the mechanistic (formerly 
mammalian) target of rapamycin complex 1 (mTORC1) signalling pathways 
constitutively active in cancer cells and ultimately lead to sustained proliferation and 
growth (Figure 2), as described in Chapters 1.2, 1.3 and 1.4 respectively. 
 
Figure 1. Overview of the hallmarks of cancer.  
Ten hallmarks of cancer have been proposed, based on current knowledge of the 
mechanisms underlying cancer development, to characterize the distinctions between 
cancer and normal cells. Cancer cells have acquired the capabilities of persistent cell 
growth (increase of cell size) and proliferation (increase of cell number), and the 
involved hallmarks include the continuously active growth-promoting signalling 
pathways, replicative immortality, evasion of growth suppressors, repression of 
programmed cell death apoptosis and avoidance of immune destruction. In addition, 
cancer cells are capable of inducing angiogenesis and reprogramming energy and 
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nutrient metabolism, which fuels their rapid proliferation and growth. Moreover, 
genomic instability, resulting from alteration in genes involved in DNA repair 
process such as the tumour repressor BRCA1, is the most prominent enabling 
characteristic of the above acquired capabilities of cancer cells. Furthermore, cancer 
cells are able to invade and colonize other parts of the body, which is the process of 
metastasis. Cancer development is also accompanied by inflammation that 
contributes to the tumour-promoting microenvironment [1].  
 
Defects in the negative regulation of the aforementioned signalling pathways are also 
important in promoting cancer development [1]. There are many negative-feedback 
loops that normally operate to dampen the growth-promoting signalling and thereby 
maintain a homeostatic flux of signals that flow through the proliferative signalling 
circuit. For example, the tumour suppressor phosphatase and tensin homolog 
(PTEN), which is the most important negative regulator of PI3K/Akt signalling 
pathway, functions to degrade the PI3K product PIP3, thereby counteracting the 
signalling (Figure 5) [9]. Loss-of-function mutations of PTEN result in upregulation 
of the PI3K/Akt signalling and are associated with 15 human cancer types, such as 
head and neck, lung and prostate cancers [10]. Moreover, there are also negative-
feedback loops between the three proliferative signalling pathways. Growth factor-
induced activation of the PI3K/Akt and MAPK/ERK signalling pathways leads to 
activation of mTORC1 signalling, which in turn promotes inhibition of both 
PI3K/Akt and MAPK/ERK pathways [11] (Figure 2). In addition, active Akt 
phosphorylates and inhibits RAF, counteracting the MAPK/ERK signalling [12].  
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Figure 2. Crosstalk between PI3K/Akt, MAPK/ERK and mTORC1 pathways.  
Insulin receptor substrate 1 (IRS1) can be activated by insulin and insulin-like 
growth factor 1 (IGF1) receptors, which are RTKs that bind to growth factor ligands. 
Activated IRS1 stimulates the activation of RAS, leading to activation of the 
PI3K/Akt and MAPK/ERK signalling pathways. IRS1 also directly activates PI3K. 
Both Akt and ERK1/2 are capable of promoting activation of mTORC1 signalling 
pathway, which in turn causes repression of these two pathways by inhibiting IRS1. 
In addition, activated Akt counteracts the MAPK/ERK signalling by restraining the 
activity of RAF. Moreover, stress-activated p53 promotes the inhibition of both 
PI3K/Akt and mTORC1 signalling pathways. Regular arrows represent activation 
and blunt arrows inhibition, the same for all figures in this thesis where applicable. 
This figure is modified from reference [11]. 
 
1.2 The PI3K/Akt signalling pathway  
The PI3K/Akt signalling pathway regulates a number of essential cellular processes, 
including cell cycle progression, apoptosis and metabolism, and aberrant activation 
of this pathway is commonly found in solid tumours and hematologic malignancies, 
such as breast cancer, melanomas and leukaemia [13, 14]. The PI3K/Akt signalling 
pathway mediates the process of signal transduction from cell membrane to 
intracellular corresponding effectors, and involves growth receptor RTKs and the 
small G protein RAS amongst other components [14].  
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1.2.1 RTKs are a group of transmembrane receptors 
RTKs are a group of transmembrane glycoproteins that act to receive extracellular 
signals and mediate cellular responses [3]. RTKs include the insulin receptor and the 
receptors for many growth factors including EGF, fibroblast growth factor (FGF), 
platelet-derived growth factor (PDGF) and vascular endothelial growth factor 
(VEGF). Abnormal changes in the activity, cellular abundance and subcellular 
distribution of RTKs, resulting from genetic mutations or amplification and/or 
increase of the ligands, leads to aberrant activation of the corresponding signalling 
pathways, which is causally linked to numerous diseases and notably cancer [2, 3]. 
RTKs share the typical structure that is required to transduce extracellular signals 
into the intracellular mediators (Figure 3): the ligand binding domain within the 
extracellular region, a single transmembrane α helix and the intracellular regions that 
contain a tyrosine kinase domain (TKD), juxtamembrane regulatory and C-terminal 
regions [3].  
 
Figure 3. Schematic representation of RTK structure.  
A typical transmembrane receptor RTK consists of the extracellular region 
containing the ligand-binding site, the transmembrane α helix and the intracellular 
domains containing TKD and regulatory domains. Growth factor ligands bind to the 
extracellular region of RTKs, which stimulates the dimerization and subsequent 
trans-autophosphorylation of RTKs. This figure is based on description of RTK 
structure in reference [3]. The most common EGFR mutations delE746-A750 and 
L858R in the TKD, as indicated by red arrow, activate the kinase activity of EGFR 
via a ligand-independent mechanism [4, 15].  
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In the inactive state, RTKs are monomeric and auto-inhibited by the key tyrosine in 
the intracellular regions contacting the active site which is otherwise phosphorylated 
by TKD [3]. Such configuration renders RTKs inaccessible by adenosine 
triphosphate (ATP) and substrates. Generally, a bivalent ligand simultaneously binds 
to the extracellular fragments of two corresponding RTK molecules, which induces 
dimerization and trans-phosphorylation (phosphorylation by its partner) of the two 
tyrosine residues [3]. This event disrupts the auto-inhibitory contacts and enables 
auto-phosphorylation of the active site, which then acts as a docking site for 
assembly and activation of the specific downstream molecules in signalling 
pathways including PI3K/Akt and MAPK/ERK [3, 16].  
 
1.2.2 Aberrant activation of EGFR in cancer  
Overexpression of EGFR has been identified in a number of cancer types, including 
head and neck, breast, ovarian, cervical bladder, endometrial and colorectal cancers 
[17]. Particularly, EGFR is found overexpressed in 62% of NSCLC [4], which 
accounts for about 85% of all lung cancers [8]. Overexpression of EGFR causes 
increased local concentration of the receptor and leads to overwhelming activation of 
the downstream signalling pathways [16]. This type of abnormal activation mainly 
results from genetic amplification and is linked with poor prognosis [16]. In addition 
to being amplified, EGFR is often mutated in cancer. The most common mutations 
found are a deletion of three amino acid residues at positions 747 to 749 (Leu-Arg-
Glu, referred to as delE746-A750) and a missense mutation EGFR L858R, which 
account for 46% and 39% of EGFR mutations respectively [5, 6]. These two 
mutations render EGFR active independently of ligands by disrupting the auto-
inhibitory interactions (Figure 3) [4, 15].  
 
Small compounds called EGFR tyrosine kinase inhibitors have been developed to 
specifically inhibit EGFR activity by competitively binding the ATP-binding pocket 
within TKD, such as erlotinib and gefitinib (also known as tarceva and iressa 
respectively) [5]. 10% of NSCLC patients possess activating EGFR mutations and 
response to EGFR inhibitor therapy [18]. However, a majority of these patients 
acquire inhibitor resistance after 9-11 months of treatment [4, 19], and 
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approximately 50% of acquired resistance results from the second activating EGFR 
mutation T790M that affects the ATP-binding pocket of TKD [20].  
 
1.2.3 The small G protein RAS  
The RAS proteins, which consist of HRAS, NRAS, and KRAS isoforms [21], belong 
to the small guanine nucleotide-binding protein (G protein) family. These proteins 
are guanosine triphosphate (GTP)ases that are capable of hydrolyzing GTP and act 
as molecular switches in transmitting signals within the cell [22]. GTPases switch 
between two states, the active GTP-bound and the inactive guanosine diphosphate 
(GDP)-bound form, which are tightly regulated by their corresponding guanine 
nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs) [22]. 
GEFs bind to GDP-bound GTPases and catalyze dissociation of GDP, which allows 
GTP to bind the GTPases; whilst GAPs interact with GTP-bound GTPases and 
stimulate their GTPase activity that hydrolyzes GTP, returning them to the inactive 
GDP-bound state (Figure 4).  
 
Figure 4. Regulation of GTPase by GEF and GAP.  
GEF activates GTPase by inducing its dissociation from GDP and thus association 
with GTP, whereas GAP inactivates GTPase by stimulating its hydrolysis of GTP.  
 
RAS proteins are critical signal transducers of RTKs, and the isoforms KRAS and 
HRAS are the main activators of MAPK/ERK and PI3K/Akt signalling pathways 
respectively [23]. Activating mutations in RAS genes are present in 30% of all 
human cancers [7]. KRAS is the most frequently mutated isoform that accounts for 
85% of all RAS mutations [21], and KRAS mutations are found in 22% of all human 
cancers [24]. Notably, KRAS mutations are present in about 90% of pancreatic 
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cancers, 45% of colorectal cancer (CRC) and 35% of lung cancers [25]. The most 
frequent mutations occur on amino acid glycine at the position 12 (G12) with single 
base substitutions, such as G12D, G12V and G12C, all of which render KRAS 
defective in GAP-mediated GTP hydrolysis, leading to accumulation of GTP-bound 
KRAS and constitutively activated downstream signalling [21].  
 
1.2.4 Activation of the PI3K/Akt signalling pathway  
The family of PI3Ks can be divided into three classes based on the primary structure 
and substrate specificity, and Class IA PI3K is mainly associated with cancer 
(hereafter also called PI3K for brevity) [26]. PI3K is a heterodimer that consists of 
the p85 regulatory and the p110 catalytic subunits [14]. PI3KCA is the gene that 
encodes the p110 subunit and the mutation PI3KCA H1047R, where a histidine is 
substituted by an arginine at the position 1047, renders PI3K constitutively active, 
and is the most frequent PI3K mutation found in cancer [27]. The lipid kinase PI3K 
phosphorylates the phosphatidylinositol (4,5)-bisphosphate (PIP2) and converts it 
into phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which acts to recruit specific 
substrates containing the pleckstrin-homology (PH)-domain onto plasma membrane 
for activation [14]. Akt is a serine/threonine kinase and is the major downstream 
effector of PI3K [9]. PIP3 is maintained at low levels in un-stimulated cells by the 
action of phosphatases, mainly PTEN that hydrolyzes PIP3 to PIP2 [9], antagonizing 
the PI3K/Akt signalling. In addition, stress-activated p53 upregulates the cellular 
level of PTEN, resulting in inhibition of the PI3K/Akt signalling [28].  
 
The PI3K/Akt signalling pathway is activated by RTKs (Figure 5). Interaction of 
RTKs with ligands induces auto-phosphorylation of tyrosines that allows binding to 
specific substrates containing the Src homology 2 (SH2) domain, such as growth 
factor receptor-bound protein 2 (Grb2) [26]. Grb2 then interacts with and activates 
the protein son of sevenless (SOS), thereby recruiting it to the plasma membrane. 
SOS is a GEF for RAS that converts it into the active GTP-bound state. Membrane-
localized GTP-bound RAS interacts with the p85 regulatory subunit of PI3K, which 
stimulates the kinase activity of the p110 subunit [29]. Activated PI3K generates the 
lipid second messenger PIP3 that binds to Akt. Membrane-localized Akt is then 
activated through phosphorylation on Thr308 and Ser473 by membrane protein 3-
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phosphoinositide-dependent protein kinase-1 (PDK1) [30] and mTOR complex 2 
(mTORC2) respectively [31]. Activated Akt phosphorylates several components 
involved in regulation of cell survival and apoptosis [27]. Akt phosphorylates and 
inhibits pro-apoptotic proteins Bad and protease caspase-9 (see Chapter 1.6.1), 
thereby inhibiting apoptosis. In addition, Akt phosphorylates mouse double minute 2 
homolog (MDM2), which increases its affinity for p53 and ultimately leads to 
enhanced degradation of p53 (see Chapter 1.5) and thus repression of apoptosis [32]. 
Furthermore, Akt phosphorylates and inhibits the tumour suppressor TSC2, leading 
to mTORC1 activation that promotes protein synthesis [33].  
 
Figure 5. Schematic representation of the PI3K/Akt pathway.  
Upon activation by ligand-bound RTKs and GTP-bound RAS, PI3K phosphorylates 
PIP2 into PIP3, which binds to and recruits Akt onto cell membrane, allowing for its 
activation by membrane protein PDK1 and mTORC2. Activated Akt in turn 
phosphorylates multiple substrates including the p53 binding partner MDM2 and the 
mTORC1 inhibitor TSC2, leading to cell cycle progression, repression of apoptosis, 
and activation of the mTORC1 signalling. PIP3 is dephosphorylated by PTEN, 
thereby antagonizing the PI3K/Akt signalling. P53 binds to PTEN and stimulates its 
transcription, resulting in inhibition of the PI3K/Akt signalling. RTKs and RAS are 
also activators of the MAPK/ERK signalling pathway by stimulating activation of 
RAF. Notably, activated Akt also phosphorylates and inhibits RAF, counteracting 
the MAPK/ERK signalling. This figure is modified from reference [14].  
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1.3 The MAPK/ERK cascade 
MAPKs are a group of serine/threonine kinases involved in transduction of signals 
from the cell surface to the intracellular effectors (reviewed in reference [34]). They 
are critical in regulating various cellular processes, such as differentiation, cell cycle 
progression, migration, angiogenesis and apoptosis. MAPKs comprise three families: 
ERK, p38 isoforms and c-Jun amino-terminal kinases (JNKs). The RAS-RAF-
MEK1/2-ERK1/2 pathway, also termed MAPK/ERK pathway, is central in 
controlling cell proliferation and survival. Overexpression and mutations of the 
members within this pathway, particularly RAS and RAF, are one of the most 
common sources for cancer transformation and progression [35, 36].  
 
1.3.1 The serine/threonine kinase RAF  
RAF proteins, ARAF, BRAF, CRAF (also called RAF-1), are serine/threonine 
kinases and core downstream effectors of RAS [35]. Membrane-localized GTP-
bound RAS interacts with RAF and stimulates its activation. Once activated, RAF 
binds to and phosphorylates MEK1 and MEK2, which in turn activate and 
phosphorylate ERK1 and ERK2. Activated ERKs regulate a wide range of substrates 
and ultimately promote cell proliferation and survival [35] (Figure 6). Of the three 
RAF isoforms, BRAF is the main activator of the MAPK/ERK signalling pathway 
[37], and is the most frequently mutated RAF isoform in cancer [35]. BRAF 
mutations have been found in 8% of all human cancers [8]. Particularly, the mutant 
BRAF V600E, where a valine is substituted by a glutamic acid at position 600, 
renders BRAF constitutively active and constitutes 90% of all BRAF mutations [38]. 
This mutation has been found in 70-80% of melanoma [35], as well as 1-2% of 
NSCLC [8].  
 
1.3.2 MEK and ERK 
MEK isoforms, MEK1 and MEK2 (referred to as MEK1/2), are tyrosine and 
serine/threonine dual-specificity kinases that are capable of phosphorylating tyrosine, 
serine and threonine residues. They are predominantly activated by BRAF 
phosphorylating on Ser218/222 of MEK1 and Ser222/226 of MEK2 [39]. Activated 
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MEK1/2 in turn specifically activate ERK1 and ERK2 by phosphorylating 
Thr202/Tyr204 of ERK1 and Thr185/Tyr187 of ERK2 [34, 40].  
 
ERK1 and ERK2 (referred to as ERK1/2) are two isoforms with 84% amino acid 
sequence identity [40]. The two isoforms are activated in parallel and share many 
biological functions. ERK1/2 are ubiquitously expressed serine/threonine kinases 
and have a variety of substrates comprising cytoplasmic regulators and nuclear 
transcription factors (Figure 6). Once activated, a large portion of ERK1/2 undergo 
nuclear translocation, interact with and activate several transcription factors 
including c-myc, which promote expression of proteins involved in regulating cell 
proliferation and differentiation [34, 41]. Some of ERK1/2 are localized in the 
cytoplasm and phosphorylate several cytosolic regulators, such as TSC2 and p90 
ribosomal S6 kinase (RSK). ERK1/2 phosphorylates the mTORC1 inhibitor TSC2 
on Ser664, which leads to inhibition of TSC2 and thus activation of the mTORC1 
signalling as described in Chapter 1.4 [42]. Phosphorylation of RSK on Thr359 and 
Ser363 by ERK1/2 activates RSK, which on one hand stimulates cell cycle 
progression through phosphorylation of transcriptional regulators; on the other hand, 
phosphorylates and inhibits SOS, resulting in reduced concentration of GTP-bound 
RAS and thus antagonizing the MAPK/ERK signalling [43]. In addition, activated 
RSK phosphorylates and inhibits TSC2, leading to activation of mTORC1 signalling 
pathway [44].  
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Figure 6. Activation of the MAPK/ERK cascade. 
GTP-bound RAS stimulates the activation of RAF, which binds to and 
phosphorylates MEK1/2. Activated MEK1/2 interact with and catalyze dual 
phosphorylation of ERK1/2. Upon activation, a large portion of ERK1/2 accumulate 
to nucleus and activate several transcription factors, leading to cell proliferation and 
differentiation. Some ERK1/2 phosphorylate cytoplasmic regulators including RSK 
and TSC2, promoting cell cycle progression and protein synthesis respectively. In 
addition, RSK phosphorylates and inhibits the RAS activator SOS, which performs a 
negative feedback regulation of the MAPK/ERK signalling. This figure is adapted 
from reference [14]. 
  
1.4 The mTOR signalling pathways 
mTOR, also named FK506-binding proteins (FKBP)-rapamycin-associated protein 
(FRAP) [45], belongs to the serine/threonine kinase family termed PI3K-related 
kinase (PIKK) with sequence homology to PI3K (reviewed in reference [46]). 
mTOR has a central role in regulating cell growth and proliferation by acting as the 
catalytic subunit of two complexes, termed mTORC1 and mTORC2. These two 
complexes are composed of distinct subunits (Figures 8 and 9) and have distinct 
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cellular functions via different signalling pathways (Figure 10). The mTOR 
signalling pathways are frequently found over-active in many cancer types due to 
mutations in Akt and TSC2, which are upstream regulators of the mTOR kinase [10, 
47] (Figure 10).  
 
1.4.1 mTORC1 and mTORC2 possess multiple subunits  
 
1.4.1.1 mTOR structure  
mTOR is a large protein kinase with a molecular weight of 289kDa. It is constituted 
of multiple domains: the amino-terminal HEAT (Huntington, Elongation factor 3 
(EF3), A subunit of protein phosphatase-2A, and TOR) repeats, a central FAT 
(FRAP, ATM, TRAP, which are PIKK members) domain, the FRB (FKBP12-
rapamycin binding) region, the carboxyl-terminal catalytic and FAT (FATC) 
domains (reviewed in [48]), as shown in Figure 7. Rapamycin is a small compound 
with antifungal, immunosuppressive and antitumor properties, and it inhibits mTOR 
signalling through forming complexes with a group of immunophilin molecules 
termed FKBP12 (molecular weight of 12kDa).   
 
Figure 7. Linear schematic representation of mTOR structure.  
mTOR is a multi-domain protein that consists of the multiple (at least 20) HEAT 
repeats, a central FAT domain, FRB that binds to the rapamycin-FKBP12 complex, a 
kinase domain which shares sequence identity to that of PI3K and a second FAT 
domain at its carboxyl terminus (FATC). This figure is adapted from reference [48]. 
 
 
1.4.1.2 mTORC1 and mTORC2 subunits  
Common subunits  
In addition to mTOR, mTORC1 and mTORC2 contain multiple subunits that 
regulate its kinase activity and substrate specificity (Figures 7 and 8). They share 
three additional subunits: mLST8 (the positive regulator mammalian lethal with 
Sec13 protein 8) that binds to the kinase domain of mTOR [49], Deptor (DEP-
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domain-containing mTOR-interacting protein) that interacts with the central FAT 
region and negatively regulates the activity of both complexes [50], and the Tti1  
(telomere maintenance 2 (Tel2)-interacting protein 1)-Tel2 complex that associates 
with the HEAT repeats domain and stabilizes complex assembly [51].  
 
Distinct subunits of mTORC1 
In addition to the common subunits, mTORC1 also contains Raptor (the regulatory-
associated protein of mTOR) that binds the HEAT repeats region of mTOR [52-54], 
and PRAS40 (the proline-rich Akt substrate 40kDa) that interacts with Raptor [55-
57] (Figures 8 and 9). Activation of mTORC1 signalling requires that mTOR is 
catalytically active and that mTOR interacts with the downstream substrates, which 
together allow the substrates to be phosphorylated. Raptor is the defining subunit for 
mTORC1 due to its role to interact with downstream mTORC1-specific substrates 
[52, 53]. In addition, Raptor is critical for lysosomal localization of mTORC1 as 
described in Chapter 1.4.3. The association of Raptor with substrates, however, is 
disrupted by PRAS40 that competitively binds to Raptor [57]. Interaction of 
PRAS40 with Raptor dislocates the substrates away from mTOR and thus 
deactivates the mTORC1 signalling. Likewise, the mTOR inhibitor rapamycin 
inhibits mTORC1 activity by acting on Raptor [58]. The rapamycin-FKBP12 
complex interacts with the FRB domain of mTOR (Figure 8) and interrupts its 
association with Raptor, rendering mTOR unable to phosphorylate substrates even 
when it is kinase-active.  
 
Distinct subunits of mTORC2 
mTORC2 possesses three additional subunits (Figures 8 and 9), Rictor (the 
rapamycin-insensitive companion of mTOR) [31, 59], mSin1 (mammalian stress-
activated protein kinase interacting protein) [60, 61] and Protor1/2 (protein observed 
with Rictor-1 or 2) [62]. Similar to Raptor and PRAS40 in mTORC1, Rictor 
interacts with the HEAT repeats of mTOR and is the characteristic component for 
mTORC2; both mSin1 and Protor1/2 interact with Rictor. mTORC2-specific Rictor 
has similar function as mTORC1-specific Raptor that regulates complex assembly 
and acts as a scaffolding partner to recruit mTORC2-specific substrates. mSin1 
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seems to stabilize the assembly of mTORC2 and the role of Protor1/2 remains 
unknown.  
 
 
Figure 8. mTORC1 and mTORC2 subunits.  
In addition to the kinase mTOR itself, three subunits are common to mTOR 
complexes 1 and 2: the complex of Tti1 and Tel2, Deptor and mLST8, and they 
respectively bind the HEAT repeats, central FAT and kinase domains of mTOR. 
mTORC1 additionally comprises Raptor and PRAS40 while mTORC2 additionally 
possesses Rictor, mSin1 and Protor1/2. Raptor and Rictor both interact with the 
HEAT repeats of mTOR. PRAS40 interacts with Raptor whilst mSin1 and Protor1/2 
bind to Rictor. The mTOR inhibitor rapamycin forms a complex with FKBP12, 
which binds to the FRB domain of mTOR, leading to dissociation of Raptor from 
mTOR and thus inhibition of mTORC1 signalling. This figure is adapted from 
reference [48]. 
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Figure 9. Regulation of mTORC1 and mTORC2 by their subunits.  
The common subunits, Deptor and mLST8, are respectively negative and positive 
regulators of mTOR catalytic activity, whilst the Ttil-Tel2 complex regulates the 
complex assembly. Raptor and Rictor regulate substrate specificity and thus are 
respectively the characteristic components of mTORC1 and mTORC2. Raptor also 
regulates mTORC1 subcellular localization by binding to lysosomal proteins. The 
inhibitory subunit of mTORC1, PRAS40, competes with substrates to bind Raptor, 
which shifts them away from mTOR and thus deactivates the mTORC1 signalling. 
mSin1 enhances complex assembly and the role of Protor1/2 remains unknown. This 
figure is modified from reference [63]. 
 
1.4.2 Downstream of the mTOR signalling network 
Although mTORC1 and mTORC2 share the mTOR kinase and other three subunits, 
they exhibit distinct features in terms of sensitivity to rapamycin inhibition [64] and 
cellular functions [65]. Rapamycin treatment acutely diminishes mTORC1 activity, 
whereas inhibition of mTORC2 by rapamycin requires prolonged treatment [64], 
likely due to the disruption of mTORC2 assembly by rapamycin-bound mTOR [66]. 
mTORC1 and mTORC2 phosphorylate distinct substrates and therefore regulate 
different cellular processes (Figure 10). 
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1.4.2.1 mTORC1 promotes synthesis of proteins, lipids and nucleotides 
mTORC1 simultaneously integrates multiple upstream signals, such as growth 
factors and nutrients, to regulate the synthesis of essential macromolecules including 
proteins, nucleotides and lipids, as well as to regulate autophagy, contributing to 
control of cell growth and proliferation [67] (Figure 10). Aberrant activation of 
mTORC1 signalling has been implicated in various diseases, such as cancer, type II 
diabetes and neurodegenerative diseases [47, 67].  
 
Protein synthesis  
When cells are exposed to growth-promoting stimuli, such as sufficient nutrients, 
mTORC1 is activated and stimulates the anabolic processes by acting on two critical 
translational regulators, ribosomal protein p70S6 Kinase 1 (S6K1) and eukaryotic 
initiation factor-4E (eIF-4E)-binding protein 1 (4E-BP1) (reviewed in reference [46]) 
(Figure 10). mTORC1 directly phosphorylates S6K1 on residue Thr389, which 
allows for its subsequent phosphorylation and activation by PDK1. Activated S6K1 
phosphorylates and activates an array of substrates involved in mRNA translation 
initiation and elongation [68], such as ribosomal protein S6, eukaryotic elongation 
factor 2 kinase (eEF2K) and the eukaryotic translation initiation factor 4B (eIF4B) 
[68]. 4E-BP1 interacts with eIF-4E and prevents the latter from binding to the cap (a 
modified guanosine at the 5` end) structure of mRNA that is required for translation 
initiation. Phosphorylation of 4E-BP1 on residues Thr37/46/70 and Ser65 by 
mTORC1 disrupts its association with eIF-4E [69], relieving the inhibitory effect 
and thus upregulating mRNA translation.  
 
Lipid and nucleotide synthesis, ribosome biogenesis and glucose metabolism  
In addition to promoting protein synthesis, activated mTORC1 also upregulates the 
synthesis of lipids and nucleotides that are required for new membrane formation 
and DNA replication respectively [46]. mTORC1 and its key effector S6K1 promote 
lipogenesis through positively regulating the transcription factor sterol responsive 
element binding protein (SREBP), which upregulates the synthesis of enzymes 
involved in cholesterol and fatty acid biosynthesis [70, 71]. Moreover, mTORC1 
stimulates the synthesis of purine and pyrimidine respectively by upregulating the 
activating transcription factor 4 (ATF4)-dependent expression of MTHFD2, a 
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metabolic enzyme involved in the mitochondrial tetrahydrofolate cycle that provides 
one-carbon units for purine synthesis [72]; and through S6K1 that phosphorylates 
caspase-activated DNase (CAD), a key enzyme for pyrimidine synthesis [73]. 
Importantly, mTORC1 also promotes ribosome biogenesis required for protein 
synthesis, via regulating ribosomal RNA transcription and synthesis of ribosomal 
proteins and other components required for ribosome assembly [74]. Furthermore, 
mTORC1 facilitates anabolic processes by promoting glycolysis, an oxygen-
independent glucose metabolic process that provides intermediates for the synthesis 
of essential macromolecules [71]. mTORC1 stimulates the transcription of hypoxia-
inducible factor 1-alpha (HIF1α), which upregulates the glucose transporters and 
increases the expression of glycolytic enzymes.  
 
1.4.2.2 mTORC1 represses the catabolic process autophagy 
Autophagy is the catabolic process in which excessive or damaged organelles are 
degraded in lysosomes and the resulting products are reused for energy generation, 
protein synthesis, so that cell can survive nutrient scarcity [75]. One of the critical 
functions of mTORC1 is to suppress autophagy [67]. In the presence of amino acids, 
mTORC1 is activated and it phosphorylates two essential autophagy factors, 
autophagy-related gene 13 (Atg13) and unc-51-like kinase 1 (Ulk1), resulting in 
repression of their interaction with the third autophagy factor, focal adhesion kinase 
family-interacting protein of 200kDa (Fip200) [76]. Upon amino acid withdrawal, 
mTORC1 is inhibited, releasing Ulk1 and Atg13 to form a complex with Fip200 that 
is required for formation of autophagosome and initiation of autophagy [76-78]. 
Another mechanism underlying regulation of autophagy by mTORC1 involves the 
energy sensor adenosine monophosphate (AMP)-activated protein kinase (AMPK) 
[79]. Glucose deficiency activates AMPK, which directly phosphorylates and 
activates Ulk1 on Ser317/777 [79]. Activated Ulk1 phosphorylates downstream 
substrates and promotes autophagy induction, conversely nutrient-activated 
mTORC1 directly phosphorylates Ulk1 on Ser757, which disrupts its interaction 
with AMPK and thus prevents autophagy initiation [79]. 
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1.4.2.3 mTORC2 indirectly affect mTORC1 through Akt 
In contrast to mTORC1, the role of mTORC2 is not so well described in the 
literature. mTORC2 appears to regulate cell growth and cytoskeleton by 
phosphorylating and activating a series of AGC (protein kinase A/protein kinase 
G/protein kinase C) kinases, such as Akt [31], SGK1 (serum- and glucocorticoid-
induced protein kinase 1) [80] and PKC (protein kinase C) [49] (Figure 10). As 
mentioned in Chapter 1.2.4, Akt plays a critical role in regulating a variety of 
cellular processes, including metabolism, migration and proliferation [81]. 
Phosphorylation of residues Ser473 and Thr308 by mTORC2 and PDK1 respectively 
is required for Akt activation [31]. Akt further activates the mTORC1 signalling by 
acting on the mTORC1 inhibitor TSC2 [82, 83], connecting mTORC2 to mTORC1. 
mTORC2 also regulates sodium transport and cytoskeleton by phosphorylating 
SGK1 on Ser422 [80] and PKCα subunit on Ser657 respectively [49]. 
 
Figure 10. The mTOR signalling network. 
mTORC1 is activated by growth-promoting signals including growth factors and 
amino acid nutrients. Upon activation, mTORC1 phosphorylates S6K1 on Thr389, 
which stimulates S6K1 activation. Activated S6K1 promotes synthesis of proteins, 
lipids and nucleotides. mTORC1 also phosphorylates 4EBP1 on Thr37/46/70 and 
Ser65, leading to upregulation of protein synthesis. In addition, mTORC1 suppresses 
autophagy by phosphorylating and inactivating autophagy factor Ulk1. Instead of 
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integrating multiple signal inputs, mTORC2 solely senses and is activated by growth 
factors. Activated mTORC2 phosphorylates and activates Akt on Ser473. Akt is also 
activated indirectly by PI3K in response to growth factors. Activated Akt indirectly 
activates mTORC1, connecting mTORC2 to mTORC1. mTORC2 also contributes to 
the regulation of cytoskeleton and membrane sodium channels through PKC and 
SGK1 respectively. This figure is based on description of mTOR signalling in 
reference [46]. 
 
1.4.3 Upstream of mTORC1 signalling network 
 
1.4.3.1 The TSC/Rheb axis is a master regulator of mTORC1 signalling 
Since mTORC1 senses various stimuli, the mTORC1 signalling components are 
rather complex and are strictly regulated to ensure that cell growth only occurs when 
the cellular environment is favourable. The most critical regulator of this signalling 
pathway is the TSC/Rheb (Ras homolog enriched in brain) axis. TSC a trimeric 
tumour suppressor complex that consists of TSC1 (also known as hamartin), TSC2 
(also known as tuberin) and TBC1D7 (Tre2-Bub2-CDC16 (TBC) 1 domain family 
member 7) [84, 85]. Mutations of the tumour suppressors TSC1 and TSC2 
predispose patients to tuberous sclerosis, a genetic disorder with benign tumours in 
multiple organs [86]. TSC2 contains a C-terminal GAP-like domain and functions as 
a GAP for the small Ras-related GTPase Rheb, a critical activator of mTORC1 [84]. 
Association of TSC2 with TSC1 stabilizes and prevents TSC2 from degradation and 
ubiquitination, and TBC1D7 stabilizes the association of TSC2 with TSC1 [85, 87]. 
 
Rheb predominantly binds GTP and has low GTPase activity [87]. Although Rheb 
interacts with the two subunits of mTORC1, mTOR and mLST8, regardless of its 
GTP-bound state [88], only GTP-bound Rheb is capable of activating the catalytic 
activity of mTOR and thus the mTORC1 signalling [88]. Notably, activation of 
mTORC1 by GTP-bound Rheb seems to be required for all upstream signal inputs, 
though the mechanism underlying this event remains elusive [46]. Under conditions 
of low energy or nutrients, TSC2 directly inactivates Rheb by stimulating its GTP 
hydrolysis, switching off the mTORC1 signalling [84, 87]. Therefore, the TSC/Rheb 
axis acts as a master switch that integrates all of the upstream signal inputs toward 
mTORC1.  
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Like many other kinases including mTOR and S6K1, the activity of TSC2 is either 
positively or negatively regulated by posttranslational modifications. For example, 
growth factor-activated MAPK/ERK and PI3K/Akt signalling pathways inhibit 
TSC2 by phosphorylation on residues Ser939/664/1798 and Thr1462 [42, 44, 83], 
conversely cellular stress such as energy scarcity stimulates AMPK, which activates 
TSC2 via phosphorylating Thr1227 and Ser1345 residues [89].  
 
1.4.3.2 mTORC1 responds to growth factors  
Activation of mTORC1 in response to growth factors primarily involves the 
PI3K/Akt and MAPK/ERK signalling pathways, which act both upstream and 
downstream of mTORC1 (Figure 11). Growth factors stimulate these pathways, 
leading to activation of Akt [33, 81-83], ERK1/2 [42] and RSK [44], which 
phosphorylate TSC2 on Ser939/Thr1462, Ser664 and Ser1798 respectively. 
Phosphorylation of these resides disrupts the association of TSC2 and TSC1, which 
destabilizes TSC2 and leads to activation of Rheb and thus mTORC1 [84, 88]. In 
addition, phosphorylation of TSC2 by Akt promotes the dissociation of TSC2 from 
lysosomal surface [90], thereby preventing GTP hydrolysis of Rheb, as described in 
Chapter 1.4.3.4. PI3K/Akt and MAPK/ERK also promote mTORC1 activation 
independently of TSC2, through acting on the distinct subunits of mTORC1. For 
example, Akt phosphorylates PRAS40 on Thr246, which dissociates PRAS40 from 
Raptor and thus relieves its inhibitory effect on mTORC1 [55]. RSK phosphorylates 
Raptor on residues Ser719/ 721/722, leading to elevated mTORC1 activity [91]. 
Moreover, the mTORC1 effector S6K1 in turn directly phosphorylates and inhibits 
IRS1, an upstream activator of MAPK/ERK cascade and PI3K/Akt [92] (Figure 11), 
although it is unclear whether S6K1 inhibits other RTK substrates. Through S6K1, 
mTORC1 stimulates a negative feedback regulation of both MAPK/ERK and 
PI3K/Akt signalling pathways. This negative feedback loop possibly explains why 
patients with tuberous sclerosis do not develop malignant tumours. It also has 
significant implication in cancers that are resistant to mTOR inhibitors [48], in that 
suppression of mTORC1 activity results in adaptive activation of MAPK/ERK and 
PI3K/Akt signalling pathways that contribute to proliferation of cancer cells.  
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Figure 11. TSC/Rheb regulates mTORC1 activity.  
In the presence of growth factors, the MAPK/ERK cascade and PI3K/Akt are 
activated by RTK and the corresponding substrates. Activated ERK1/2, RSK and 
Akt phosphorylate TSC2 on multiple sites and inhibit its GAP activity toward Rheb. 
GTP-bound Rheb then binds to and activates mTORC1, which further stimulates 
S6K1 activation. S6K1 in turn phosphorylates and inhibits the insulin receptor 
substrate 1 (IRS1), resulting in repression of the MAPK/ERK, PI3K/Akt and 
mTORC1 signalling pathways. This figure is based on description of mTORC1 
signalling in reference [92]. 
 
1.4.3.3 mTORC1 responds to energy, oxygen and DNA damage  
AMPK is the major regulator of mTORC1 signalling in response to energy stress. 
Reduction in energy or oxygen levels decreases the ATP/AMP ratio, which activates 
AMPK [79]. Activated AMPK represses mTORC1 activity indirectly through 
phosphorylation and activation of TSC2 and directly through phosphorylation of the 
defining mTORC1 subunit Raptor [89, 93]. AMPK phosphorylates TSC2 on 
Thr1227 and Ser1345, which stabilizes TSC2 [89] and results in inhibition of  
mTORC1 [84, 88]. Phosphorylation of Raptor on Ser722/792 by AMPK 
disassociates it from mTOR [93] and thereby destabilizes the mTORC1 assembly 
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[52, 53]. In addition, AMPK and TSC2 are both upregulated by p53 in response to 
DNA-damaging stress, resulting in mTORC1 inhibition [94].  
 
1.4.3.4 mTORC1 responds to amino acid availability 
Amino acids seem to be the indispensable stimulus for mTORC1 activation [46], 
since, for example, growth factors fail to fully stimulate mTORC1 activity when 
amino acids are removed. mTORC1 activation requires both lysosomal translocation 
and GTP-bound Rheb [88, 95]. The first process is controlled by amino acid 
availability [95] and the second by already described TSC2 [88]. The Ras-related 
small GTPase (Rag) proteins [96, 97] and Ragulator [95, 98] are critical mediators 
that recruit mTORC1 onto lysosomes in response to amino acid sufficiency.  
 
Rag proteins interact with Ragulator  
Mammalian cells contain four Rag GTPases (hereinafter referred to as Rags), RagA, 
B, C and D. RagA and B share approximately 90%, whilst RagC and D share 81% 
sequence homology [96]. The guanine nucleotide-binding state of Rags is essential 
for their function and is regulated by amino acid availability. Rags function as 
heterodimers, which switch between the active and inactive conformations in 
response to amino acid sufficiency and deficiency respectively [96]. The active Rag 
heterodimer consists of either GTP-bound RagA or RagB and GDP-bound RagC or 
RagD, while the inactive heterodimer is constituted of either GDP-bound RagA or 
RagB and GTP-bound RagC or RagD (Figure 12). Rags have been found to localize 
on lysosomes by associating with the lysosomal protein complex, Ragulator, 
regardless of amino acid availability [95]. Ragulator is a complex composed of five 
subunits: p18, p14, MP1 (MAPK binding partner 1), C7orf59 and HBXIP (hepatitis 
B X-interacting protein [95, 98]. These subunits are alternatively termed LAMTOR 
(late endosomal/lysosomal adaptor and MAPK and mTOR activator) 1-5 
respectively.  
 
Rags interact with mTORC1 and recruit it onto lysosomes 
Both mTOR and Raptor, the defining subunit of mTORC1, are found to co-localize 
with lysosomes under the condition of amino acid sufficiency and they become 
diffused and cytosolic upon amino acid removal, as detected by immunofluorescence 
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staining [95, 97]. Such amino acid availability-controlled lysosomal recruitment and 
release are critical for mTORC1 activation and inactivation, and these processes are 
found to be mediated by the Rag heterodimers [95, 97] (Figure 12). In the presence 
of amino acids, the Rag heterodimer is dominant in the active conformation and 
interacts with Raptor, which recruits mTORC1 onto lysosomal surface [95, 97]. 
Once localized on lysosomes, mTORC1 is in proximity to Rheb, which allows it to 
interact with and be activated by GTP-bound Rheb [88, 95]. In the absence of amino 
acids, Rag heterodimer is switched into the inactive conformation and Rheb binds 
GDP due to TSC2 activity, leading to release of mTORC1 into cytosol and its 
inactivation [95, 97, 99] (Figure 12).  
 
Rags interact with TSC and recruit it onto lysosomes 
The master inhibitor of mTORC1, TSC2, is also found to undergo lysosomal 
translocation, however, in an opposite manner [99]. Unlike mTORC1 that co-
localizes with lysosomes in the presence of amino acid, TSC2 moves to lysosomal 
surface under the condition of amino acid deficiency. The subcellular localization of 
the other two subunits of TSC, TSC1 and TBC1D7, follows the same pattern as that 
of TSC2 [85]. Like mTORC1, the lysosomal translocation of TSC2 is also found to 
be mediated by the Rag heterodimers. When amino acids are present, TSC2 is 
diffused in the cytoplasm and as such unable to bind and inactivate Rheb [99]. Upon 
amino acid withdrawal, TSC2 interacts with the inactive Rag heterodimer and thus is 
recruited onto lysosomal surface. Once localized on lysosomes, TSC2 binds to GTP-
bound Rheb and induces its GTP hydrolysis, resulting in inhibition of Rheb and 
mTORC1 [99] (Figure 12). In a recent publication, it is also suggested that TSC2 
lysosomal translocation is a universal response to all the upstream stimuli and is 
required for mTORC1 inactivation [100]. 
 
Subcellular localization of Rheb  
The subcellular localization of Rheb is still a controversial subject. For many years it 
has been thought that Rheb is localized on lysosomes where it could meet and 
activate mTORC1, regardless of the presence of amino acids [95, 101, 102]. Such 
data were obtained from analysis of overexpressed green fluorescent protein (GFP) 
tagged Rheb (GFP-Rheb) due to lack of antibody detecting endogenous Rheb by 
44 
 
 
immunofluorescence at that time. However, more recently it has been suggested that 
Rheb binds Golgi apparatus, which is in proximity to lysosomes [103]. In addition, 
an earlier report in 2013 suggests that GFP-Rheb associates with Rab7, a marker to 
late endosome [97]. Considering that molecules are transported from Golgi 
apparatus, to late endosome and continue to lysosomes, it is likely that the 
subcellular distribution of Rheb is highly dynamic. This is supported by studies 
showing that red fluorescent protein (DsRed) tagged Rheb was present in late 
endosome 8 hours post transfection in Madin-Darby Canine Kidney (MDCK) cells, 
and in lysosomes 40 hours later [102]. Considering this discrepancy in Rheb 
subcellular distribution, it has been positioned in the proximity of lysosomes in the 
model displayed in Figure 12. In addition to being an activator of mTORC1, Rheb 
has also been found to activate nucleotide synthesis by binding to CAD protein, an 
enzyme required for pyrimidine biosynthesis [104]. 
 
GAP and GEF for Rags 
In addition to regulating the lysosomal localization of Rags, Ragulator also acts as a 
GEF for RagA and B [98]. Ragulator preferentially binds GDP-bound RagA and B, 
and stimulates them to switch into the active GTP-bound state. In contrast, GATOR1 
(GAP activity toward Rags complexes 1) functions as a GAP towards RagA and B, 
and converts them into the inactive GDP-bound state [105]. The activity of 
GATOR1 is regulated by GATOR2 and is sensitive to amino acid conditions [105]. 
When amino acids are present, Ragulator is active while GATOR1 is inhibited by 
GATOR2, and thereby Rags form the active heterodimer, recruiting mTORC1 onto 
lysosomal surface [95, 97, 98]. Upon amino acid withdrawal, Ragulator becomes 
inhibited and GATOR1 is active, which renders Rags inactive and unable to recruit 
mTORC1.  
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Figure 12. A currently proposed model of mTORC1 regulation by amino acids. 
The Rag heterodimer (RagA/B or RagC/D) associates with the lysosomal protein 
complex Ragulator regardless of amino acid availability. Rheb is positioned in the 
vicinity of lysosomes in this model. Panel 1, in the presence of amino acids, the 
active Rag heterodimer (RagA/BGTP and RagC/DGDP) recruits mTORC1 to lysosomal 
membrane, which allows it to be activated by GTP-bound Rheb. Panel 2, in the 
absence of amino acids, the inactive Rag heterodimer (RagA/BGDP and RagC/DGTP) 
recruits the complex TSC onto lysosomes. Lysosome-localized TSC2 inactivates 
Rheb, resulting in inhibition of mTORC1 activity and its dissociation from 
lysosomes. This figure is adapted from reference [106]. 
 
Upstream activators and inhibitors  
Several activators that transduce amino acid stimulus to mTORC1 have been 
identified, which include vacuolar H+-ATPase (v-ATPase) [107], mitogen-activated 
protein kinase kinase kinase kinase 3 (MAP4K3) [108, 109] and phospholipase D 1 
(PLD1) [110] as shown in Figure 13. V-ATPase promotes mTORC1 by interacting 
with Ragulator. Both MAP4K3 and PLD1 are activated by amino acid sufficiency 
and stimulate mTORC1 activity. PLD1-mediated activation of mTORC1 requires the 
Class III PI3K called hVps34 [110] whilst no mediator of MAP4K3 activity towards 
mTORC1 has been described. In addition to TSC2, general control nonderepressible 
2 (GCN2), a kinase that is activated by amino acid deficiency, has been recently 
demonstrated to inhibit mTORC1 activity [111].  
 
Figure 13. Proposed activators and inhibitors of mTORC1 in response to amino 
acids.  
Three activators, v-ATPase, MAP4K3 and PLD1, have been proposed to sense 
amino acid sufficiency and activate mTORC1. TSC2 is the master inhibitor of 
mTORC1 in response to all upstream signals. GCN2 that senses amino acid 
deficiency has been recently demonstrated to regulate mTORC1 inactivation.  
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Unsolved puzzles  
Of all the upstream stimuli inputs toward mTORC1, the amino acids stimulus is the 
most interesting, in that it is indispensable for mTORC1 activation [112] and sensing 
amino acids seems to be a unique function of mTORC1 since other proliferative 
signalling pathways including MAPK/ERK and PI3K/Akt do not respond to amino 
acids [112]. In addition, cancer cells demonstrate high demands for certain amino 
acids, in addition to glucose [113], thereby targeting the mechanism underlying 
amino acids-mediated activation of mTORC1 might be a promising approach for 
cancer therapeutics. In spite of many intensive studies that have been conducted, 
there are still puzzles in the amino acid-mediated mTORC1 signalling. These puzzles 
include the compartment where endogenous Rheb exactly localizes and whether its 
localization is regulated by amino acids or growth factors, the mechanism of how 
exactly GTP-bound Rheb activates mTORC1, regulators of lysosomal translocation 
of TSC2 in addition to Rags, mechanisms underlying activation and inhibition of 
mTORC1 signalling by GCN2 and MAP4K3 respectively.  
 
1.4.4 GCN2 senses amino acid deficiency and represses protein synthesis 
GCN2, encoded by eukaryotic initiation factor 2 (eIF2) alpha kinase 4 (EIF2AK4) 
gene, is a protein kinase that represses protein synthesis via phosphorylation of eIF2 
alpha subunit (eIF2α), which is the only described substrate of GCN2 [114]. GCN2 
possesses five domains [115] (Figure 13): a N-terminal GCN1 and GCN20-binding 
region (GCN1/GCN20), a degenerate protein kinase domain with unknown function; 
a serine/threonine protein kinase domain, a regulatory domain homologous to 
histidyl-tRNA synthetases (HisRS-like) that binds deacylated (uncharged) tRNA 
[116, 117] and the C-terminal region (Cterm) that is required for its kinase activity.  
 
Deficiency in amino acids results in elevated concentration of uncharged tRNAs, 
which bind to the HisRS-like region of GCN2 [116, 117]. This stimulates the 
transition of GCN2-GCN2 dimer from inhibited to catalytically active conformation. 
Activated GCN2 phosphorylates eIF2α on Ser51 [118-120], which converts eIF2 
into an inhibitor of its GEF eIF2B [121] (Figure 14). eIF2 is thereby sequestered in 
the GDP-bound state, which interferes with formation of the eIF2-GTP and Met-
tRNA complex that is required for protein translation initiation [121]. eIF2α 
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phosphorylation by GCN2 results in general inhibition of protein synthesis, but also 
upregulation of the transcription factor ATF4 [122], which stimulates expression of 
amino acid transporters [123] and amino acid synthetases [124] to restore amino acid 
homeostasis during amino acid deprivation.  
 
Figure 14. GCN2 senses amino acid deficiency and inhibits protein synthesis.  
GCN2 consists of a GCN1 and GCN20-binding region (GCN1/GCN20), a 
degenerate protein kinase domain (ψKD), a serine/threonine protein kinase domain 
(Kinase domain), a regulatory domain homologous to histidyl-tRNA synthetases 
(HisRS-like) and the C-terminal region (Cterm). Amino acid starvation increases the 
level of uncharged tRNAs, which bind to the HisRS-like region of GCN2, leading to 
its activation. Activated GCN2 phosphorylates eIF2α on Ser51, which inhibits eIF2B, 
a GEF for eIF2. Under normal-nutrient condition, GTP-bound eIF2 and Met-tRNA 
form a complex that is required for translation initiation. Inhibition of eIF2B renders 
eIF2 sequestered in the GDP-bound state and unable to initiate translation, resulting 
in protein synthesis repression. This figure is adapted from reference [115]. 
 
1.4.5 MAP4K3 senses amino acid sufficiency and activates mTORC1  
MAP4K3, also known as germinal-centre kinase (GCK)-like kinase (GLK), is 
involved in various cellular processes, such as amino acid signalling [108, 109], 
inflammatory response [125], migration [126] and apoptosis [127, 128]. MAP4K3 
consists of eleven kinase domains, two PEST (rich in proline, glutamic acid, serine, 
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and threonine) sequences, a proline-rich core and a regulatory domain [128] (Figure 
15). The proline-rich core is composed of three proline-rich sequence motifs, and 
regulates protein-protein interaction [109, 129]. Two PESTs are associated with 
rapid protein degradation [127]. Ser170 residue in the kinase domain is a trans-
autophosphorylation site that can be phosphorylated by another MAP4K3 kinase 
[109]. It has been demonstrated that phosphorylation of Ser170 can be induced by 
amino acids and is required for MAP4K3 to activate mTORC1 [108, 109].  
 
Figure 15. Linear schematic representation of MAP4K3 structure.  
MAP4K3 from N- to C-terminus consists of eleven kinase domains containing the 
trans-autophosphorylation site Ser170, a PEST sequence rich in proline (P), glutamic 
acid (E), serine (S), and threonine (T), a proline-rich (PR) core composed of three 
PR sequence motifs, a second PEST and the citron homology (CNH) regulatory 
domain. This figure is based on description of MAP4K3 structure in reference [128].  
 
MAP4K3 seems to play complicated roles in cellular signalling (Figure 16). On one 
hand, MAP4K3 can promote apoptosis by activating the JNK signalling pathway, 
suggesting a tumour suppressor role [128]. In accordance with this, reduced 
expression of MAP4K3 is associated with pancreatic cancer [127]. On the other hand, 
MAP4K3 contributes to cell proliferation by activating PKC and mTORC1 [108, 
109, 125]. PKC activates the transcription factor nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB), which promotes cell survival under 
conditions of cellular stress [125]. MAP4K3 activates mTORC1 in response to 
amino acid sufficiency, though the mechanism remains elusive [108, 109]. In 
consistent with its tumour-promoting role, high levels of MAP4K3 are associated 
with metastasis, invasion and poor survival in NSCLC patients [126, 130].  
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Figure 16. MAP4K3 is a putative tumour suppressor and promoter.  
MAP4K3 acts as an apoptosis inducer by activating the JNK signalling, suggesting a 
tumour suppressor role; on the other hand, it promotes cell growth and survival by 
activating PKC and mTORC1, indicating that it might contribute to tumorigenesis.  
 
1.5 Role of tumour suppressor p53 in cancer development 
The tumour suppressor p53 (tumour protein 53), encoded by the TP53 gene, is a 
transcription factor that has been found to regulate expression of more than 500 
genes [131]. Among these genes are important regulators of apoptosis, DNA repair, 
metabolism and growth factors signalling including PI3K/Akt and mTORC1. P53 
has a pivotal role in regulating a wide range of cellular responses to different types 
of stress, including DNA damage, hypoxia and oncogene activation [132] (Figure 
17). The role of p53 being a tumour suppressor is predominantly attributed to its 
ability to promote apoptosis and induce cell cycle arrest, which contribute to 
elimination of cancer cells and suppression of tumorigenesis [133]. Most common 
tumour-associated mutations of p53 are within the DNA binding domain, rendering 
p53 transcriptionally inactive. As a results of these mutations, cells become 
unresponsive to pro-apoptotic signals and therefore evade cell death [132]. P53 also 
has a role in regulating senescence and differentiation, which inhibit proliferation 
and pluripotency of cancer stem cells [134, 135]. Activation of p53 does not 
necessarily results in cell death. When the DNA-damaging stress is moderate, p53 
promotes cell cycle arrest and DNA repair by upregulating cell cycle regulator p21 
and also DNA repair pathways such as DNA repair protein poly(ADP-ribose) 
polymerase 1 (PARP1) [132]. Therefore, the normal function of p53 is critical for 
maintaining the genetic fidelity and thus the whole genomic stability, and it is not 
surprising that p53 has been called “the guardian of the genome” [136]. In addition, 
p53 prevents tumorigenesis also via suppressing glycolysis [137]. Cancer cells 
universally re-direct the oxidative phosphorylation to aerobic glycolysis, presumably 
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because the glycolytic pathway provides intermediates that are required for cell 
growth and division, and also the oxidative phosphorylation produces more reactive 
oxygen species (ROS) that cancer cells are not well equipped to deal with [138]. 
P53, by inhibiting key glycolytic enzymes, suppresses glycolysis and inhibits cell 
growth and proliferation. Therefore, loss of p53 expression or function, due to 
mutations or viral oncoproteins, results in high rates of mutations and evasion of cell 
death, leading to cancer progression, and indeed, p53 is the most frequently mutated 
gene in all human cancers [139, 140].  
 
Figure 17. Overview of p53 in cellular responses.  
P53 regulates various aspects of cell behaviour in response to a different forms of 
stress, including DNA damage, oxidative stress, hypoxia, viral infection and 
oncogene activation, to ensure gene fidelity, normal cell growth and to suppress 
tumorigenesis. P53 promotes cell-cycle arrest and DNA repair in response to DNA-
damaging insults. P53 also stimulates the apoptotic pathway, senescence and 
autophagy to eliminate dangerous cells and inhibit proliferation. Induction of p53 
during immune response promotes angiogenesis for cell survival. Suppression of 
glycolysis by p53 also contributes to inhibition of cell proliferation. This figure is 
based on description of the role of p53 in reference [132] 
 
P53 is subject to a variety of post-translational modifications, including 
phosphorylation, ubiquitination, methylation and farnesylation, which together with 
its binding partners modulate the subcellular localization, stability and conformation 
of p53 [132]. One of the central mechanisms that regulate p53 function is regulation 
of its stability by the ubiquitin ligase MDM2, which targets p53 for degradation as 
well as directly inhibits its activity by binding to the transcriptional activation 
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domain [141]. Upon DNA damage, p53 is phosphorylated on Ser15 by the 
serine/threonine kinase ATM (ataxia-telangiectasia mutated), which disrupts the 
interaction of p53 with MDM2 and leads to activation of p53 [142]. Activated p53 
can induce the expression of MDM2, generating a negative auto-regulatory feedback 
loop between these two proteins [143]. P53 also has tight links with the growth 
factor signalling pathways, including PI3K/Akt and mTORC1 (Figure 18), so that a 
balance between cell growth and stress responses can be achieved and cells 
proliferate without accumulating damaged DNA [28, 94].  
 
Figure 18. Crosstalk between p53 and PI3K/Akt and mTORC1 pathways. 
Growth factors stimulate activation of PI3K/Akt, MAPK/ERK and mTORC1 
signalling pathways. Moderate stress-activated p53 upregulates the expression of 
PTEN and AMPKβ, which are the inhibitors of PI3K/Akt and mTORC1 respectively, 
leading to suppression of the downstream signalling effectors. This figure is 
modified from reference [144]. 
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1.6 Role of programmed cell death (PCD) in cancer development  
PCD is a process during which cells are eliminated in a genetically-determined 
fashion and is essential for maintaining cell number and homeostasis within the 
tissue [145]. The three forms of PCD, apoptosis, autophagic cell death and 
necroptosis (programmed necrosis) can be distinguished by their morphological and 
biochemical features [146] (Figure 19 and Table 1). Ferroptosis is an emerging form 
of PCD, characterized by iron (ferrous) dependence and is a type of oxidative cell 
death that is distinct from other forms of PCD [147]. Morphological features of 
ferroptosis have not been well established yet, but it has been suggested that 
ferroptosis is accompanied by mitochondrial shrinkage [147] (Table 1). Apoptosis is 
the major form of PCD and dysregulation of apoptosis is associated with a wide 
variety of pathological conditions, such as neurodegenerative diseases, ischemic 
damage and notably cancer.  
 
Figure 19. Main forms of cell death.  
Cell death can be divided into two groups, programmed and non-programmed death. 
The former comprises apoptosis and non-apoptosis, and the latter is necrosis. Non-
apoptotic cell death includes ferroptosis, necroptosis and autophagic cell death. This 
figure is based on description of cell death classification in reference [145]. 
 
Table 1. Morphological changes during different types of cell death 
Necrosis. Irreversible cellular damage resulting from external factors such as 
injury and infection, with rupture of plasma membrane and organelles swelling.   
Necroptosis. A regulated form of necrosis as a result of inflammatory response.  
Apoptosis. A precisely regulated form of cell death in response to both intra- and 
extra-cellular stimuli, with cell shrinkage, chromatin condensation, formation of 
apoptotic bodies containing intact organelles.  
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Ferroptosis: An iron-dependent oxidative cell death that is induced by excessive 
accumulation of lipid ROS and inhibition of GPX4, and is accompanied by 
mitochondrial shrinkage.  
Autophagic cell death. A form of cell death in response to nutrient insufficiency, 
with massive double-membrane vacuoles containing deteriorate organelles.  
 
1.6.1 Apoptosis 
Apoptosis is the major type of cell death [146], and is vital for a number of essential 
processes including embryonic development and immune response [145]. Apoptosis 
is accurately controlled under physiological conditions to ensure appropriate 
development of the system. It is also induced as a part of the defence system to 
eliminate damaged cells resulting from infection or cytotoxic agents [145]. 
Inappropriate apoptosis is associated with many diseases, such as neurodegenerative 
diseases due to upregulation of apoptosis, and conversely many types of cancer 
owing to downregulation of apoptosis.  
 
Apoptosis is characterized by a sequence of morphological alterations that ultimately 
leads to degradation of the cellular components, and these alterations include 
shrinkage of the cell and the nucleus, condensation and margination of nuclear 
chromatin, destructive fragmentation of the nucleus, cell detachment from the 
surrounding tissue, formation of apoptotic bodies that contain cellular organelles and 
fragments of nucleus, and final phagocytosis of these apoptotic bodies into 
neighbouring cells [148].  
 
On genetic and biochemical levels, apoptosis is tightly controlled by the Bcl-2 
family and caspases [149, 150]. The Bcl-2 family comprises more than 20 members 
that can be divided into three groups based on the presence of conserved Bcl-2 
homology (BH) regions (Figure 20): the anti-apoptotic members with all four BH 
regions including Bcl-2, Bcl-XL, Bcl-w, Mcl-1; two pro-apoptotic subsets which are 
the BH3-only proteins (share the BH3 region only) including Bid, Bim, Bad and 
others, and the death effectors Bax, Bak and Bok that share BH 1-3 regions [150]. 
Caspases are a class of cysteine protease enzymes that act as apoptosis executioners 
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[146]. They are constitutively synthesized as inactive procaspases, and are activated 
by pro-apoptotic signals in a self-amplifying and proteolytic manner [145].  
 
Figure 20. Structural and functional classification of the Bcl-2 proteins.  
Bcl-2 proteins are subdivided into three groups according to conserved Bcl-2 
homology (BH) domains. Abbreviation: TM, transmembrane domain. This figure is 
adapted from reference [151]. 
 
Apoptosis occurs mainly through the extrinsic death receptor and intrinsic 
mitochondrial pathways depending the sources of stimuli and biochemical 
mechanisms (reviewed in references [145, 146]) (Figure 21). The extrinsic pathway 
is stimulated as a part of immune responses through extracellular ligands that bind to 
and activate the membrane death receptors. The best characterized ligands and 
corresponding receptors include first apoptosis signal receptor (Fas) ligand 
(FasL)/Fas and tumour necrosis factor (TNF)-α/TNFR1 [145]. Activated Fas 
interacts with and activates the adapter protein Fas-associating protein with death 
domain (FADD), which associates with pro-caspase-8, leading to formation of death-
inducing signalling complex (DISC) and activation of caspcase-8 [146]. Upon 
activation, caspase-8 promotes the activation of the apoptosis executioner caspase-3 
and the Bcl-2 family member Bid [145, 152]. Bid then binds to Bim and induces 
activation of Bax and Bak [152], initiating the intrinsic pathway.    
 
The intrinsic pathway is initiated by intracellular stimuli such as deprivation of 
growth factors or hormone [145] (Figure 21). These stimuli activate BH3-only 
proteins including Bad and Bim, which further inhibit anti-apoptotic proteins and 
activate pro-apoptotic proteins [152], particularly Bax and Bak, leading to 
permeabilization of the mitochondrial outer membrane and thus release of two 
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groups of pro-apoptotic factors into cytoplasm [145, 153]. The first group comprises 
cytochrome c, second mitochondria-derived activator of caspase (Smac) and the 
serine protease high temperature requirement protein A2 (HtrA2), all of which 
promote the caspase-3 activation [145]. Cytoplasmic cytochrome c, apoptotic 
protease activating factor 1 (Apaf1) and pro-caspase-9 forms the complex called 
apoptosome, leading to activation of caspase-9, which in turn promotes activation of 
caspase-3 [145]. Caspase-3 then cleaves various substrates including inhibitor of 
caspase-activated DNase (ICAD) and poly(ADP-ribose) polymerase (PARP), which 
ultimately causes DNA fragmentation. The second group of pro-apoptotic factors are 
apoptosis-inducing factor (AIF), endonuclease G (Endo G) and CAD [146], which 
translocate to the nucleus and promote DNA fragmentation. This pathway is also 
stimulated by cytotoxic agents and irradiation that cause DNA damage and 
activation of p53. Activated p53 binds to and activates Bax and Bak, leading to 
further apoptotic response [152]. Moreover, apoptosis is accompanied by elevated 
accumulation of mitochondrial ROS. ROS is a natural by-product of oxygen 
metabolism (see Chapter 1.6.2.1) and can induce oxidative modification of proteins 
including the mitochondrial permeability transition complex, leading to 
hyperpolarization of mitochondrial membranes and thus initiation of the intrinsic 
apoptotic pathway [154, 155]. 
 
Apoptosis is considered as the natural barrier to cancer development [1] and defects 
in apoptosis are frequently found in cancer [156]. It seems that these defects do not 
originate from the apoptotic machinery, in that mutations or overexpression of the 
Bcl-2 family and caspases are not common in cancer. Instead, evasion of cell death 
in cancer usually results from mutations of the upstream mediators, such as the 
tumour suppressor p53 that drives the apoptotic response [145].   
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Figure 21. Extrinsic and intrinsic apoptotic pathways.  
Extrinsic pathway: inflammation-stimulated death ligands, such as FasL and TNF-α, 
bind to the transmembrane death receptor, which stimulates the activation of 
caspase-8 and thus the apoptosis executioner caspase-3. Activated caspase-3 cleaves 
and inhibits ICAD and PARP, leading to DNA fragmentation and thereby apoptosis. 
The intrinsic pathway can be induced by three groups of stimuli, the growth factor 
deprivation and hypoxia that activate BH3 only proteins, cytotoxic agents and 
irradiation that cause DNA damage and subsequent activation of p53, and 
mitochondrial ROS that induce oxidative modification of mitochondrial proteins. 
These stimuli cause permeabilization of the mitochondrial outer membrane and 
consequently cytosolic translocation of pro-apoptotic factors including cytochrome 
c, Smac, HtrA2 and CAD, leading to activation of caspase-3 and DNA 
fragmentation. This figure is modified from reference [146]. 
 
 
 
58 
 
 
1.6.2 Ferroptosis is an oxidative non-apoptotic form of cell death 
 
1.6.2.1 Oxidative stress and antioxidant systems 
Reactive oxygen species (ROS) definition and function 
ROS are highly reactive molecules derived from oxygen (O2) and they are divided 
into two groups: free radicals that contain unpaired electrons such as hydroxyl 
radicals (HO•) and superoxide anions (O2•−); and non-radicals that do not contain 
unpaired electrons such as hydrogen peroxide (H2O2) [157, 158]. HO•, O2•− and 
H2O2 are the three major ROS in cells and have significant cellular functions. O2
•− is 
converted into H2O2 by superoxide dismutase and it also reacts with H2O to generate 
HO• [158]. ROS act as second messengers to mediate diverse cellular processes, 
including MAPK/ERK and PI3K/Akt signalling pathways that regulate cell growth 
and proliferation, immune and hypoxic responses [157, 159-162]. ROS can promote 
cell growth through two mechanisms: ROS 1) induce auto-phosphorylation of 
growth factor receptors including EGFR and PDGFR independently of growth factor 
ligands; 2) activate RAS through oxidative modification that inhibits its GDP/GTP 
exchange, both of which activate the MAPK/ERK and PI3K/Akt pathways [160]. 
Moreover, H2O2 can activate transcription factor NF-KB that regulates immune 
response [161]. Moderate cellular levels of ROS are counterbalanced by antioxidant 
defence systems, however, excessive ROS induce oxidative modification and thus 
degradation of essential cell structures including lipids, proteins and DNA [158, 159, 
163-166]. Among these ROS, HO• is most reactive and induces 1) DNA breakage by 
oxidizing all four nucleotide bases [164]; 2) protein damage by oxidizing the protein 
polypeptide backbone [165]; and 3) lipid peroxidation by oxidizing polyunsaturated 
fatty acids (PUFAs) whereby the membrane lipid bilayer arrangement is disrupted 
[166]. O2
•− and H2O2 indirectly damage DNA, protein and lipid by generating HO•. 
Furthermore, ROS initiate the intrinsic apoptotic cascade by inducing 
hyperpolarization of mitochondrial membrane and hence cytochrome c release and 
mitochondrial translocation of Bax and Bad [155].  
 
Sources of ROS 
ROS can originate from exogenous and intracellular sources. Exogenous sources 
include toxic agents such as cigarette smoke that contains oxidants and free radicals, 
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hyperoxia and ionizing radiation [158]. Most intracellular ROS are formed in 
mitochondria as a by-product of the respiratory chain reactions that reduce oxygen to 
water [167]. Intracellular ROS can also be produced in other cellular compartments, 
such as lipid membranes, peroxisomes, cytoplasm, mitochondria, endoplasmic 
reticulum (ER) and lysosomes, by the action of membrane-bound NADPH oxidases 
(NOX) that convert O2 to O2
•− and H2O2 [158, 159, 168] (Figure 22). Five isoforms 
of NOX have been identified in humans and they are encoded by different genes 
[169]. NOX3 is mainly expressed in foetal tissues whilst the other NOXs (1, 2, 4 and 
5) are ubiquitously expressed in many cell types.  
 
Antioxidant systems 
Antioxidants act as scavengers of ROS and effectively remove their oxidative effects 
[158]. They can be grouped into enzymatic and non-enzymatic categories. Non-
enzymatic antioxidants are a group of low-molecular-weight compounds and 
molecules containing a thiol group, capable of being oxidized by ROS, such as 
vitamins C and E, and the amino acid glutathione [158]. Glutathione is highly 
abundant in all cellular compartments and exists in reduced (GSH) and oxidized 
(GSSG) forms (Figure 22). GSH is a tripeptide composed of cysteine, glycine and 
glutamate, and it is the major soluble antioxidant in cells. The amino acid cysteine is 
unstable and reduced from cystine following uptake by the cystine/glutamate 
antiporter system xc
- consisting of SLC3A2 and SLC7A11 [170]. Because 
intracellular cystine is much less abundant than glycine and glutamate, 
cystine/cysteine is the rate-limiting precursor in GSH synthesis. One of the major 
enzymatic antioxidants is the glutathione peroxidase (GPX) family [171, 172]. Four 
GPX isoforms have been described and they vary in subcellular location and 
substrate specificity. Cytoplasmic GPX1 and membrane-bound GPX4 are ubiquitous 
and target H2O2 and lipid hydroperoxides (lipid-H2O2) respectively (Figure 22). 
GPX2 is expressed in gastrointestinal epithelial cells and acts on dietary peroxides 
whilst GPX3 is localized in extracellular compartment. GPX catalyses the oxidation 
of GSH to GSSG whereby harmful H2O2 and lipid-H2O2 are reduced to harmless 
water and alcohol (Figure 22) [172]. GSH thus donates an electron to neutralize 
H2O2, whilst the resulting GSSG accepts an electron from NADPH and converts into 
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GSH. Glutathione and GPX4 are therefore particularly important in protecting lipid 
membranes from oxidative damage of lipid ROS. 
 
Figure 22. The GSH/GPX4 antioxidant system.  
Extracellular amino acid cystine is imported into cells via the cystine/glutamate 
antiporter system xc
- that concomitantly exports glutamate. Cystine is the oxidized, 
more stable form of cysteine. Once inside the cell, two cystine molecules are reduced 
to form one cysteine molecule. Glutathione is synthesized from cysteine, glutamate 
and glycine, and cysteine is the rate-limiting precursor due to its low intracellular 
concentration. The lipid repair enzyme GPX4 catalyses oxidation of GSH (reduced 
form of glutathione) into GSSG (oxidized form of glutathione), in which GSH 
donates an electron to lipid hydroperoxides (lipid-H2O2) and reduces the latter into 
corresponding alcohols (lipid-H2O). GSSG is then recycled into GSH by glutathione 
reductase, using an electron from NADPH. This figure is adapted from reference 
[173].  
 
1.6.1.2 Ferroptosis  
Ferroptosis was first described in 2012 by the research group of Professor Brent 
Stockwell as a unique form of non-apoptotic cell death with extreme dependence on 
the divalent iron (ferrous) [147]. In their experiments that led to the discovery of 
ferroptosis, the cell death was induced by the small molecule erastin that depletes the 
intracellular cystine pool by inhibiting the cystine/glutamate antiporter system xc
-. 
Subsequent study has demonstrated that ferroptosis is in fact an ancient form of cells 
death driven by peroxidation of PUFAs in lipids [174]. PUFAs incorporated into 
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cellular membranes enhance membrane fluidity, which is essential for the function of 
membrane-associated proteins and other biomolecules. However, the composition of 
PUFAs within membranes renders the lipids susceptible to oxidative damage [174], 
in that PUFAs can react with lipid ROS, which induces oxidative degradation of 
lipids (lipid peroxidation). Ferroptosis is morphologically, biochemically and 
genetically distinct from other forms of cell death and is implicated in 
neurodegenerative diseases [175] and cancer [147].  
 
Biochemical features 
The process of ferroptotic cell death involves a variety of biochemical reactions 
including metabolisms of iron, amino acids, and PUFAs, and biosynthesis of 
glutathione and NADPH (reviewed in [173, 176]). Ferroptosis is induced by ROS, 
particularly lipid ROS, since this form of cellular death can be suppressed by 
lipophilic antioxidants such as ferrostatin-1 [147] and α-tocopherol (vitamin E) [177, 
178] (Figure 23). Notably, the level of mitochondrial ROS has been demonstrated to 
remain unchanged during ferroptosis [147], whereas apoptotic cell death is 
accompanied by elevated mitochondrial ROS. Moreover, induction of ferroptosis by 
lipid ROS is highly dependent on iron abundance, in that knockdown of transferrin 
and transferrin receptor (TFR) that import iron inhibits ferroptosis [179, 180]. 
Ferroptosis is also suppressed by treatment with iron chelators, such as deferoxamine 
(DFO), which competitively bind iron and remove it from reactions [147]. The 
precise mechanism of iron promoting ferroptosis remains elusive, although it is 
likely that iron interacts with lipid peroxides, which converts them into lipid free 
radicals that are destructive to lipids and cells [181]. 
 
The antioxidants glutathione and GPX4 are critical in suppressing ferroptosis due to 
their capability of detoxifying lipid ROS [173, 182, 183]. The first discovered 
ferroptosis inducer, erastin [147], is an inhibitor of the glutamate/cystine antiporter 
in the plasma membrane [182]. Inhibition of the antiporter blocks uptake of cystine, 
thereby depletes the glutathione pool. Likewise, buthionine sulfoximine (BSO) is 
found to induce ferroptosis by inhibiting glutathione biosynthesis [184]. Depletion of 
intracellular glutathione causes excessive accumulation of lipid ROS [185] and 
renders the cells vulnerable to oxidative damage. Another initially identified 
62 
 
 
ferroptosis inducer is RSL3, a Ras-selective lethal compound [147], which is an 
inhibitor of the phospholipid enzyme GPX4 [183]. As described previously, GPX4 
converts lipid hydroperoxides into lipid alcohols, thereby protects cells from 
oxidative damage [186], conversely inhibition of GPX4 results in elevated 
accumulation of lipid ROS and thus ferroptotic cell death.  
 
Figure 23. Ferroptosis is an iron-dependent oxidative non-apoptotic cell death. 
Ferroptosis is induced by excessive accumulation of lipid ROS and is highly 
dependent on iron abundance. The small compounds, erastin (an inhibitor of system 
xc
-) and ferrostatin-1 (a lipophilic antioxidant), are respectively inducer and inhibitor 
of ferroptosis. Erastin prevents uptake of cystine, leading to depletion of antioxidant 
glutathione. Cellular antioxidants and ferrostatin-1 eliminate lipid ROS and thus 
supress ferroptosis. Iron chelating agents such as deferoxamine bind to iron and 
remove it from reactions, leading to inhibition of ferroptosis. This figure is based on 
description of ferroptosis in reference [147]. 
 
Whilst it is unclear whether there are any genetic factors contributing to ferroptosis, 
the susceptibility to ferroptosis appears to be tightly linked to certain genetic 
contexts. Ferroptosis has been reported to occur in RAS (NRAS, KRAS or HRAS) 
mutated cancer cells [147], however, mechanisms of how the downstream signalling 
pathways such as MAPK/ERK regulate ferroptosis remain elusive. Regardless, cells 
expressing the RAS mutations that sensitize them to ferroptosis are found to harbour 
increased levels of transferrin receptor (reviewed in [187]). In addition, p53 has been 
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demonstrated to promote ferroptosis by repressing expression of the 
glutamate/cystine antiporter and thus inhibiting cystine uptake [182, 188]. mTORC1 
has been reported to promote ferroptosis [189] possibly through regulating iron 
metabolism [190].  
 
1.7 Synthetic lethality is a promising approach for cancer therapeutics  
For decades, radiation and toxic chemicals were the most commonly used therapies 
for cancer patients, both of which also cause dramatic damages to normal tissues. 
Although discoveries of small-molecule and antibody-based inhibitors that target 
oncogenes have personalised cancer therapies, resistance to these therapies arises 
and loss-of-function tumour suppressors remain un-targetable (reviewed in [191]). 
Identification of cancer-specific vulnerabilities or dependencies has emerged as a 
promising therapeutic strategy that selectively induces lethality in cancer cells while 
leaving normal cells undamaged or little damaged. Synthetic lethality screens have 
provided such an approach to distinguish genetic dependencies associated with the 
driver mutation in cancer cells. The American geneticist Calvin Bridges first 
reported synthetic lethality in 1922 when he observed in the fruit fly Drosophila 
melanogaster that mutations in two genes lead to cell death, although neither of these 
genes are individually required for viability [192]. Geneticist Theodore Dobzhansky 
also observed the similar genetic interaction and coined it as “synthetic lethality” 
[193]. Synthetic lethality thus describes genetic interactions where simultaneous 
disruption of two genes induces cell lethality, whereas disruption of either gene 
alone is viable. In the context of cancer, synthetic lethality creates a second-site gene 
target for a cancer-driving mutation (reviewed in [194]) (Figure 24). This overcomes 
the limitations of the conventional chemotherapy and expands the repertoire of 
anticancer therapeutic agents. Firstly, targeting the gene synthetic lethal to the 
cancer-driving mutation selectively kills cancer cells and spare normal cells, which 
should be efficacious with fewer side effects. Secondly, by targeting the second-site 
gene instead of the loss-of-function mutation itself, synthetic lethality opens the 
opportunities to certain cancer types with loss of tumour suppressor genes that are 
non-druggable by the conventional chemotherapy. For example, inhibitors targeting 
poly (ADP-ribose) polymerase (PARP) have been clinically approved for therapies 
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of cancer patients carrying mutations in the tumour suppressor genes BRCA1 or 
BRCA2 that functions to repair damaged DNA when normally expressed [195]. 
BRCA1 or BRCA2 mutations render patients defective in one specific DNA repair 
process, and PARP inhibitors, by targeting the PARP-mediated DNA repair process, 
have become lethal to cells with these mutations.  
   
The concept of synthetic lethality has been extended to identify metabolic 
vulnerabilities of cancer cells that undergo metabolic re-programming and are 
addicted to certain metabolites. Such metabolic alterations in cancer cells include 
increased glucose uptake and glycolysis [196], nucleotide biosynthesis [197] and 
uptake of certain specific amino acids such as glutamine, serine, glycine, proline and 
arginine [198, 199]. Identification of the specific metabolic pathways is likely to 
offer opportunities for effective cancer-specific treatments and for treatments of 
cancers that are resistant to inhibitory agents.  
 
Figure 24. Schematic representation of synthetic lethality. 
Targeting gene A causes lethality in cancer cells expressing the mutation B whereas 
normal cells survive. This figure is modified from reference [200].     
 
1.8 Project strategies and aims  
In this study, we focused on the proliferative signalling pathways, mTORC1, 
PI3K/Akt and MAPK/ERK, and their association with nutrient amino acids, the 
building blocks of proteins. The work presented in this thesis is mainly divided into 
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two parts, identification of mechanisms involved in mTORC1 inhibition in response 
to amino acid deprivation (Results Chapter 3.1) and identification of amino acid-
associated vulnerabilities specific to the common mutations in oncogenes PI3K, 
EGFR, KRAS and BRAF (Chapter 3.3). In addition, this thesis also contains two 
minor parts, investigation of MAP4K3 as a tumour promoter and tumour suppressor 
(Chapter 3.2), and investigation of association of the tumour suppressor p53 with 
amino acids and mTORC1 (Chapter 3.4), which are present in the Results Chapter 
but not included in the Discussion Chapter due to lack of consistency to the main 
work.  
 
The study on mTORC1 aimed to identify novel regulators and mechanisms involved 
in mTORC1 signalling in response to amino acid deprivation by centring on the 
recent findings that TSC2 undergoes lysosomal translocation and Rag GTPases 
mediates the lysosomal translocation of both mTORC1 and TSC2. To identify novel 
mediators of TSC2 subcellular localization, which would potentially reveal the 
additional mechanisms of its inhibition on mTORC1, a high-throughput quantitative 
cell imaging siRNA was performed. The resulting candidates were selected based on 
their association with amino acids and the relationship with TSC2 was examined 
using independent siRNAs and specific inhibitors. It has been demonstrated that the 
Rag GTPases regulate TSC2 lysosomal localization, we further investigated whether 
TSC2 affected Rag GTPases, by examining the localization of RagA and RagC in 
cells lacking TSC2. Rheb is critical for mTORC1 activation due to its ability to 
activate the catalytic activity of mTORC1. We then explored the role of Rheb in the 
lysosomal translocation of both mTORC1 and TSC2, via siRNA-induced 
suppression of Rheb. Since lysosomal translocation of mTORC1 and TSC2 is 
stimulated by amino acid sufficiency and deficiency respectively and is important for 
mTORC1 activation and inactivation, media shift treatment, which is switch from 
medium containing amino acids (the normal culture medium) to medium lacking 
amino acids (reconstituted medium according to the formulation of culture medium 
but omit all amino acids, see Material Chapter 2.1.10), was utilized throughout this 
work and also work on MAP4K3 and p53.  
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EGFR delE746-A750, KRAS G13D, BRAF V600E and PIK3CA H1047R are 
frequently found in multiple cancer types. To identify amino acid-associated 
vulnerabilities specific to these mutations, we have taken advantages of the hTERT 
human mammary epithelial (HME) cell lines established by the group of Professor 
Alberto Bardelli [201], and also an amino acid dropout screen. The four mutations 
have been knocked into the HME cell lines and demonstrated to activate the 
corresponding signalling pathways. These isogenic HME cell lines therefore provide 
a genetic context that is significantly less complicated than that in the cancer cell 
lines, which presumably allows the properties specific to these mutations to be 
characterized. By reconstituting media omitting one specific amino acid, an amino 
acid dropout screen could be performed. Based on the observation that depletion of 
which specific amino acid would cause lethality only in the mutant cells but not wild 
type, a cancer-specific vulnerability could be potentially established. Inhibitors 
specific to the mutations and downstream signalling effectors were also utilized to 
verify which pathway exactly was associated with the lethality caused by deprivation 
of the specific amino acid. To investigate the mechanisms involved in the distinct 
responses between mutant and wild type cells, the level of intracellular amino acids 
was examined and the specific amino acid-associated subcellular response was 
investigated. A panel of nine NSCLC cell lines were utilized so that the study in 
these isogenic HME cells could be expanded into the heterogeneous context of 
cancer cells, and the cell line that was susceptible to deprivation of the specific 
amino acid was selected for further engrafted tumour study in a mouse model. To 
mimic the media shift treatment, an engineered enzyme that degrades the specific 
amino acid was also utilized in both cell culture and the mouse model.  
 
The work presented in this thesis has been re-directed several times due to 
unforeseen circumstances, however, the molecules that were studied, without 
exception, contribute to cancer development, and all the work centred on the cellular 
responses to amino acid conditions.  
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Chapter 2 - Materials and Methods 
2.1 Materials 
2.1.1 Chemicals  
 Acetonitrile (HPLC) (Fisher Scientific, A998-1) 
 Acrylamide (30%) (Geneflow, A2-0072) 
 Adenosine 5’-triphosphate (ATP) (Cell signaling, 9804) 
 Agar (Invitrogen, 30391-049)  
 Agarose (Sigma, A9539) 
 Albumin from bovine serum (BSA) (Sigma, A3059) 
 Ammonium persulfate (APS) (Sigma, A3678)  
 ATP, [γ-32P]- 3000Ci/mmol 10mCi/ml, 250 µci (PerkinElmer, BLU002A250UC) 
 Bacto-peptone (BD Biosciences, 211677) 
 Bio-Rad protein assay dye reagent (Bio-Rad Laboratories, 500-0006) 
 C11-BODIPY581⁄591 (Thermo Fisher, D3861) 
 CellTiter-Glo reagent (Promega, G7571) 
 Complete protease inhibitor cocktail tablets (Roche Diagnostics, 11873580001) 
 Dako faramount aqueous mounting medium (Dako North America, S3025) 
 ddH2O (lab supplied through a Millipore Q 0.22μM filter system) 
 Deoxynucleotide (dNTP) solution mix (New England BioLabs, N0447S) 
 D-Glucose (Fischer Scientific, G/0500/53)  
 Digitonin (Sigma, D141) 
 Dimethylsulfoxide (DMSO) (Sigma, D8418) 
 Dithiothreitol (DTT) (Sigma, 43817) 
 1kb DNA ladder (New England BioLabs, N3232S) 
 Dried skimmed milk (Marvel) 
 Dulbecco’s phosphate buffered saline (DPBS) (Invitrogen, 17104) 
 Dulbecco's Modified Eagle Medium (DMEM) (Life Technologies, 31966021) 
 DMEM low glucose, w/o amino acids, pyr (powder) (USBiological, D9800-13) 
 ECL western blotting detection reagents (Fisher Scientific, RPN2106) 
 EDTA (Fisher Scientific, 1021-3570) 
 EGTA (Sigma, E3889) 
 Ethanol (Fischer Scientific, E/0056DF/P17) 
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 Etoposide (Sigma, E1383) 
 Fetal bovine serum (FBS) (Life Technologies, 10270106) 
 Glycerol (Sigma, G3664-500UN) 
 β-Glycerophosphate disodium salt hydrate (β-GP) (Sigma, G9422) 
 Glycine (Fischer Scientific, 10080160) 
 Goat serum (Sigma, G9023) 
 Hydrochloric acid (37%) (Sigma, 320331) 
 Hydrocortisome (25mg/ml) (Sigma, H0888) 
 Hydrogen peroxide, 30% in water (Fisher Scientific, 10386643) 
 Hyperfilm ECL (GE Healthcare Life Sciences, 28-9068-37) 
 Immersion oil immersol 518F fluorescence free (Carl Zeiss, 444962-0000-000) 
 Insulin solution from bovine pancreas (Sigma, I0516) 
 Isoproponal (Fisher scientific, 11805725) 
 L-Amino acids (Sigma, LAA21) 
 L-Buthionine-sulfoximine (Sigma, B2515) 
 L-Glutamic acid (Sigma, G1251) 
 Lipofectamine 2000 Transfection Reagent (Life Technologies, 11668019) 
 Lithium chloride (LiCl) (Sigma, 203637) 
 Lithium dodecyl sulfate (LDS) sample buffer (Life Technologies, NP0007) 
 Luminol (Sigma, A8511) 
 Magnesium chloride hexahydrate (Sigma, M2670) 
 Methanol (HPLC) (Fisher Scientific, 10675112) 
 β-Mercaptoethanol (β-ME) (Sigma, M3148) 
 Minimum essential medium (MEM) amino acids solution (Invitrogen, 11130-051) 
 NEB 10-β competent E. coli (New England Biolabs, C3019I) 
 Okadaic acid potassium salt (O.A.) (Sigma, O7885) 
 Paraformaldehyde (PFA) (Sigma, 158127) 
 p-Coumaric acid (Sigma,  C9008) 
 Penicillin streptomycin (Pen strep) (Life Technologies, 15140122) 
 Phosphate buffered saline solution (Fisher Scientific, 10649744) 
 Phosphate buffered saline (PBS) for cell culture (Thermo Fisher, 10010023) 
 Polyvinylidene difluoride (PVDF) membrane (Millipore, IPVH00010) 
 Ponceau S solution (Sigma, P7170) 
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 Protein marker (Fisher Scientific, RPN800E) 
 Purple DNA loading buffer (New England BioLabs, B7024S) 
 Qiagen Plasmid Maxiprep Kit (Qiagen, 12163) 
 QIAprep Spin Miniprep Kit (Qiagen, 27104) 
 QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies, 200521) 
 Recombinant human EGF (PeproTech House, AF-100-15) 
 RG x-ray Developer (Jet X-Ray, RTU Developer)  
 RG x-ray Fixer (Jet X-Ray, RTU Fixer) 
 RPMI 1640 medium (Life Technologies, 61870010) 
 SafeView nucleic acid stain (NBS Biologicals, NBS-SV) 
 Snakeskin dialysis tubing, 3.5K MWCO (Fisher Scientific, 88244) 
 SOC growth medium (BioLabs, B9020S) 
 Sodium chloride (NaCl) (Fisher Scientific, 10428420) 
 Sodium dodecyl sulfate (SDS) (Sigma, L6026) 
 Sucrose (Sigma, S0389) 
 TEMED (Sigma, T9281) 
 Tris-acetate-EDTA (TAE) solution (Fisher Scientific, 10490264) 
 Tris base (Fischer Scientific, 10376743) 
 Triton X-100 (Sigma, T8787) 
 Trypsin 0.25% EDTA (Life Technologies, 25200072) 
 Tryptone microbial media (Fisher chemical, F24965) 
 Tween 20 (Fisher Scientific, 10485733) 
 Ultrapure DNAse/RNAse-free Water (Life Technologies, 10977035) 
 Water HPLC (Fisher Scientific, 1070-6501) 
 XL-10-GOLD competent cell (Agilent Technologies, 220314) 
 Yeast extract powder (Fisher Scientific, 10697612) 
 
2.1.2 Antibodies  
The specificity of antibodies had been established by the lab group using 
corresponding siRNAs. Primary antibodies for western blotting (WB) were 
purchased from Cell Signaling Technology (CST) unless otherwise indicated.  
 Actin goat pAb (Santa Cruz Biotechnology, CK1705)  
 Akt rabbit pAb (Merck, 07-416) 
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 Cyclooxygenase-2 (COX2) (CX229) mouse mAb (Cayman Chemical, 160112) 
 EGFR rabbit pAb (2232) 
 EIF2α rabbit pAb (9722) 
 ERK1/2 (K-23) rabbit pAb (Santa Cruz Biotechnology, C2410)  
 Flag (M2) mouse mAb (Sigma, F3165) 
 GCN2 rabbit pAb (3302) 
 Glutathione peroxidase 1 (GPX1) goat pAb (Biotechne, AF3798)  
 Glutathione peroxidase 2 (GPX2) (496010) mouse mAb (Biotechne, MAB5470)  
 Glutathione peroxidase 3 (GPX3) goat pAb (Biotechne, AF4199-SP)  
 Glutathione peroxidase 4 (GPX4) (EPNCIR144) rabbit mAb (Abcam, ab125066) 
 GST (B-14) mouse mAb (Santa Cruz Biotechnology, sc-138)  
 Hemagglutinin (HA)-tag (6E2) mouse mAb (2367)  
 MAP4K3 rabbit (Institute of Cancer Research, London, U.K.)  
 mTOR (7C10) rabbit mAb (2983)  
 Myc-tag (9E10) mouse mAb (Cedarlane/Millipore, 05-419)  
 NADPH oxidase 1 (NOX1) rabbit pAb (Abcam, ab55831) 
 NADPH oxidase 4 (NOX4) (N3C3) rabbit mAb (Abcam, ab133303) 
 Phospho-Ser15 p53 rabbit pAb (9284) 
 Phospho-Ser51 eIF2α (D9G8) rabbit mAb (3398) 
 Phospho-Ser170 MAP4K3 goat (Ctiakrks Figtpy)  
 Phospho-Ser473 Akt (11E6) rabbit mAb (9271) 
 Phospho-Thr147 PLD1 rabbit pAb (3831)   
 Phospho-Thr202/Tyr204 ERK (D13.14.4E) rabbit mAb (4370)  
 Phospho-Thr359 p90RSK (D1E9) rabbit mAb (8753) 
 Phospho-Thr389 p70S6 Kinase rabbit pAb (9205) 
 Phospho-Thr899 GCN2 rabbit pAb (Cedarlane/Epitomics, 2425-1) 
 Phospho-Tyr1068 EGFR (D7A5) rabbit mAb (3777) 
 p53 (DO-1) mouse mAb (Merck, MABE327) 
 PLD1 (F-12) mouse mAb (Santa Cruz Biotechnology, sc-28314) 
 S6K1 (16/p70) mouse mAb (BD Transduction Laboratories, 611261) 
 RagA (D8B5) rabbit mAb (4357)  
 RagC (D8H5) rabbit mAb (9480) 
 Rheb (3H6) mouse mAb (Institute of Cancer Research, London, U.K.)  
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 RSK1/RSK2/RSK3 (32D7) rabbit mAb (9355) 
 TSC2 (D93F12) rabbit mAb (4308) 
 
Primary antibodies for immunofluorescence (IF) staining were purchased from CST 
unless otherwise indicated. 
 HA-tag (6E2) mouse mAb (2367)  
 Hoechst fluorescent DNA dye (4082) 
 LAMP2 (H4B4)  mouse mAb (Abcam, ab25631) 
 LAMP2 (GL2A7) rat mAb (Abcam, ab13524) 
 mTOR (7C10) rabbit mAb (2983)  
 PLD1 (F-12) mouse mAb (Santa Cruz Biotechnology, sc-28314) 
 RagC (D8H5) rabbit mAb (9480) 
 Rheb (3H6) mouse mAb (Institute of Cancer Research, London, U.K.)  
 RhoA (1B12) mouse mAb (Abnova, H00000387-M04) 
 TSC2 (D93F12) rabbit mAb (4308) 
 
Secondary antibodies for WB were purchased from Fisher Scientific. 
 Goat anti-rabbit IgG, HRP conjugate (31460) 
 Goat anti-mouse IgG, HRP conjugate (31430) 
 Rabbit anti-goat IgG, HRP conjugate (31402) 
 Rabbit anti-sheep IgG, HRP conjugate (31480) 
 
Secondary antibodies for IF were purchased from Invitrogen. 
 Alexa Fluor 488 goat anti-mouse IgG (A11029)  
 Alexa Fluor 546 goat anti-mouse IgG (A11030)  
 Alexa Fluor 594 goat anti-mouse IgG (A11032)  
 Alexa Fluor 488 goat anti-rabbit IgG (A11034)  
 Alexa Fluor 555 goat anti-rabbit IgG (A21429)  
 Alexa Fluor 488 goat anti-rat IgG (A11006)  
 Alexa Fluor 546 goat anti-rat IgG (A11081)  
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Antibody-coupled agarose beads Flag M2 (A2220), glutathione (G4510), HA 
(A2095) and protein G (11243233001) for immunoprecipitation (IP) were purchased 
from Sigma.  
2.1.3 Molecular cloning enzymes 
DNA polymerases Q5 (M0493S) and OneTaq (M0481S) were purchased from New 
England BioLabs (NEB), and Pfu (M7741) was purchased from Promega. 
Restriction enzymes AgeI (R3552S), BamHI (R3136S), DpnI (R0176S), EcoRI 
(R3101S), HindIII (R3104S), KpnI (R3142S), NotI (R3189S), SmaI (R0141S), SalI 
(R3138S), XbaI (R0145S), XhoI (R0146S) and XmaI (R0180S) were purchased 
from NEB. 
 
2.1.4 Antibiotics  
Gentamicin (G1397), ampicillin (A9518) and kanamycin (60615) were purchased 
from Sigma. They were prepared in ddH2O at 50mg/ml, filtered through a 0.22μm 
membrane filter for sterilization, stored at -20°C, and used at 1:1000 dilution for 
bacterial culture selection. 
 
2.1.5 Kinase inhibitors  
Kinase inhibitors were prepared in DMSO and stored at -20°C. Final concentration 
in the culture media for each inhibitor is shown in Table 3.  
 
Table 2. Kinase inhibitors  
Kinase  Inhibitor  Concentration (µM) Source 
GCN2  
MSC2524505 5 Merck Serono, T0077791 
MSC2526779 5 Merck Serono, T0077794 
mTORC1 Rapamycin 0.1 Millipore, 553210 
EGFR Iressa 1 Tocris, 3000 
PI3K Wortmannin 1 Sigma, W1628 
MEK 
Selumetinib 5 Selleckchem, S1008 
UO126 10 Calbiochem, 109511-58-2 
PD184352 10 Sigma, PZ0181 
PD0325901 1 Selleckchem, S1036 
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ERK 
GDC0994 5 Selleckchem, S7553 
SCH772984 5 Cayman, 942183-80-4 
 
2.1.6 Small interfering RNA (siRNA)  
siRNAs were resuspended in RNase-free siRNA buffer at 20µM. Non-targeting 
siRNA pool control siRNA (D-001206-13), siRNAs targeting human MAP4K3 (D-
003588-05, J-003588-05), RagA (L-016070-00-0005), PLD1 1-2 (custom, 
GCGUCUACAUCCCAACAUAAAUU, CCACUAGAAGACACACGUUUAUU), 
GCN2 1-2 (GGAAAUUGCUAGUUUGUCA, GACCAUCCCUAGUGACUUA) 
were purchased from Dharmacon. Human PLD1 siRNAs 3-5 (SI00686357, 
SI04369316, SI04166134) were purchased from Qiagen. siRNA targeting human 
Rheb (custom, UUUUUCUUCUGUUAACCUGAAdTdT) was purchased from 
Fisher Scientific.  
 
2.1.7 Primers  
Primers were resuspended in ddH2O at 1µg/µl and were designed for mutagenesis of 
human MAP4K3 (sequence is shown in Appendix 1) and for subsequent sequencing. 
Primers were purchased from Sigma and are listed in Appendix 2. 
 
2.1.8 Plasmid constructs  
Plasmids were dissolved in ddH2O and DNA fragments were verified on an agarose 
gel (see 2.1.13). pRK5-Myc, pRK5-Myc-GCN2, pRK5-S6K1-GST, pEGFP-TSC1, 
pRK7-Flag-TSC2, HA-PLD1, pRK5-Flag-MAP4K3, pRK5-Flag-MAP4K3 DA 
(DFG motif to AFG, kinase inactive [108]) were from laboratory storage. Nine 
MAP4K3 point mutations (D54N, V182F, E209G, N290I, E351K, Q473K, T669A, 
D715Y and R753Q) were generated using pRK5-Flag-MAP4K3 as a template and 
using the Site-Directed Mutagenesis Kit (see Methods 2.2.2).  
 
2.1.9 Cell lines  
Mammalian cell lines were used in this study. Hela, human embryonic kidney 
(HEK)293T, mouse embryonic fibroblasts (MEF) wild type, GCN2 knockout, EIF2α 
S51A and TSC2 knockout cell lines, HCT116 wild type and p53 knockout cell lines 
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were from the laboratory storage. The hTERT-HME (human mammary epithelial) 
isogenic cell lines including wild type, EGFR delE746-A750, KRAS G13D, BRAF 
V600E and PI3KCA H1047R [201] were a kind gift from Prof Alberto Bardellia. 
NSCLC cell lines (Table 3) were from the Liverpool cell line repository.  
 
Table 3. NSCLC cell lines 
 Mutations in the MAPK/ERK cascade  or PI3K 
A549 KRAS G12S 
Calu 6 KRAS Q61K  
NCI-NH1650 EGFR delE746-A750, L858R, T790M 
H1975 EGFR L858R, T790M 
H727 KRAS G12V  
H460 KRAS, PIK3CA 
H322 WT 
H3255 EGFR L858R 
PC 9    EGFR delE746-A750 
 
2.1.10 Media  
Media for bacteria growth were prepared in ddH2O and autoclaved at 121°C for 
20min using the liquid cycle. Antibiotics were added appropriately.  
 Lysogeny broth (LB) medium: 10g/l bacto-tryptone, 5g/l yeast extract powder, 
5g/l NaCl. 
 LB agar plates: 7.5g/l agar in LB medium. 
 
Laboratory-formulated media used for media switch treatments were prepared in 
ddH2O, according to the components of commercial media. Both dialysed FBS and 
formulated media were filtered through 0.22μm membrane filters.  
 Dialysed FBS (d.FBS): prepared by dialysing 50ml FBS against SnakeSkinTM 
dialysis membrane 3.5K MWCO in 4L 1X PBS at 4°C with stirring for overnight.  
 Freezing medium: 90% FBS, 10% DMSO. 
 Amino acid (AA)-free DMEM: 8.32g/l of DMEM low glucose, w/o amino acids, 
w/o pyruvic acid powder, 3.5g/l glucose (final concentration was 4.5g/l), 3.7g/l 
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sodium bicarbonate, 1mM sodium pyruvate, 1% Pen strep, pH 7.4, according to 
the USBiological recipe. 10% d.FBS was added prior to use.  
 Individual 50X amino acid solution: amino acids (Sigma) constituting original 
DMEM were formulated individually at 50X concentrations, according to the 
Sigma recipe. 
 AA-free HME medium: AA-free DMEM supplemented with 20ng/ml EGF, 
10μg/ml insulin, and 100μg/ml hydrocortisone. 
 HME complete medium: 50X amino acid solutions were added at 1X 
concentration to AA-free HME medium. 
 Cystine-free HME medium: HME complete medium lacking cystine. 
 
2.1.11 Solutions 
Solutions were prepared in ddH2O and stored at -20°C unless otherwise indicated. 
 Homemade enhanced chemilumescent (ECL) reagents were used for detection of 
horseradish peroxidase (HRP) enzyme activity and the recipes are displayed in 
Tables 5 and 6. Stock solutions of luminol and p-coumaric acid were made in 
DMSO. Equivalent volumes of reagents 1 and 2 were added to the membrane 
prior to detection.  
 
Table 4. Homemade ECL reagent 1 recipe  
Chemicals  Stock  Working 
Luminol 250mM 2.5µM 
P-coumaric acid 90mM 405µM 
Tris-HCl pH 8.5 1M 100µM 
 
Table 5. Homemade ECL reagent 2 recipe 
Chemicals  Stock  Working 
Tris-HCl pH 8.5 1M 100µM 
Hydrogen peroxide 30% 0.018% 
 
 Digitonin was prepared in PBS at 5% as stock solution and used at a final 
concentration of 0.01% in PBS.  
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 4% Paraformaldehyde (PFA) was prepared by dissolving PFA in pre-heated PBS.  
 Okadaic acid (O.A.) is an inhibitor of phosphatases and was used for routine cell 
lysis. Stock solution was 200μM in DMSO and was added at a final 
concentration of 60nM to Jośe buffer (see 2.1.12) prior to use. 
 Metabolite extraction solution: 50% methanol, 30% acetonitrile, 20% water.  
 
2.1.12 Buffers 
Buffers were prepared in ddH2O unless otherwise indicated.  
 Jośe buffer was used to lyse cells. It was stored at -20°C for long-term and 4°C 
for short-term use. The compositions of Jośe buffer are shown is Table 7. 
 
Table 6. Jośe buffer recipe 
 Stock concentration (M) Working concentration (mM) 
Tris-HCl pH 7.6 1 50 
EDTA 0.5 1 
EGTA 0.2 1 
Na3VO4 1 1 
NaF 1 50 
β-GP  1 50 
β-ME (v/v) 100% 0.1% 
Triton X-100 (v/v) 100% 1% 
Sucrose 270 
Complete protease inhibitor cocktail tablets 1 tablet/50ml 
 
 PBST: 0.2% Tween 20 in 1X PBS. 
 10X Tris-glycine buffer: 144g/l glycine, 30g/l Tris, pH 8.4. 
 SDS running buffer: 1X Tris-glycine buffer, 0.1% SDS. 
 Western blot blocking buffer: 5% dried skimmed milk in PBST. 
 Western blot stripping buffer: 62.5mM Tris pH 6.8, 2% SDS. 
 Western blot transfer buffer: 1X Tris-glycine buffer, 20% methanol. 
 Ste20 kinase assay buffer: 20mM Tris-HCl pH 7.2, 25mM β-GP, 5mM EGTA, 
1mM Na3VO4, 0.1% β-ME, 15mM MgCl2 [108].   
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2.1.13 Gel electrophoresis systems 
Two types of gel electrophoresis were used: agarose gel for DNA fragment analysis 
and SDS-PAGE for protein analysis.  
 1% Agarose gel: 1% agarose in TAE buffer was microwaved for 2.5min at 50% 
power to dissolve. Solution was mixed with 0.005% Safeview nucleic acid stain 
and set in the cassette. DNA samples were prepared using 6X DNA loading dye 
and loaded into wells in the agarose gel. An additional well was loaded with 
0.5μg 1kb DNA ladder (NEB). Gels were run at 130V for 40min before 
visualization under ultraviolet (UV) light. 
 SDS-PAGE is a common technique for separation of proteins based on their 
molecular weight. Typically a 10% resolving gel was used. Resolving gel: 3.8ml 
ddH2O, 2ml 40% acrylamide, 2ml 1.5M Tris pH 8.8, 80μl 10% SDS, 80μl 10% 
APS, 8μl TEMED. Stacking gel (6%): 2.9ml ddH2O, 0.75ml 40% acrylamide, 
1.25ml 0.5M Tris pH 6.8, 50μl 10% SDS, 50μl 10% APS, 5μl TEMED. Gels 
were run at 120V for 90-120min.  
2.2 Methods  
Procedures were performed at room temperature unless otherwise indicated.  
 
2.2.1 Bacterial culture  
Bacterial culture was used to amplify plasmid DNA, which were then extracted and 
purified using the Qiagen Kits and used for transfection. Bacterial culture work was 
performed using aseptic techniques.  
 Glycerol stock of bacterial culture: 800μl LB culture was mixed with 200μl 
absolute glycerol, snap frozen in liquid nitrogen and stored at -80°C. 
 Bacterial inoculation: glycerol stock or a single colony was inoculated into LB 
medium containing antibiotic, and the culture was incubated at 37°C with 
shaking at 225 rpm for overnight. 
 Transformation: 30μl chemically competent E. coli were incubated with 5ng 
plasmid for 30min on ice, heat shocked at 42°C for 45sec and immediately 
placed on ice for 2min. Bacteria were resuspended in 900μl SOC medium and 
incubated at 37°C with shaking at 225 rpm for 1 hour before centrifuged at 1,000 
xg for 1min. 800μl supernatant was discarded and pellet was resuspended in the 
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remaining 100μl media, and spread onto LB agar plates containing antibiotics to 
form colonies at 37°C for overnight. 
 
2.2.2 Molecular cloning  
 Site-directed mutagenesis was performed to generate point-mutations of human 
MAP4K3 inserted in the pRK5-Flag vector. Primers were designed to introduce 
intentional mutations, and the protocol of polymerase chain reaction (PCR) in the 
Site-Directed Mutagenesis Kit (Agilent) was followed. PCR reaction was 
conducted at 95°C, 60°C and 68°C in the sequence shown in Appendix 3 for 
denaturation, annealing and extension respectively. Amplification was confirmed 
by running 10µl out of 50µl PCR product on a 1% agarose gel. Mutations were 
verified by DNA sequencing from Source Biosience Company.  
 Plasmid DNA digestion: diagnostic restriction enzyme digestion was performed 
to verify plasmid DNA, based on their molecular weight and conformations. 
Typically 500ng of plasmid DNA were incubated with or without (uncut, control) 
single or double restriction enzymes in compatible buffer at 37°C for 1 hour 
before heat-inactivation at 65°C for 20min and agarose gel analysis. 
 Plasmid DNA isolation: Qiagen plasmid DNA purification kits of miniprep and 
maxiprep were used to analyze bacterial clones and obtain large-scale purified 
plasmid DNA respectively. Purified plasmid DNA was then quantified using 
Nanodrop and verified on an agarose gel. Maxiprep: briefly 500ml LB culture 
was pelleted at 6000 xg for 15min at 4°C and pellets were resuspended in 10ml 
Buffer P1 containing RNase A. Cellular contents were extracted by incubating in 
10ml Buffer P2 for 3min and plasmid DNA was separated from genomic DNA 
and proteins by adding 10ml Buffer N3 and centrifuging at 20,000 xg for 30min 
at 4°C. Supernatant containing plasmid DNA was subjected to column 
purification which selectively binds DNA. Plasmid DNA was then eluted from 
the column by adding 8ml Buffer QF and precipitated by adding 4ml isopropanol 
and incubating at -20°C for 1 hour. DNA pellet was collected by centrifuging at 
15,000 xg for 30min at 4°C and washed twice with 70% ethanol. The pellet was 
then left to air-dry for 10min and dissolved in 300µl ddH2O. Miniprep: briefly 
2ml LB culture was pelleted at 6000 xg for 3min and pellets were resuspended in 
100µl Buffer P1. 100µl Buffer P2 and 150µl Buffer N3 were sequentially added 
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and the resulting mixture was centrifuged at 16,000 xg for 10min. Supernatant 
was transferred into the small column, which was then washed once by adding 
Buffer PE and centrifuging for 1min. DNA was eluted in 50μl warm ddH2O by 
centrifuging for 1min.  
 
2.2.3 Cell culture  
Cell culture flasks were maintained at 37°C in a humidified incubator in an 
atmosphere of 5% CO2-95% air and passaged at a 1:5 ratio using trypsin every 3-5 
days. Fresh culture medium was warmed at 37°C water bath for 30min prior to use. 
Cell culture manipulations were performed in a Class II laminar flow cabinet using 
aseptic techniques. All culture media were supplemented with 10% FBS and 1% Pen 
strep except for HCT116 cell lines. Specifically, Hela, HEK293T and MEF cell lines 
were cultured in DMEM, HME cell lines in DMEM additionally supplemented with 
20ng/ml EGF, 10μg/ml insulin, and 100μg/ml hydrocortisone, and NSCLC cell lines 
in RPMI 1640 medium. HCT116 cell lines were cultured in RPMI 1640 medium 
supplemented with 10% d.FBS.  
 
2.2.4 Media switch treatments 
In order to investigate the effects of amino acid deprivation on protein translocation 
and cell proliferation, all treatment media were supplemented with 10% dialysed 
FBS. Cells were cultured in commercial media containing FBS and amino acids 
prior to media switch treatments. Three types of media switch were performed. 
Differences between treatments were amino acid compositions in media and times of 
treatments.  
 Amino acid deprivation and re-stimulation treatment: cells in duplicate wells 
were washed twice using and incubated in AA-free DMEM medium for 1 or 4 
hours. One of the two wells was stimulated for 15min with minimum essential 
medium (MEM) amino acids by adding 50X MEM amino acid solution 
(Invitrogen) to a final 1X concentration.  
 Amino acid dropout screen for HME cell lines: to deprive individual or all amino 
acids, cells were washed twice using AA-free HME medium and incubated in 
HME complete medium lacking specific amino acid for 72 hours (related to 
Figure 44).  
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 Cystine deprivation treatment for HME cell lines: cells in duplicate wells were 
washed twice using AA-free HME medium, and one was incubated in cystine-
free HME medium and the other one in HME complete medium. Treatment 
times were 12 and 16 hours for FACS and cell viability analysis respectively.  
 
2.2.5 Transient vector transfection  
Lipofectamine 2000 (Invitrogen) was used as a transfection reagent to introduce 
plasmid DNA and siRNA into cells for transient gene overexpression and 
suppression respectively. Briefly, cells were seeded at a required density (300,000 
cells/well for overexpression and 100,000 cells/well for siRNA transfection) in 6-
well plates (the well contained two coverslips when IF staining was required) for 
overnight. For each well, two portions of 250μl DMEM were prepared, with one 
incubated with 5μl lipofectamine 2000 for 5min, and the other mixed with plasmid 
DNA (the amount varied depending on experiment) or siRNA (a final concentration 
of 67pM). The two portions were then mixed and incubated for 40min before 1ml of 
20% FBS was added. Each well was washed once using DMEM medium without 
FBS and antibiotics, and incubated in the 1.5ml transfection mixer for overnight. Pen 
strep was added 1-2 hours post transfection at a final concentration of 1%. Cells 
were harvested the following day for overexpression transfection or switched to 
fresh DMEM medium supplemented with 10% FBS and 1% Pen strep the next day 
and harvested 72 hours post siRNA transfection.  
 
2.2.6 Bradford assay 
Bradford assay is a quick and accurate spectroscopic analytical procedure to 
determine protein concentrations. Cell lysates in Jośe buffer were scraped off plates 
and centrifuged at 16,000 xg for 10min at 4°C. Supernatants were collected and 
concentration of total protein was determined by incubating 1μl of cell lysates with 
200μl Bradford reagent blue dye in a 96-well plate for 1min with vortexing at 600 
rpm and measuring absorbance at A595nm using Spectra Max Plus plate reader with 
the SoftMax Pro 6 software. 1μl  of Jośe buffer and bovine serum albumin (BSA) 
standards made in Jośe buffer at concentrations of 0.25, 0.5, 1, 2, 4, 8μg/μl were 
used for blank and standard curve respectively. Since absorbance was proportional to 
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the amount of bound dye and hence to the amount of protein present, concentrations 
of protein in cell lysates were quantified against the standard curve. 
 
2.2.7 Western blotting 
Western blotting was mostly used in this study to examine protein expression and 
phosphorylation levels. 
 
 SDS-PAGE: typically 20-25μg protein were prepared using 4X LDS sample 
buffer containing 5% β-ME, heated at 97°C for 5min and subjected to SDS-
PAGE resolving. 5μl of protein ladder were loaded on both sides.  
 Electrophoretic transfer enables protein from a gel matrix to bind and be 
transferred to a membrane. The SDS-PAGE gel was assembled with methanol-
activated PVDF membrane in transfer buffer, and transferred at 100V for 1 hour 
at 4°C by wet electroblotting (tank transfer). Membrane was then rinsed with 
ddH2O and stained with Ponseau S solution to detect general protein bands.  
 Immunoblotting: membrane was incubated in blocking buffer for 1 hour with 
shaking prior to incubation with primary antibody in blocking buffer overnight at 
4°C with rotating. Membrane was then washed for 15min in PBST and incubated 
with secondary antibody in blocking buffer for 1 hour, followed by wash in 
PBST for 30-60min.  
 Detection: membrane was incubated with ECL solutions for 2min. Protein bands 
were visualized using the x-ray films or Bio-Rad ChemiDoc Imager. 
 Membrane stripping for re-probing: membrane was incubated in stripping buffer 
containing fresh 0.7% β-ME at 60°C for 25-30min.  
 
2.2.8 Immunoprecipitation (IP) 
Immunoprecipitation (IP) was used to examine interactions between proteins. Briefly 
800,000 HEK293T cells/dish in 60mm dishes were transfected with plasmid DNA 
containing an HA or Flag tags, and lysed in 500μl Jośe buffer 40 hours post 
transfection. Tagged protein was purified by incubation of cell lysates with HA or 
Flag-agarose (alternatively protein G-agarose and HA or Flag antibodies) for 2-4 
hours at 4°C with rotating, and beads were washed three times with Jośe buffer 
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containing 0.5M LiCl. Plasmids used for different IP experiments are listed in Table 
8. 
 
Table 7. Transfection conditions for IP  
IP antibodies  Plasmid DNA  Amounts (μg)/dish  
HA 
pRK5-Flag MAP4K3 WT or DA 2.5 
HA-PLD1 0.25 
Flag 
pRK5-Myc-GCN2 2 
pEGFP-TSC1 2 
pRK7-Flag-TSC2 4 
 
2.2.9 S6K1 reporter assay  
800,000 HEK293T cells/well in 6-well plates were transfected with 2.5μg pRK5-
Myc vector (mock), pRK5-Flag-MAP4K3 wild-type (WT), kinase-inactive (DA) or 
the nine pRK5-Flag MAP4K3 mutant constructs (see 2.1.8), co-transfected with 
100ng pRK5-S6K1-GST. 24 hours post transfection, two mock transfected wells 
were switched to DMEM lacking FBS (serum starvation) for 16 hours, and one was 
re-stimulated with FBS at a final concentration of 10% for 30min before cell lysis.  
 
2.2.10. In vitro kinase assay 
2000,000 HEK293T cells/dish in 60mm dishes were transfected with 8μg pRK5-
Flag MAP4K3 WT, DA or mutations, and lysed in 500μl Jośe buffer 40 hours post 
transfection. Flag-tagged MAP4K3 was isolated using the Flag-IP procedure and 
washed once with Ste20 kinase assay buffer prior to kinase assay. The kinase assay 
was performed at 30°C in 50μl kinase buffer supplemented with 100μM ATP, 3μCi 
of [γ-32P]ATP and 5μg of myelin basic protein (MBP), and terminated after 30min 
by adding 2X LDS sample buffer [108]. Samples were subjected to SDS-PAGE and 
transfer, and 32P incorporated into MBP and MAP4K3 (autophosphorylation) were 
detected by x-ray films. 
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2.2.11 Immunofluorescence (IF)  
Cells on coverslips were fixed in 4% PFA for 15min, permeabilized in 0.01% 
digitonin for 10min and blocked with 10% goat serum in PBS for 30min, prior to 
sequential incubation with primary and secondary antibodies for 1 hour. Coverslips 
were washed in PBS for 15min with shaking before and after secondary antibody 
incubation, and once with ddH2O prior to mounting onto slides with mounting 
medium. Confocal immunofluorescence micrographs were acquired using the 3i 
Marianas fluorescence microscope with SlideBook 6 software. Identical exposure 
times were used for comparative analysis. The co-localization efficiency was 
quantified from 20-50 cells using the software ImageJ Just Another Colocalisation 
Plugin (JACoP). 
 
2.2.12 Intracellular amino acid extraction  
5,000,000 wild type and EGFR mutant HME cells/dish were seeded in seven 100mm 
dishes. On the third day cells were washed twice with DPBS and three dishes of each 
cell line were incubated in cystine-free and complete HME media for 4 hours. Cells 
in the last dish were trypsinized and counted, and the cell count was used to calculate 
the volume of extraction solution so that the final cell concentrations in the 
extraction solution were around 1,000,000 cells/ml. Cells were washed three times 
with cold PBS and incubated with extraction solution for 5min at 4°C with shaking. 
The extraction solution containing cells was collected into eppendorf tubes, shaken 
in Thermomixer (Eppendorf AG) at 1,400 rpm for 10min at 4°C to extract 
intracellular metabolites, and centrifuged at 16,000 xg for 10min at 4°C to 
precipitate any proteins present. The supernatants were transferred into glass HPLC 
vials and stored at -80°C prior to liquid chromatography-mass spectrometry (LC-
MS) quantification of free amino acids, which was conducted by Dr Christiaan 
Labuschagne at the University of Glasgow (related to Figure 47).   
 
2.2.13 Cell viability assay 
Cell viability was determined using the CellTiter-Glo assay (Promega) that uses ATP 
as an indicator of metabolic active cells. ATP is a co-factor of the luciferase reaction 
and the resulting luminescence is proportional to the amount of ATP present, which 
is an indicator of cellular metabolic activity. Briefly 50,000 cells/well in triplicate 
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wells in a 96-well plate (NUNC, Thermofisher) were mixed with 20μl medium (the 
medium used for cell treatment) and 20μl CellTiter-Glo reagent (mixture of 
CellTiter-Glo buffer and substrate) for 2min with shaking at 1,000 rpm to allow cell 
lysis. Plates were incubated for another 10min on bench to stabilize luminescent 
signal and the emitted luminescence was then detected using a plate reading 
luminometer (Tecan Genios). Three additional wells containing medium and reagent 
without cells were used to obtain a value for background luminescence.  
 
2.2.14 Flow cytometry (FACS analysis) 
The level of cellular lipid ROS was quantified using the C11-BODIPY581/591 dyes 
which is a lipid peroxidation sensor, and using flow cytometry. 200,000 cells/well 
were seeded in a 6-well plate and switched to cystine-free or complete HME media 
for 12 hours prior to flow cytometry analysis. Following cystine deprivation, cells 
were washed once with PBS and sequentially incubated with 2μM C11-
BODIPY581/591 dyes in DPBS for 30min, trypsinized with 0.25% Trypsin-EDTA 
and resuspended in PBS containing 1% FBS. Resuspended cells were collected into 
1.5ml eppendorf tubes and analysed using the Attune NxT flow cytometer (Thermo 
Fisher). A minimum of 5,000 cells were loaded and the dyes were excited using a 
blue 488nm laser, and emission was recorded on channel BL1 (530/30).  
 
2.2.15 Statistical analysis  
The ImageJ software was used to quantify immunoblotting bands, and ImageJ 
JACoP to quantify the percentage of co-localization [202, 203]. Images of 
immunoblots, phase-contrast and IF confocal microscopy, are representative of at 
least two independent experiments. Quantification data were analyzed using 
Microsoft Excel and are presented as mean values ± standard error of the mean 
(SEM) of three biological replicates. Statistical significance was set at p<0.05 and p 
value was calculated using two-tailed Student’s T test.  
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Chapter 3 
                                                 Results    
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Chapter 3-Results  
3.1 Mechanisms involved in amino acid regulation of mTORC1 
The mTORC1 signalling pathway coordinates various environmental signals to 
control cell growth via regulating synthesis of proteins, lipids and nucleotides, as 
well as the catabolic process autophagy [46]. Activation of mTORC1 is promoted by 
the Rheb GTPase and is associated with translocation to late-endosomal/lysosomal 
membrane [88, 95]. S6K1 is the critical downstream effector of mTORC1 and 
phosphorylation of S6K1 on residue Thr389 by mTORC1 stimulates the activation 
of S6K1, which then promotes the synthesis of the enumerated macromolecules [68, 
71, 73]. TSC2, by deactivating GTP-bound Rheb which is the crucial activator of 
mTORC1, functions as the master inhibitor of the mTORC1 signalling [84]. Among 
all of the growth-promoting stimuli, amino acids seem to be indispensable for 
mTORC1 activation [46]. In the presence of amino acids, mTORC1 translocates to 
lysosomal membrane, which allows it to be activated by GTP-bound Rheb; whilst 
upon amino acid removal, mTORC1 is released from lysosomes and becomes 
inactive [95, 97]. In contrast to mTORC1, TSC2 complexed with TSC1 and 
TBC1D7 has been found to associate with lysosomes under the condition of amino 
acid deficiency and becomes cytosolic when amino acids are present [99]. 
Recruitment of mTORC1 and TSC2 appears to be mediated by the Rag GTPase 
heterodimer (RagA/B-RagC/D) [96, 97], however, the exact mechanisms of their 
lysosomal translocation and dissociation remain elusive. The aim of the studies 
presented in this section was to investigate the molecular mechanisms underlying 
TSC2 subcellular localization by exploring recent findings on the Rag GTPases.  
 
3.1.1 GCN2 inhibits mTORC1 potentially by regulating TSC2 lysosomal 
translocation 
 
3.1.1.1 GCN2 promotes TSC2 lysosomal translocation  
To identify mediators of TSC2 subcellular localization, Dr Richard Lamb and his 
colleagues in Dr Chris Bakal’s group at the Institute of Cancer Research have 
performed a high-throughput quantitative cell imaging siRNA screen of around 975 
protein kinases/phosphatases in Hela cells under normal-nutrient and amino acid-
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deprived conditions (Figure 25). This screen revealed an array of potential regulators 
of TSC2 lysosomal localization, among which GCN2 kinase (red box in Figure 25C) 
was of particular interest in that it is known to sense amino acid deficiency and 
repress protein synthesis.  
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Figure 25. Image-based screening for regulators of TSC2 subcellular 
distribution.  
A. Hela cells were transfected with a siRNA library targeting all human kinases in 
four equal replicates on 384-well plates. After 48h two of the four replicates were 
washed in PBS and switched to reconstituted DMEM media with 10% d.FBS either 
containing or lacking amino acids (AA) for 1 hour, and stained against nuclear, 
TSC2 and LAMP2 (a lysosome marker). Confocal microscope images were 
sequentially acquired and simultaneously analyzed using Acapella 2.5 software 
(PerkinElmer). B. Examples of images acquired from A. Panel 1, nuclear channel; 
panel 2, TSC2 channel; panel 3, filtering of incomplete, border cells, mitotic cells, 
late apoptotic cells and artefacts based on morphological properties of the initially 
segmented cells, and out-of-focus objects; panel 4, segmentation of lysosomes; panel 
5, systematic morphological profiling of lysosomes; panel 6, gathering of basic 
phenotypic parameters and calculation of TSC2 lysosome/cytoplasmic ratio based on 
panel 4. C. Normalizations/ranking calculations of TSC2 lysosome/cytoplasmic ratio. 
EIF2AK4/GCN2 kinase (red box) is one of the candidates that potentially regulate 
the lysosomal localization of TSC2. Z score shows normalized percentage of TSC2-
lysosome co-localization. Experiments shown in this figure were performed by Drs 
Richard Lamb and Chris Bakal’s group at The Institute of Cancer Research.   
 
In order to investigate whether GCN2 regulates TSC2 lysosomal localization in 
response to amino acid deprivation, GCN2 was knocked-down in Hela cells using 
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two independent siRNAs targeting GCN2 (GCN2 siRNA1 and 2, distinct from those 
used in the screen) and the effects on TSC2 lysosomal localization was examined 
using a rabbit monoclonal antibody (TSC2 clone D93F12 from CST) that 
specifically recognizes the endogenous TSC2 and also a mouse monoclonal antibody 
(LAMP2, clone H4B4 from Abcam) that detects LAMP2 (lysosomal associated 
membrane protein 2), a marker of late-endosomes/lysosomes (henceforward referred 
to as lysosomes) [85]. Hela cells were treated with medium lacking amino acid (-AA) 
for 30min following siRNA transfection and were then fixed and stained with the 
two antibodies and the corresponding fluorescently-labelled anti-rabbit and anti-
mouse secondary antibodies for co-localization analysis. The staining results were 
captured using a confocal microscope and the individual monochrome (grey) and 
merge (green and red) micrographs were displayed in Figure 26A. The efficiency of 
TSC2-lysosome co-localization was quantified from the confocal micrographs using 
the software ImageJ the Just Another Colocalisation Plugin (JACoP) and was 
displayed in Figure 26B. As shown in Figure 26A, TSC2 (stained in green) rapidly 
accumulated on lysosomes (stained in red) within 30min following amino acid (AA) 
withdrawal in cells transfected with control (Ctrl) siRNA. The co-localization of 
TSC2 with lysosomes was demonstrated by the yellow clusters in the merge channel, 
which were eliminated in cells transfected with GCN2 siRNAs. The quantification 
results were consistent with the image data, showing that knockdown of GCN2 
remarkably decreased the co-localization of TSC2 with lysosomes under the 
condition of amino acid withdrawal, to a similar extent in the control group (Ctrl 
siRNA) cultured in medium containing amino acids (+AA). These results suggested 
that GCN2 was required for TSC2 lysosomal localization and were in agreement 
with the siRNA screen data.  
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Figure 26. GCN2 promotes TSC2 lysosomal translocation upon amino acid 
removal.  
Hela cells were subjected to amino acid deprivation (-AA) for 30min following 
transfection with control (Ctrl) or two GCN2-specific siRNAs. A. Monochrome 
(grey) and merge confocal immunofluorescence (IF) micrographs of cells stained 
with antibodies detecting endogenous TSC2 (green) and LAMP2 (red). B. Co-
localization analysis of TSC2 with lysosomes. Y-axis represents the percentage of 
LAMP2-positive TSC2 over the total TSC2. Experiments displayed in this figure 
were performed by Drs Richard Lamb and Rebecca Lamond.  
 
3.1.1.2 GCN2 promotes inhibition of mTORC1 in response to amino acid 
deprivation 
Following data showing that GCN2 positively regulates TSC2-lysosome 
translocation, which is critical for mTORC1 inhibition, we asked if GCN2 
contributes to mTORC1 inactivation upon amino acid removal. We firstly tested 
whether GCN2 activation induced by amino acid depletion correlates with down-
regulation of mTORC1 activity in Hela cells (Figure 27A). Hela cells were treated 
with medium lacking amino acids (-AA) for different times from 5min up to 30min 
(left panel) or for 10min followed by amino acid re-addition for up to 15min (right 
panel). Cell lysates were analyzed by western blot and the activity of GCN2 and 
mTORC1 was indicated by auto-phosphorylated Thr899 of GCN2 (pGCN2 T899) 
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and mTORC1-phosphorylated Thr389 of S6K1 (pS6K1 T389), respectively. The 
level of total GCN2 and S6K1 was also analyzed so that the relative activity under 
different conditions was comparable. Upon amino acid withdrawal (-AA), inhibition 
of mTORC1 activity was seen in HeLa cells as soon as within 10min, with a 
complete inhibition after 30min, as demonstrated by S6K1 phosphorylation on 
Thr389 (left panel). The decreased mTORC1 activity caused by amino acid 
deprivation for 10min was restored immediately by adding amino acids back for 2 
minutes (right panel). In contrast, GCN2 was rapidly activated and auto-
phosphorylated on Thr899 following removal of amino acids (within 10min) and the 
activity was significantly reduced within re-addition of amino acids for 2min after 
deprivation for 10min (right panel), suggesting an immediate response of GCN2 
activation to amino acid deprivation. Thus, the activation of mTORC1 and GCN2 is 
respectively regulated by the presence and absence of amino acids.  
 
Whether GCN2 was required for mTORC1 inhibition was then examined in GCN2 
wild-type (WT) and knockout (KO) MEF (mouse embryonic fibroblasts) cells 
(Figure 27B). The level of S6K1 phosphorylation on T389 was barely detectable 
following deprivation of leucine (-Leu), arginine (-Arg) or all amino acids (-AA) for 
30 minutes in control MEF cells (GCN2 WT), and was significantly increased by re-
addition of leucine (+Leu), arginine (+Arg) or MEM (minimum essential medium) 
amino acids (+AA) for 30 minutes. However, this pattern that mTORC1 activity was 
inhibited in response to amino acid deprivation has disappeared in cells lacking 
GCN2. mTORC1 became constitutively active and unresponsive to amino acid 
deprivation in GCN2 KO cells, suggesting an inhibitory function of GCN2 on 
mTORC1 activity. Together, these data demonstrated that GCN2, potentially by 
regulating TSC2 lysosomal localization, acts as an upstream inhibitor of the 
mTORC1 signalling pathway in response to amino acid depletion.  
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Figure 27. GCN2 senses amino acid deficiency and inhibits mTORC1 
activation.  
A. Amino acid deprivation activates GCN2. Immunoblot analysis of lysates from 
Hela cells treated with amino acid-free (-AA) medium for up to 30min (left panel) or 
for 10min followed by amino acid re-addition for up to 15min (right panel). 
Immunoblots were probed with antibodies detecting auto-phosphorylated Thr899 of 
GCN2 (pGCN2 T899) and phosphorylated Thr389 of S6K1 (pS6K1 T389), as well 
as detecting total GCN2 and S6K1. B. GCN2 is required for mTORC1 inactivation 
following amino acid deprivation. GCN2 wild type (WT) and knock out (GCN2 KO) 
MEF cells were treated with media lacking amino acids (-AA), leucine (-Leu) or 
arginine (-Arg) for 30min, or were deprived and stimulated with MEM amino acids 
(+AA), leucine (+Leu) or arginine (+Arg) for 30min. Immunoblots were probed for 
pS6K1 T389, total S6K1 and GCN2. Experiments displayed in this figure were 
performed by Dr Richard Lamb’s group at University of Alberta. 
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3.1.1.3 The kinase activity is required for GCN2 to regulate TSC2 localization  
We further examined whether the kinase activity of GCN2 was required for TSC2 
lysosomal translocation using two recently developed GCN2-specific inhibitors 
(Merck Company). One of the GCN2 siRNAs used in the experiment displayed in 
Figure 26 was also used in this experiment to serve as a positive control for the 
disruption of TSC2 lysosomal translocation (Figure 28). Control siRNA transfected 
Hela cells were pre-treated with GCN2 inhibitors for 30min and switched to medium 
lacking amino acids for 60min in the continued presence of inhibitors (GCN2 
inhibitor 1 and 2). The inhibition of GCN2 activity by the specific inhibitors was 
confirmed by western blot analysis showing the disappearance of auto-
phosphorylated GCN2 (Figure 28A, pGCN2 T899). Likewise, the level of total 
GCN2 was much lower in cells transfected with GCN2 siRNA, confirming the 
decent level of suppression. As shown in Figure 28B, TSC2 (stained in green) 
displayed a diffused pattern in the presence of amino acids in control siRNA 
transfected cells, and switched to a lysosome-associated pattern upon amino acid 
deprivation as demonstrated by the yellow clusters in the merge channel (Ctrl siRNA 
-AA). Consistent with the previous experiment (Figure 26), TSC2-lysosome 
association was diminished in cells transfected with GCN2 siRNA (Figure 28 B and 
C, GCN2 siRNA, –AA). The GCN2 inhibitor treatment has decreased TSC2-
lysosome association to similar extents, suggesting that kinase activity of GCN2 
seemed to be required for regulation of TSC2 lysosomal localization. Since eIF-2α is 
the only known substrate of GCN2, GCN2 might regulate the TSC2 lysosomal 
translocation through eIF-2α. The different patterns of GCN2 auto-phosphorylation 
affected by amino acid conditions in Figure 28A and Figure 27A might be due to 
different times of amino acid deprivation treatment. GCN2 autophosphorylation 
somehow appeared decreased following amino acid deprivation for 1 hour in Figure 
28A. 
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Figure 28. GCN2 activity is required for TSC2 translocation to lysosomes. 
Control (Ctrl) or GCN2-specific siRNA transfected Hela cells were washed in DPBS 
and switched to reconstituted DMEM media with 10% d.FBS lacking amino acids 
for 60 minutes (-AA), or deprived and stimulated with MEM amino acids for 30min 
(+AA). For inhibitor treatment, Ctrl siRNA transfected cells were pre-treated with 
5μM GCN2-specific inhibitors 1 and 2 for 30 minutes prior to amino acid 
deprivation/stimulation in the continued presence of inhibitors. A. Immunoblots of 
cell lysates probed for pGCN2 T899, total GCN2 and ERK1/2 as a loading control. 
B. Confocal immunofluorescence micrographs of cells stained to TSC2 (green) and 
LAMP2 (red). Images in the merge channel are amplified from areas in the white 
dotted boxes in the monochrome images to display more details. C. Quantitative 
analysis of co-localization of TSC2 with LAMP2-positive lysosomes. Y-axis 
represents the percentage of LAPM2-positive TSC2 over the total TSC2. 
 
3.1.1.4 GCN2 regulates TSC2 translocation to lysosomes independently of eIF2α 
The data presented above support a model whereby GCN2 inhibits mTORC1 
signalling potentially through regulating the lysosomal translocation of TSC2, and 
the kinase activity of GCN2 seems to be required for the regulation. We therefore 
asked whether eIF2α, the only known substrate of GCN2 kinase [116, 204], 
mediated the effect of GCN2 on TSC2 translocation. GCN2 controls translational 
repression via phosphorylation of the initiation factor eIF2α on Ser51, which was 
found to correlate with decrease in tRNA charging resulting from amino acid 
deprivation [205]. To determine whether GCN2 was affecting TSC1/2 via similar 
mechanism, we examined TSC2 translocation in MEF cells expressing a non-
phosphorylatable knock-in mutant of eIF2α, eIF2α S51A where serine at position 51 
was substituted by alanine [118]. As shown in Figure 29A, TSC2 was diffused in the 
99 
 
 
presence of amino acids (+AA) in all the four MEF cells lines, GCN2 wild type, 
eIF2α wild type, GCN2 knockout and eIF2α S51A, in a pattern that was not 
concentrated on lysosomes. Following amino acid deprivation (-AA), TSC2 
accumulated on lysosomes in three cell lines, GCN2 wild type, eIF2α wild type and 
eIF2α S51A, but not GCN2 knockout (Figure 29B). Surprisingly, eIF2α S51A did 
not reduce the TSC2-lysosome association under the condition of amino acid 
deprivation, in contrast to that in GCN2 knockout cells, suggesting that GCN2 
regulates TSC2 lysosomal translocation independently of eIF2α phosphorylation. 
Therefore, there are likely to be other cellular substrates of the GCN2 kinase that 
might play a role in mediating TSC2 lysosomal translocation.  
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Figure 29. GCN2 regulates TSC2 lysosomal translocation independently of 
eIF2α.  
Four MEF cells lines, GCN2 wild type, eIF2α wild type, GCN2 knockout and eIF2α 
S51A were treated with normal medium (A.) or medium lacking amino acids (B.) for 
4 hours. A and B. Confocal immunofluorescence micrographs of MEF cells stained 
to TSC2 (green) and LAMP2 (red). C. Quantitative analysis of co-localization of 
TSC2 with LAMP2-positive lysosomes in the absence (-AA) or presence (+AA) of 
amino acids. Y-axis represents the percentage of LAPM2-positive TSC2 over the 
total TSC2. Experiments displayed in this figure were performed by Drs Richard 
Lamb and Rebecca Lamond. 
 
3.1.1.5 TSC2 is unlikely a substrate of GCN2 
We then examined whether TSC2 itself was a substrate of GCN2 via co-
immunoprecipitation (co-IP) of extracts from HEK293T cells simultaneously 
overexpressing myc-GCN2, Flag-TSC2 and GFP-TSC1. As shown in Figure 30, 
although TSC1 was pulled down with Flag-IP, no GCN2 was detected in the IP 
samples, demonstrating that TSC2 does not interact with GCN2 or their interaction is 
too weak that had been interrupted during the lysis and IP procedures.  
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Figure 30. GCN2 does not interact with TSC2.  
HEK293T cells were simultaneously transfected with plasmids containing Myc 
tagged GCN2, GFP tagged TSC1 and Flag tagged TSC2, and pre-treated with the 
vehicle control DMSO or GCN2 inhibitors for 30min prior to amino acid deprivation 
(-AA) for 20min in the continuous presence of the inhibitors. Cell lysates were 
subjected to Flag-IP and subsequent immunoblots probed with antibodies against 
Myc, GFP and Flag.  
 
3.1.2 RagA and Rheb promotes TSC2 lysosomal translocation  
It has been demonstrated that Rheb and the Rag GTPases are required for 
recruitment of TSC2 to the lysosomal surface [90, 99], we wanted to examine 
whether this was repeatable in our cell culture system. Hela cells were subjected to 
amino acid deprivation treatment following transfection with siRNAs designed to 
target human Rheb and RagA. The suppression efficiency by siRNAs was confirmed 
by immunoblot analysis (Figure 31A) and the effects on TSC2-lysosome co-
localization was analyzed by immunofluorescence staining. Indeed, suppression of 
Rheb or RagA resulted in a diffused and non-lysosomal pattern for TSC2 
localization in Hela cells deprived of amino acids for 1 hour, in contrast to that in 
control siRNA transfected cells (Figure 31B). The co-localization efficiencies of 
TSC2 with lysosomes, as demonstrated in the quantification analysis in Figure 30C, 
were considerably reduced following suppression of Rheb or RagA. Therefore, both 
Rheb and RagA are required for TSC2 to localize on lysosomes. 
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Figure 31. Rheb and RagA promote TSC2 translocation to lysosomes.  
Hela cells were treated with medium lacking amino acids (-AA) for 60min or 
deprived and stimulated with MEM amino acids for 30min (+AA) following 
transfection with siRNAs that target none (Ctrl), human GCN2, Rheb or RagA. A. 
Immunoblots of cell extracts probed with antibodies to GCN2, Rheb and RagA. B. 
Confocal immunofluorescence micrographs of cells stained with antibodies to TSC2 
(green) and LAMP2 (red). C. Quantitative analysis of co-localization of TSC2 with 
LAMP2-positive lysosomes. Y-axis represents the percentage of LAPM2-positive 
TSC2 over the total TSC2. 
 
3.1.3 TSC2 preferentially binds RagC  
Recruitment of mTORC1 and TSC2 to lysosomal membrane seems to be mediated 
through their interaction with the Rag GTPase heterodimer [95, 99]. Hence, we 
sought to investigate whether TSC2 interacted with Rag GTPases and which Rag 
GTPase via GST pull down assay. As shown in Figure 32, GST-tagged RagC alone 
or the RagA/C heterodimer, but not RagA alone, co-immunoprecipitated with 
endogenous TSC2 in HEK293T cells following amino acid deprivation (-AA) for 
60min. To verify that the interaction of TSC2 with Rag GTPase was specific, we 
have used a control protein, Rap2A that also belongs to the Ras-related small G 
protein family, and it did not bind TSC2. In addition, the interaction of TSC2 with 
RagC and RagC/RagA heterodimer seemed to decrease following re-addition of 
amino acids (+AA) for 30min. Therefore, it is likely that RagC interacts with TSC2 
and recruits it to lysosomal membrane in response to amino acid deprivation.  
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Figure 32. TSC2 preferentially interacts with RagC.  
GST pull down assay of extracts from HEK293T cells treated with medium lacking 
amino acid for 60min (-AA) or deprived and stimulated with MEM amino acids for 
30min (+AA) following transfection with plasmids containing GST tagged proteins 
as indicated on the top. Immunoblots were probed with antibodies detecting 
endogenous TSC2, GST tagged RagC, RagA and the control protein Rap2A. The 
molecular weights of these proteins are indicated in the brackets. Experiment 
displayed in this figure was performed by Drs Richard Lamb and Rebecca Lamond.  
 
3.1.4 Rheb does not associate with lysosomes 
We next investigated if endogenous Rheb itself associated with lysosomes using an 
antibody verified as specifically detecting Rheb (clone 3H6, mouse monoclonal 
antibody that was generated at Institute of Cancer Research) by immunofluorescence. 
The specificity of this antibody had been established using the Rheb siRNAs. 
However, although TSC2 associated with lysosomes following amino acid depletion 
(Figure 33A, -AA), Rheb does not exhibit lysosomal localization in the presence or 
absence of amino acids (Figure 33B, +AA and -AA), in a similar pattern with that of 
RhoA, a cytosolic GTPase (Figure 33C).  
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Figure 33. Rheb does not associate with lysosomes.  
Confocal immunofluorescence analysis of TSC2, Rheb and RhoA localization in the 
absence (-AA, 60min) or presence (+AA, 30min) of amino acids in Hela cells. TSC2, 
Rheb and RhoA were stained in green in panel A, B and C respectively and LAMP2 
in red. D. Quantitative analysis of co-localization of TSC2 with LAMP2-positive 
lysosomes. Y-axis represents the percentage of LAPM2-positive TSC2 over the total 
TSC2. Experiments displayed in this figure were performed by Drs Richard Lamb 
and Rebecca Lamond.  
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3.1.5 Rheb promotes lysosomal localization of mTOR and RagC  
The data presented so far suggest that amino acid deficiency-induced translocation of 
TSC2 to lysosomes requires both Rheb and RagA, whilst TSC2 appears to bind 
preferentially to RagC. In addition, the sub-cellular localisation of Rheb is found to 
be cytoplasmic. Based on these findings, it is possible that Rheb promotes the 
association of the TSC2 with lysosomes indirectly by affecting the lysosomal 
localisation of the Rag GTPases. To investigate whether Rheb played a role in the 
lysosomal localization of RagC, Rheb was suppressed in HeLa cells using siRNA 
and the resulting co-localization of RagC/mTOR was analyzed by 
immunofluorescence staining. As shown in Figure 34A, suppression of Rheb led to a 
dramatic reduction of mTORC1 activity as demonstrated by the ratio of relative 
pS6K1 T389 to total S6K1, which is in support of Rheb being the critical activator of 
mTORC1. In control siRNA transfected cells, mTOR accumulated on lysosomes 
under normal nutrient condition (+AA) and dissociated from lysosomes upon amino 
acid withdrawal (-AA) (Figure 34B and C), as expected. In contrast, RagC was 
localised on lysosomes under both conditions (+AA and –AA) (Figure 34D and E). 
Interestingly, neither mTOR nor RagC accumulated on lysosomes following 
suppression of Rheb (Figure 34B. D and E). The quantitative analysis (Figure 34F) 
accords with the confocal micrographs data, demonstrating that Rheb regulates 
lysosomal localization of both mTOR and RagC. In addition, the reduction of 
mTORC1 activity caused by suppression of Rheb is consistent with dissociation of 
mTOR from lysosomes following Rheb suppression.  
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Figure 34. mTOR and RagC localize with lysosomes in a Rheb-dependent 
mechanism. 
Hela cells were treated with medium lacking amino acids for 60min (-AA) or 
deprived and stimulated with MEM amino acids for 15min (+AA) following 
transfection with control (Ctrl) or Rheb-specific siRNAs. A. Immunoblots of cell 
extracts probed with antibodies to pS6K1 T389, total S6K1, Rheb and ERK1/2. 
Relative T389/S6K1 ratio was the average value from three biological repeats and 
was calculated using the ImageJ software from scanned autoradiographs, with the 
ratio in control siRNA-transfected cells in the presence of amino acid (Ctrl siRNA 
+AA) assigned the value of 1. B-E. Confocal immunofluorescence micrographs of 
cells stained to mTOR (green in B and C) or RagC (green in D and E) and LAMP2 
(red). Amplified micrographs were shown in this figure to display more details. The 
original micrographs were shown in the supplementary figure Appendix 4. F. 
Quantitative analysis of co-localization of mTOR or RagC with LAMP2-positive 
lysosomes. Y-axis represents the percentage of LAPM2-positive mTOR/RagC over 
the total mTOR/RagC. 
 
3.1.6 Rheb promotes the association of RagA and lysosomes 
Previously published data suggest that Rag GTPases interact with the lysosomal 
protein Ragulator, which together mediate the recruitment of mTORC1 to lysosomal 
surface [95, 98]. We therefore asked whether Rheb mediated the association of RagA 
with lysosomes. Due to lack of immunofluorescence antibody detecting endogenous 
RagA, we have examined the interaction of RagA with LAMTOR1, a component of 
the Ragulator complex, via co-IP analysis following Rheb suppression; we also 
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examined whether Rheb affected the localization of transiently overexpressed HA 
tagged RagA via immunofluorescence staining against HA.  
 
3.1.6.1 Interaction of RagA with LAMTOR1 requires Rheb  
As shown in Figure 35, endogenous RagA was co-immunoprecipitated with 
LAMTOR1-IP, but not the control IgG-IP, and the interaction has been eliminated 
by suppression of Rheb using siRNA. Immunoblots were also probed for 
LAMTOR3, another component of the Ragulator complex, which bound LAMTOR1 
regardless of the presence of Rheb and served as a positive control for interaction 
with LAMTOR1. Therefore, Rheb seems to promote the interaction of RagA with 
LAMTOR1.  
 
Figure 35. Interaction of RagA with LAMTOR1 requires Rheb.  
113 
 
 
Co-IP analysis of Hela cell extracts subjected to LAMTOR1- or control IgG-IPs and 
probed with antibodies detecting endogenous RagA, LAMTORs 1 and 3. Cell lysates 
(Lysates) were probed with the same antibodies and an additional antibody to Rheb 
to show siRNA knockdown. Experiment displayed in this figure was performed by 
Drs Richard Lamb and Rebecca Lamond. 
3.1.6.2. TSC2 inhibits the interaction of RagA with lysosomes 
We have further examined whether the TSC2/Rheb axis played a role in regulating 
the lysosomal localization of RagA and RagC by transiently expressing HA tagged 
RagA or RagC in MEF TSC2 knockout (KO) cells (Figure 36A). Following amino 
acid deprivation, HA tagged RagA exhibited a pattern that did not concentrate on 
lysosomes in cells expressing TSC2, but it was found to almost completely associate 
with lysosomes in cells lacking TSC2, suggesting that TSC2 may promote the 
dissociation of RagA from lysosomes during amino acid deprivation. This is also in 
accordance with the conclusion that Rheb promotes the RagA-lysosome/Ragulator 
association (Figure 35), in that Rheb is predominantly in the active GTP-bound state 
in TSC2 knockout cells. In contrast to RagA, HA tagged RagC was found to 
associate with lysosomes independently of TSC2 (Figure 36B).  
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Figure 36. TSC2 promotes dissociation of RagA from lysosomes in response to 
amino acid deprivation.  
Confocal immunofluorescence micrographs of MEF cells expressing (TSC2 WT) or 
lacking (TSC2 knockout, KO) TSC2. Cells were subjected to deprivation of amino 
acids for 4 hours (-AA) following transfection with plasmids containing HA-tagged 
RagA or RagC. Cells were stained with antibodies to HA (green) and LAMP2 (red) 
to respectively mark overexpressed RagA (A) or RagC (B) and endogenous 
lysosomes. Experiments displayed in this figure were performed by Drs Richard 
Lamb and Rebecca Lamond (Panel B), and me (Panel A).  
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3.2. MAP4K3 is an activator of mTORC1 
MAP4K3 plays a complex role in cellular signalling. On one hand, it can activate 
mTORC1 in response to amino acids [108], suggesting a cancer-promoting function; 
on the other hand, MAP4K3 can induce apoptosis through the JNK pathway [128], 
which suppresses cancer progression. The aim of this section is to investigate the 
mechanism of MAP4K3-mediated activation of mTORC1, and to characterize nine 
MAP4K3 mutants identified in Cosmic Sanger Database.  
 
3.2.1. PLD1 is a downstream effector of MAP4K3  
 
3.2.1.1 Preliminary work: PLD1 is a potential mediator between MAP4K3 and 
mTORC1  
MAP4K3 has been demonstrated by Dr Richard Lamb’s group in 2007 to activate 
mTORC1 signalling in response to amino acid sufficiency and the kinase activity of 
MAP4K3 is required [108] (Figure 37A). Thus it had been proposed that the 
substrate of MAP4K3 might act as a mediator to activate mTORC1. To identify 
potential substrates of MAP4K3, Dr Richard Lamb and his colleagues at Yale 
University have initially established the substrate specificity of MAP4K3, and 
revealed a particularly interesting candidate, the substrate site (Thr147) within the 
PX domain of PLD1 (Figure 37B), in that PLD1 and its metabolic product, 
phosphatidic acid (PA), had been implicated as the upstream activators of mTORC1 
[206-211]. To investigate whether MAP4K3 indeed regulated PLD1, the expression 
of MAP4K3 was suppressed in Hela cells using two independent siRNAs 
(MAP4K3-1 and MAP4K3-2) targeting distinct sites of MAP4K3, and the effects on 
phosphorylation of PLD1 was examined by western blot. Due to lack of an antibody 
detecting endogenous phosphorylated Thr147 of PLD1 (the antibody used in this 
study only detects overexpressed PLD1 Thr147), the phosphorylation state of PLD1 
was evaluated by its SDS-PAGE migration, in which slow migrating bands were 
presumably indicative of phosphorylated PLD1 due to additional phosphoryl groups. 
As shown in Figure 37C, suppression of MAP4K3 has indeed caused the 
disappearance of the slow-migrating phospho-PLD1 band on SDS/PAGE, compared 
to that of control siRNA transfected cells (left panel). In accordance with this, 
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overexpression of wild type (WT) but not the kinase-inactive mutant of MAP4K3 
(DA, where the kinase-active DFG motif is mutated to inactive AFG [108]) resulted 
in a significant increase in phospho-PLD1 (Thr147-P) (right panel). Therefore, 
MAP4K3 seems to act as an upstream kinase that stimulates the phosphorylation of 
PLD1 and the stimulation is dependent on its kinase activity. Based on this, a model 
has been proposed where PLD1 has been positioned downstream of MAP4K3 and 
upstream of mTORC1. 
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Figure 37. PLD1 is a potential substrate of MAP4K3.  
A. MAP4K3 is an activator of mTORC1. Immunoblots of extracts from Hela cells 
transfected with control (Ctrl), Rheb and MAP4K3 siRNAs, and were probed for 
pS6K1 T389, total S6K1, Rheb and MAP4K3. Rheb siRNA was used here as a 
positive control for impaired mTORC1 activity. B. Left panel, the peptide array 
analysis of MAP4K3 substrate consensus shows specificity for the Threonine (Thr) 
motif; right panel, candidates containing the motif from searching Scansite including 
PLD1 Thr147 (red box). C. MAP4K3 potentially stimulates phosphorylation of 
PLD1 on Thr147. Left panel, immunoblots of extracts from Hela cells transfected 
with control or MAP4K3 siRNAs. MAP4K3 silencing resulted in  smaller-size 
(dephosphorylating) shifts of PLD1 compared to that in control group; right panel, 
HA-PLD1 was co-expressed in HEK293T cells with empty vector, vectors 
expressing myc-MAP4K3 kinase inactive (DA) or myc-MAP4K3 wild-type (WT). 
Upper panels, HA-IP probed with phospho-PLD1 (Thr147) and HA antibodies; 
lower panel, immunoblots of cell lysates (Lysates) probed with the 9E10 antibody 
against the Myc epitope for Myc-MAP4K3.  
 
3.2.1.2 MAP4K3 stimulates PLD1 phosphorylation on Thr147 
To validate whether MAP4K3 mediated the phosphorylation of PLD1-Thr147, we 
analysed Thr147 phosphorylation of co-expressed HA-PLD1 induced by wild type 
MAP4K3 and by the kinase-inactive MAP4K3 mutant (DA). Overexpression of wild 
type MAP4K3, but not inactive MAP4K3, led to increased HA-PLD1 Thr147 
phosphorylation (Figure 38), consistent with preliminary work demonstrating that 
MAP4K3 regulates phosphorylation of PLD1-Thr147, and the kinase activity of 
MAP4K3 is required. The phospho-PLD1 Thr147 band can only be detected when 
PLD1 is overexpressed probably because of its low cellular basal activity [209]. In 
addition, the overexpressed MAP4K3 could not be detected from the HA-IP samples, 
suggesting that there was no interaction between MAP4K3 and PLD1, or the 
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interaction was so weak that it had been interrupted during the lysis process. Thus, 
MAP4K3 stimulates the phosphorylation of PLD1-Thr147, likely in an indirect way.  
 
Figure 38. MAP4K3 stimulates phosphorylation of PLD1-Thr147. 
HEK293T cells were co-transfected with pRK5-Flag-MAP4K3 wild type (WT) or 
kinase-inactive (DA), and HA-PLD1 plasmids. Lysates were collected 40 hours post 
transfection and subjected to HA-IP. Immunoblots were probed for phospho-PLD1 
(Thr147) and re-probed with the HA antibody for HA-PLD1, as well as the Flag 
antibody for Flag-MAP4K3.  
 
3.2.2. mTORC1 activation and lysosomal translocation are independent of 
PLD1 
 
3.2.2.1 mTORC1 activation by amino acids is independent of PLD1    
Following validation of PLD1 as a downstream effector of MAP4K3, we wanted to 
examine whether PLD1 played a role in activating mTORC1. Amino acids are 
known to be the indispensable stimuli of mTORC1 activation [46] and in support of 
this, the mTORC1 activity was complete inhibited following amino acid deprivation 
(-AA) for 60min in the control siRNA transfected cells, as demonstrated by the 
disappearance of pS6K1 T389 band on immunoblots (Figure 39A Ctrl siRNA). The 
mTORC1 activity was re-stimulated as soon as within 15min following amino acid 
re-addition (-/+AA). Previous publication has demonstrated that PLD1 is required 
for mTORC1 activation in Hela cells [110], however, when PLD1 was knocked-
down using the two siRNAs with the same sequence as in the publication (PLD1 
siRNA1 and 2) in our Hela cells, the level of phospho-S6K1 T389 in the presence of 
amino acids (-/+AA) did not seem to reduce on the immunoblots, compared to that 
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of the control siRNA transfected cells (Figure 39A). The results suggest that 
mTORC1 activation by amino acids seems to be independent of PLD1. The level of 
pS6K1 T389 was low in the normal medium (Figure 39A, +AA) most likely because 
the medium was not fresh prior to analysis and most nutrients including amino acids 
had been consumed. To avoid the possible off-target effects of the two PLD1 
siRNAs, we have utilized another three independent siRNAs from Qiagen, PLD1 
siRNA 3-5, and examined their effects on mTORC1 activity. As shown in Figure 
39B, suppression of PLD1 in Hela cells using these five independent siRNAs, 
likewise, did not alter the level of pS6K1 T389 in the presence of amino acids, 
compared to that of control siRNA transfected cells. Therefore, it seems that the 
activation of mTORC1 by amino acids is independent of PLD1.  
 
 
Figure 39. Amino acids activate mTORC1 in a PLD1-independent mechanism. 
Immunoblots of lysates from Hela cells transfected with control (Ctrl) siRNA or two 
(A) to five (B) PLD1-specific siRNAs followed by treatment with medium lacking 
amino acids with 10% d. FBS (-AA) for 60min, or deprived and stimulated with 
MEM amino acids for 15min (-/+AA). The condition where medium was not 
changed post transfection was labelled “ +AA” in A, and the condition where 
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medium was changed to culture medium on the following day of transfection was 
labelled “+AA” in B. Cells lysates were prepared 72 hours post transfection in both 
A and B. Immunoblots were probed for PLD1, pS6K1 T389, total S6K1 and ERK1/2.  
 
3.2.2.2 mTOR translocates to lysosomes independently of MAP4K3 and PLD1 
In parallel to investigating whether suppression of PLD1 affected mTORC1 activity, 
we have also examined, using IF staining, whether PLD1 might regulate mTORC1 
lysosomal translocation that is required for mTORC1 activation. As shown in Figure 
40A, mTOR displayed a disperse pattern following amino acid deprivation for 
60min in control siRNA transfected cells, whilst re-supplying the cells with amino 
acids immediately (15min) stimulated accumulation of mTOR onto lysosomes. This 
co-localization of mTOR with lysosomes induced by amino acids did not alter 
obviously when PLD1 and MAP4K3 were suppressed using siRNAs (Figure 40B), 
suggesting that neither MAP4K3 nor PLD1 seem to regulate the co-localization of 
mTOR with lysosomes. Since HA tagged PLD1 has been demonstrated, in the same 
publication [110], to undergo lysosomal translocation in response to amino acid 
sufficiency, we also examined the subcellular distribution of PLD1 using a recent 
commercially available IF antibody (clone F-12, mouse monoclonal) that detects 
endogenous human PLD1. The specificity of this antibody was firstly validated via 
PLD1 siRNA (Figure 40C). However, endogenous PLD1 displayed a disperse 
pattern and did not localize with lysosomes regardless of amino acids availability 
(Figure 40D). Therefore, it is unlikely that PLD1 regulates mTORC1 activity or its 
lysosomal translocation, and PLD1 itself does not seem to associate with lysosomes.  
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Figure 40. mTOR translocates to lysosomes in a PLD1-independent mechanism. 
Confocal immunofluorescence micrographs of Hela cells transfected with siRNAs 
targeting none (Ctrl), human PLD1 or MAP4K3, followed by treatment with 
medium lacking amino acids with 10% d.FBS (-AA) for 60min, or deprived and 
stimulated by MEM amino acids for 15min (-/+AA). Nucleus was stained in blue 
using Hoechst blue dye, mTOR (clone 7C10, rabbit monoclonal antibody in A and 
B) and PLD1 (clone F-12, mouse monoclonal antibody in C and D) in green, and 
LAMP2 (clone H4B4, mouse monoclonal antibody in A and B, clone GL2A7, rat 
monoclonal antibody in C and D) in red. Micrographs in the final lane are amplified 
from areas in the white dashed box. Two independent siRNAs were used in each 
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knockdown experiment and they exhibited similar effects, thereby only one group 
was displayed in this figure.  
 
3.2.3 Characterization of cancer-associated MAP4K3 mutations 
MAP4K3 has been implicated as an apoptosis inducer through the JNK signalling 
pathway [128], which suppresses cancer progression. An array of MAP4K3 
mutations have been identified in human cancer and are collected in the Sanger 
Centre Cosmic Database, but their current relevance to MAP4K3 function and 
cancer development is unknown. Characterization of the MAP4K3 mutations may 
contribute to further understanding of the role of MAP4K3 in carcinogenesis and 
distinguish between cancer-promoting and cancer-suppressive functions of the 
MAP4K3 kinase. In this section, nine MAP4K3 mutations (Figure 41) from the 
Cosmic Database were sub-cloned into the pRK5-Flag vector, and their gain- and 
loss-of function was examined including activation of mTORC1 and the kinase 
activity.  
 
Figure 41. Linear schematic representation of MAP4K3 structure and 
mutations.  
MAP4K3 consists of a kinase domain, a middle proline-rich core, two PEST 
domains and the CNH regulatory domain. S170 in the kinase domain is one of the 
trans-autophosphorylation sites. Positions of the nine MAP4K3 mutants in the linear 
structure are indicated by arrows.  
 
3.2.3.1 Analysis of mTORC1 activation by MAP4K3 mutants 
To investigate whether these MAP4K3 mutants displayed gain- and loss-of function 
in activating mTORC1, a S6K1-GST reporter was co-expressed with Flag-tagged 
MAP4K3 wild-type (WT), kinase-inactive (DA) or mutants in HEK293T cells 
(Figure 42). Transfected cells were starved from serum for 16 hours to avoid the 
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saturation of mTORC1 activity so that the increased activity due to active MAP4K3 
were comparable on immunoblots. Two additional wells of cells were co-transfected 
with the empty vector pRK5-Myc and the S6K1-GST vector, both starved from 
serum for 16 hours, and one was stimulated with 10% FBS for 30min. These two 
wells served as controls for the inactive and activated mTORC1 respectively. As 
shown in Figure 42, serum starvation inhibited mTORC1 activity, as indicated by the 
level of phosphorylated S6K1-GST, which was remarkably restored by 
overexpressed wild type MAP4K3. The overexpressed kinase-inactive MAP4K3 
(DA), as expected, failed to compensate for the inhibition of mTORC1 activity by 
serum starvation. These results are in accordance with kinase-active MAP4K3 being 
an activator of mTORC1 [108]. The kinase-domain mutants V182F and E209G 
continuously exhibited loss-of-function in activating mTORC1 in repeated 
experiments. Similar to the kinase-inactive MAP4K3, V182F mutant was unable to 
activate mTORC1. The level of phosphorylated S6K1-GST was barely detectable in 
cells transfected with the E209G mutant, suggesting that this mutant has somehow 
impaired the ability of endogenous MAP4K3 to activate mTORC1. One probable 
explanation could be that the E209G mutant formed a complex with the endogenous 
MAP4K3, which has compromised the kinase activity or led to degradation of the 
complex.  
 
Figure 42. Analysis of mTORC1 activation by MAP4K3 mutants.  
HEK293T cells were co-transfected with a S6K1-GST reporter vector and pRK5-
Myc vector, pRK5-Flag MAP4K3 WT, kinase-inactive (DA), or nine mutants, 
followed by incubation in serum (FBS)-free medium for 16 hours, and one of the 
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Myc vector group was switched to medium containing 10% FBS for 30 min. 
Immunoblots were probed with antibodies detecting the GST tag for S6K1-GST 
expression, phosphorylated S6K1 T389 for the reporter and the Flag tag for Flag-
MAP4K3 expression, respectively. The T389-P S6K1-GST has a molecular weight 
26kDa higher than the endogenous phospho-S6K1 T389 due to the additional GST 
tag, thereby they were well separated on the immunoblots. The two loss-of-function 
mutants V182F and E209G are labelled in green. 
 
3.2.3.2 Analysis of the kinase activity of MAP4K3 mutants  
We also examined the kinase activity of these MAP4K3 mutants via the in vitro 
kinase assay using Flag-beads purified MAP4K3 and generic myelin basic protein 
(MBP) as the substrates (Figure 43). Ser170 within the kinase domain of MAP4K3 
has been demonstrated as a transautophosphorylation site [109], and in support of 
this, the purified WT MAP4K3 displayed a high level of phosphorylated Ser170 on 
the immunoblots and conversely no phosphorylated Ser170 was detected with the 
DA MAP4K3. Phosphorylation of MBP followed the same pattern, as expected.  The 
two mutants V182F and E209G that had displayed loss-of-function in mTORC1 
activation also showed impaired kinase activity as demonstrated respectively by 
markedly lower and undetectable levels of phosphorylated MBP and Ser170. In 
addition, the binding efficiency of the inactive MAP4K3 including DA, V182F and 
E209G to the anti-Flag beads seemed significantly higher than that of WT and other 
seven mutants, indicating that these proteins may have become unfolded and thus the 
binding sites were more accessible by the anti-Flag beads.  
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Figure 43. In vitro kinase assay of Flag-purified MAP4K3.  
Flag tagged MAP4K3 (WT, DA and nine mutants) were overexpressed in HEK293T 
cells, purified using the anti-Flag beads and subjected to the kinase assay using MBP 
as substrates. Panel 1, autoradiograph displaying phosphorylated MBP. Panel 2, 
Ponceau S staining of total MBP. Panel 3, immunoblots of Ser170 auto-
phosphorylation probed with a specific phospho-S170 peptide. Panel 4, 
autoradiograph displaying auto-phosphorylated MAP4K3. Panel 5, immunoblots of 
purified MAP4K3 probed against the Flag tag. The two loss-of-function mutants 
V182F and E209G are labelled in green. 
 
3.2.3.3 Investigation of the subcellular distribution of MAP4K3 mutants  
Subcellular localization of a kinase is closely correlated with its function and 
therefore we continued to examine the localization of these nine cancer-associated 
MAP4K3 mutants. Flag-tagged MAP4K3 (WT, DA and nine mutants) were 
expressed in HEK293T cells and the subcellular localization was analysed by 
immunofluorescence staining against the Flag epitope. As shown in Figure 44, WT 
MAP4K3 and the three kinase-inactive MAP4K3 (DA, V182F and E209G) exhibited 
two distinct patterns of localization. Unlike the WT MAP4K3, the inactive ones 
seemed to associate with microtubular structures. Cells overexpressing these 
MAP4K3 constructs were also co-stained with antibodies targeting perinuclear 
organelles including lysosome and also endoplasmic reticulum (ER), such as protein 
disulfide isomerase (PDI), KDEL (lysine-aspartic acid-glutamic acid-leucine, a 
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target peptide), and calreticulin,  however, no co-localization was observed (data not 
shown).  
 
Figure 44. Investigation of MAP4K3 subcellular distribution. 
Monochromic confocal micrographs of Flag-MAP4K3 (WT, DA and nine mutants) 
stained with the anti-Flag antibody following overexpression in HEK293T cells. The 
subcellular distribution of other seven mutants was also investigated and all 
exhibited the similar patterns to WT MAP4K3, thus the images are not displayed in 
this figure.  
 
3.3 MAPK/ERK promotes ferroptosis in response to cystine deprivation  
Results described in this section have been published in a paper that can be found in 
Appendix 6. Figures were generated based on the results from experiments 
performed by me, or my colleague Dr Ioannis Poursaitidis (a senior PhD student at 
the time), or together with colleagues from Glasgow or Austin, as indicated in figure 
legend. 
 
Cancer cells reprogram their metabolism, altering both uptake and utilization of 
extracellular nutrients, to supply their rapid growth and proliferation. We therefore 
sought to investigate whether the high demands for nutrients, particularly amino 
acids, of cancer cells could be potentially exploited to identify cancer-specific 
vulnerabilities. In this study, we have taken advantages of the isogenic hTERT 
human mammary epithelial (HME) cell lines and the amino acid deprivation strategy. 
Four common oncogenic mutations including EGFR delE746-A750, KRAS G13D, 
BRAF V600E and PIK3CA H1047R had been individually knocked into the HME 
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cells and they have been demonstrated to activate the corresponding downstream 
signalling pathways [201]. In contrast to primary cancer cell lines that are extremely 
heterogeneous, such HME cell lines provide a much less complicated genetic context, 
which allows the gene-specific features to be characterized. By utilizing the amino 
acid deprivation strategy, synthetic lethal partners of the enumerated oncogenes 
could be potentially identified and exploited for cancer therapy.  
  
3.3.1 Cystine deprivation selectively kills EGFR delE746-A750 HME cells  
We firstly performed an amino acid dropout screen in the four HME cell lines, 
EGFR (delE746-A750), KRAS (G13D), BRAF (V600E) and PIK3CA (H1047R) 
(hereinafter referred to as EGFR, KRAS, BRAF, and PI3K mutant cells respectively 
for brevity), together with the wild type (WT) HME cell line.  The media used for 
this screen were reconstituted according to the formulation of commercial media 
used to culture these cells, but to omit one specific amino acid, with 10% dialysed 
FBS to retain other growth supplements such as growth factors. Cells were 
maintained in normal medium for 24 hours before switched to media lacking the 
individual amino acid for 72 hours. Cell viability was then examined via CellTiter-
Glo assay that detects ATP produced by viable cells. As shown in Figure 45A, 
among 15 amino acids deprived, deprivation of cystine (Cys) inhibited the viability 
of EGFR and BRAF mutant cells by more than 80% relative to control complete 
media (+AA, Chapter 2.1.10), whilst about 50% of WT cells remained alive under 
the same condition. This suggests that EGFR and BRAF mutant cells are more 
sensitive than WT cells to cysteine deprivation. As mentioned earlier, all of the four 
mutations are constitutively active due to the structural alterations. In support of this, 
these cell lines exhibited much higher levels of phosphorylated EGFR (pEGFR), Akt 
(pAKT) and ERK1/2 (ppERK) respectively than the WT cells, as examined by 
immunoblotting (Figure 45B). In addition, cystine deprivation did not seem to cause 
obvious changes of this pattern, supporting that both the MAPK/ERK and PI3K/Akt 
signalling pathways do not sense the conditions of amino acids [112]. Therefore, it 
was likely that cystine deprivation had triggered a certain cellular response that act 
synergistically with the activating MAPK/ERK signalling pathway to induce cell 
death.  
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Figure 45. Cystine deprivation selectively kills EGFR delE746-A750 HME cells.  
A. Amino acid dropout screen in EGFR, KRAS, BRAF and PI3K mutant and WT 
HME cells. After seeding for 24 hours in normal media, cells were washed once in 
medium lacking all amino acids (-AA) and switched to media lacking specific amino 
acid for 72 hours, followed by Celltiter-Glo viability assay. Each amino acid is 
represented by its corresponding three- or four-letter abbreviation. Histograms 
represent the average viability ± SEM of three biological replicates relative to 
complete media (+AA) that was assigned a value of 1. Arrows indicate cystine (Cys) 
deprivation condition of EGFR and BRAF mutant cells. B. Immunoblots of lysates 
from EGFR, KRAS, BRAF and PI3K mutant and WT HME cells cultured in normal 
or cystine-free (-Cys) media for 12 hours. Immunoblots were probed with antibodies 
detecting phosphorylated EGFR (pEGFR), AKT (pAKT S473) and ERK (ppERK), 
and re-probed for total EGFR, AKT, and ERK (ERK1/2). Experiments shown in this 
figure have been performed by Ioannis Poursaitidis (Panel A) and me (Panel B).  
 
3.3.2 Cystine deprivation induces ferroptosis in EGFR delE746-A750 HME cells  
To determine whether such synchronous mechanisms exist, we needed to understand 
the nature of cell death in cystine-deprived EGFR mutant cells. We firstly asked 
whether the cell death occurred via apoptosis, a common form of programmed cell 
death with well-defined morphological features. Morphology of EGFR mutant and 
WT cells was analyzed by microscopy, and this has shown that cystine deprivation 
for 24 hours induced a widespread loss of viability in EGFR mutant, but not WT 
cells, with most EGFR mutant cells exhibiting a swollen morphology and loss of 
membrane integrity (Appendix 6). These morphological changes, however, were 
distinct from that during apoptosis, and therefore suggestive of an alternative form of 
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cell death. Since ferroptosis had previously been demonstrated to associate with the 
MAPK/ERK pathway (EGFR is the upstream activator) [147, 184, 187], it has been 
hypothesised that cell death in cystine-deprived EGFR mutant cells might occur by 
ferroptosis.  
 
Because accumulation of ROS, particularly lipid ROS, is a key feature of ferroptosis, 
levels of total and lipid ROS were examined via fluorescence-activated cell sorting 
(FACS) analysis using the CMDCFDA and C11 BODIPY dyes respectively, and the 
results showed that levels of both total and lipid ROS in EGFR mutant cells indeed 
increased markedly following cystine deprivation whilst they were barely changed in 
WT cells (Figure 1E in Appendix 6). Further experiment using the iron chelator 
DFO suggested that this type of cell death was also dependent on cellular iron. 
Taken together with the data from ferroptosis inducer and inhibitor experiments, this 
has led to the conclusion that cell death in cystine-deprived EGFR mutant cells 
occurred by ferroptosis. Figures demonstrating this conclusion can be found in 
Figure 1 in Appendix 6.  
 
3.3.3 Active MAPK/ERK cascade promotes cystine deprivation-induced cell 
death  
Activation of EGFR stimulates multiple downstream signalling pathways, including 
MAPK/ERK and PI3K/Akt. We therefore asked whether inhibition of MAPK/ERK 
or PI3K/Akt signalling pathways by specific inhibitors could block ferroptosis in 
cystine-deprived EGFR mutant cells. To do this, we treated the cells with an EGFR 
inhibitor iressa, a MEK1/2 inhibitor selumetinib, and a PI3K inhibitor wortmannin 
(Figure 46). Iressa (ZD1839) is an effective drug for lung, breast and other cancers 
with activating mutation of or overexpressed EGFR [5]. Selumetinib (AZD6244) is a 
drug that specifically inhibits MEK1 and MEK2, and is currently being investigated 
for the treatment of various types of cancer, such as NSCLC [212]. Wortmannin is 
compound commonly used to inhibit PI3K in cell biology research.  
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Figure 46. Inhibitors of MAPK/ERK and PI3K/Akt pathways.  
 
Inhibition of the active EGFR (pEGFR), MEK1/2 (represented by ppERK) and PI3K 
(represented by pAKT) respectively by iressa, selumetinib and wortmannin in EGFR 
mutant cells were confirmed by immunoblots and not surprisingly their inhibitory 
effects displayed similar patterns under normal and cystine-deprived conditions 
(Figure 47A). As shown in the phase-contrast micrographs in Figure 47B, 
deprivation of cystine for 16 hours has caused dramatic cell death in DMSO-treated 
(vehicle control) EGFR mutant cells (Panel 2) whereas WT cells largely remained 
viable following deprivation of cystine for up to 24 hours (Panel 1). Cell death was 
markedly prevented by treatment with iressa and selumetinib, the inhibitors of EGFR 
and MEK1/2 respectively, but not with the PI3K inhibitor wortmannin. These 
observations were further supported by cell viability assay (Figure 47C) showing 
that treatment of cystine-deprived EGFR mutant cells with inhibitors of EGFR and 
MEK1/2, but not PI3K, significantly improved cell survival. In accordance with this, 
the FACS analysis of lipid ROS (Figure 47D) showed that iressa and selumetinib 
treatment in cystine-deprived EGFR mutant cells has led to a shift of lipid ROS back 
to that under the condition of normal medium, in contrast to that in control DMSO or 
wortmannin treated cells. Therefore, it seemed that the active MAPK/ERK signalling 
pathway in EGFR mutant cells has somehow promoted the accumulation of lipid 
ROS during cystine deprivation and rendered them highly sensitive to such stress, 
which has ultimately led to cell death.  
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Figure 47. MAPK/ERK promotes cell death in response to cystine deprivation.  
EGFR mutant cells cultured in normal media (Normal) or cystine-free media (-Cys) 
for 12 hours (A and D) or 16 hours (B and C), in the absence (replaced with the 
vehicle control DMSO) or presence of inhibitors iressa, selumetinib and wortmannin 
for a total of 30 hours. A. Immunoblotting analysis of effects of the inhibitors on the 
MAPK/ERK cascade in EGFR mutant cells. Immunoblots were probed for pEGFR, 
pAKT and ppERK, and re-probed for total EGFR, AKT and ERK1/2. B. phase-
contrast micrographs of EGFR mutant cells and WT cells maintained in cystine-free 
medium for 24 hours. Micrographs were captured using a 10X microscope objective. 
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C. CellTiter-Glo viability assay of EGFR mutant cells. Histograms represent the 
average viability ± SEM of three biological replicates relative to normal media that 
was assigned a value of 1. Dark and light bars indicate conditions of normal 
(Normal) and cystine-free media (-Cys) respectively. D. FACS analysis of lipid ROS 
using C11-BODIPY dyes (a membrane-targeted lipid ROS sensor) in EGFR mutant 
cells. Dark and light traces indicate conditions of normal (Normal) and cystine-free 
media (-Cys) respectively. Y-axis shows cell counts (events) and X-axis C11 
fluorescence intensity using an emission channel of BL1. Experiments shown in this 
figure have been performed by Ioannis Poursaitidis. 
 
3.3.4 Active MAPK/ERK cascade promotes lipid ROS independently of 
glutathione  
Increased accumulation of lipid ROS can result from enhanced production of lipid 
ROS and/or decreased synthesis of cellular antioxidants. The reduced glutathione 
(GSH) is the major antioxidant in most mammalian cells and is biosynthesized from 
three amino acids: cysteine (reduced from cystine), glycine and glutamate, of which 
cysteine is the rate-limiting precursor [158]. We thus reasoned that one possible 
mechanism for WT cells to resist ferroptosis might be that they have preserved the 
intracellular abundance of either cysteine or GSH to counterbalance the toxicity of 
lipid ROS during cystine deprivation. To address this possibility, intracellular amino 
acids were extracted from WT and EGFR mutant cells cultured in normal and 
cystine-free media and subjected to LC-MS/MS analysis [183] to determine the 
quantity of 18 standard amino acids as well as cystine, reduced  (GSH) and oxidized 
(GSSG) glutathione. Surprisingly, WT and EGFR mutant cells contained similar 
amounts of basal cystine under the normal-nutrient condition, and the amounts 
decreased to similar extents following extracellular cystine deprivation (Figure 48). 
The levels of glycine, glutamate and glutamine (converted to glutamate by 
glutaminase) were similar in WT and EGFR mutant cells, and they were scarcely 
altered when cystine was removed. These results indicated that WT and EGFR 
mutant cells are likely to harbour similar capacities to synthesize GSH. This was 
supported by the measurements of GSH and GSSG, both of which decreased 
dramatically and similarly following cystine deprivation in WT and EGFR mutant 
cells. Therefore, it seems that the active MAPK/ERK cascade promotes lipid ROS 
accumulation in a glutathione-independent mechanism.  
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Figure 48. Analysis of the intracellular amino acids in EGFR delE746-A750 and 
WT HME cells.  
Quantification of intracellular cystine, glycine, glutamine, glutamate, reduced (GSH) 
and oxidized (GSSG) glutathione using LC-MS. Metabolites were extracted from 
WT and EGFR mutant cells cultured in normal (Normal, light bars) or cystine-free (-
Cys, dark bars) media for 4 hours. Histograms represent the average values ± SEM 
of three biological replicates and the level of WT cells in normal medium was 
assigned the value of 1.  
 
3.3.5 The MAPK/ERK cascade promotes lipid ROS by regulating GPX4 and 
NOX4  
Since the active MAPK/ERK cascade seems to promote lipid ROS in a glutathione-
independent mechanism, we sought to identify potential mediators that act 
downstream of this cascade and are associated with the accumulation of lipid ROS. 
136 
 
 
As described in the introduction part, GPX4 catalyses the oxidation of GSH to 
GSSG, concomitantly detoxifying lipid ROS to corresponding alcohol. It has been 
demonstrated that loss of GPX4 activity can drive ferroptotic cancer cell death [183]. 
On the other hand, NOX4 is a membrane-bound enzyme that senses oxygen and 
promotes reactions to generate lipid ROS and it has also been reported to promote 
ferroptotic cell death [147]. We therefore hypothesized that the MAPK/ERK 
signalling pathway might promote the accumulation of lipid ROS by regulating 
GPX4 and NOX4 (Figure 49).  
 
Figure 49. Hypothesized mechanisms of lipid ROS regulation by MAPK/ERK.  
GPX4 acts to scavenge lipid ROS and thus inhibit ferroptosis by catalysing the 
oxidation of GSH. NOX4 on the other hand promotes ferroptosis through stimulating 
the production of lipid ROS. Both GPX4 and NOX4 were hypothesized mediators 
downstream of the MAPK/ERK signalling pathway.  
 
3.3.5.1 GPX4 is downregulated by the active MAPK/ERK cascade   
Analysis of the level of endogenous GPX4 by western blot in WT and EGFR, KRAS, 
BRAF, or PI3K mutant cells has shown that EGFR and PI3K mutant cells harboured 
lower levels of GPX4 expression than WT, KRAS or BRAF mutant cells, and this 
pattern did not seem to change following cystine deprivation (Figure 49A). To 
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determine whether downregulation of GPX4 was a consequence of the activated 
MAPK/ERK cascade, we utilized selumetinib to disrupt the MAPK/ERK signalling 
in EGFR and BRAF mutant cells and examined the effect on GPX4 levels by 
western blot. As described previously, selumetinib is a selective inhibitor of MEK1/2, 
a downstream effector of EGFR and RAF. As shown previously in Figure 45, the 
MAPK/ERK signalling was activated in EGFR and BRAF mutant cells, and both 
lines were sensitive to cystine deprivation. Following selumetinib treatment, GPX4 
expression was increased in EGFR mutant cells, to a comparable extent as in WT 
cells (Figure 50B). Selumetinib treatment did not alter the level of GPX4 expression 
in BRAF mutant cells, possibly because GPX4 in these cells was already expressed 
at a high level (Figure 50A), indicating the possibility that other mechanism(s) might 
counteract the downregulation of GPX4 by activated BRAF. Conversely, the PI3K 
mutant cells, although insensitive to cystine deprivation (Figure 45), has exhibited a 
decreased level of GPX4 (Figure 50A), relative to WT cells, indicating that GPX4 
might not be the sole enzyme that protects these cells from ferroptotic death.  
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Figure 50. Analysis of GPX1 and GPX4 expression in HME cell lines.  
A. Immunoblots of lysates from WT, EGFR, KRAS, BRAF and PI3K mutant cells 
cultured in normal (Normal) or cystine-free (-Cys) media for 24 hours were probed 
with antibodies detecting GPX4 and total ERK (ERK1/2, a loading control). B. 
Immunoblots of lysates from WT, EGFR and BRAF mutant cells cultured in normal 
medium in the presence of DMSO or MEK1/2 inhibitor selumetinib for 30 hours 
were probed with antibodies detecting GPX1, GPX4 and total EKR1/2. A sample of 
lysates from mouse liver (Liver) was loaded as a positive control for expression of 
GPX1 and GPX4.  
 
In accordance with the previous inhibitor experiment (Figure 47), treatment with 
iressa and selumetinib, but not wortmannin, has increased the expression of GPX4 in 
EGFR mutant cells (Figure 51), suggesting that the downregulation of GPX4 in 
EGFR mutant cells was due to the active MAPK/ERK but not PI3K/AKT signalling 
pathways. Effects of other MAPK/ERK inhibitors on GPX4 expression in EGFR 
mutant cells have also been tested, to void potential off-target effects, and the level 
of GPX4 expression was increased by different extents under both normal-nutrient 
and cystine-deprivation conditions (Figure 52). Taken together, these data suggest 
that GPX4 lies downstream of the MAPK/ERK cascade and is downregulated by the 
active MAPK/ERK signalling.  
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Figure 51. MAPK/ERK cascade downregulates GPX4 expression.  
Immunoblots of lysates from WT and EGFR mutant cells cultured in normal 
medium in the presence of DMSO, iressa, selumetinib or wortmannin for a total of 
30 hours were probed with antibodies detecting phosphorylated ERK (ppERK), 
GPX4 and total ERK1/2. Relative GPX4/ERK ratio was the average value from 
three biological repeats and was calculated using the ImageJ software from scanned 
autoradiographs, with the ratio in DMSO-treated EGFR mutant cells assigned the 
value of 1.  
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Figure 52. Inhibition of the MAPK/ERK cascade upregulates GPX4.  
A. Schematic representation of the MAPK/ERK signalling pathway showing the 
targets of the five inhibitors. B. Immunoblots of EGFR mutant cell lysates probed 
with antibodies detecting phosphorylated RSK (T359-P), total RSK, GPX4 and total 
ERK1/2. A sample of lysates from mouse liver (Liver) was loaded as a positive 
control for expression of GPX4. C. Immunoblots of WT and EGFR mutant cell 
141 
 
 
lysates probed for phosphorylated ERK (ppERK), GPX4 and total ERK1/2. DMSO 
and inhibitors were added for 30 hours in B and C, and the cystine deprivation was 
for 12 hours in C.  
 
To further investigate whether the MAPK/ERK cascade regulated GPX4 specifically, 
the expression of other isoforms of GPX, including GPX1, GPX2 and GPX3, was 
analyzed by western blot. A sample lysate from mouse liver was used in this 
experiment as a positive control for expression of GPX1, GPX2 and GPX4. GPX3 
was not detected in either EGFR/WT cells or the liver sample. GPX2, although 
present in the liver lysate, was not expressed in either WT or EGFR mutant cells 
(Figure 53). GPX1 was detected in WT, EGFR and BRAF mutant cells, and no overt 
difference was observed between DMSO- and selumetinib-treated cells (Figure 50B). 
The various expression of these isoforms was not surprising, since GPX2 and GPX3 
are differentially expressed in mammalian tissues and GPX1 is abundantly expressed 
in nearly all mammalian tissues [172]. 
 
Figure 53. GPX2 is not expressed in WT or EGFR delE746-A750 HME cells. 
Immunoblots of WT and EGFR mutant cell lysates probed for GPX2 and Actin (a 
loading control). DMSO, iressa or selumetinib were added for 30 hours. A sample of 
lysates from mouse liver (Liver) was loaded as a positive control for expression of 
GPX2. 
 
3.3.5.2 NOX4 is upregulated by the active MAPK/ERK cascade 
The level of endogenous NOX4 in WT and EGFR mutant cells was also analyzed by 
western blot. In contrast to GPX4, NOX4 was highly expressed in EGFR mutant 
cells whereas it was barely detectable in WT cells (Figure 54A. left panel), and this 
high expression of NOX4 was significantly suppressed by inhibitors of EGFR and 
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MEK1/2 (Figure 52A. right panel), suggesting that NOX4 lies downstream of the 
MAPK/ERK cascade and is upregulated by the active MAPK/ERK signalling. 
 
Figure 54. MAPK/ERK cascade upregulates NOX4 expression.  
Immunoblots of WT and EGFR mutant cell lysates probed with antibodies detecting 
NOX4 and total ERK1/2. DMSO, iressa or selumetinib were added for 30 hours.  
 
3.3.6 Cystine deprivation inhibits the viability of three NSCLC cell lines. 
Based on the results described so far, it can be concluded that cystine/GSH is a 
synthetic lethal partner of the MAPK/ERK signalling pathway, which is associated 
with GPX4 and NOX4 that both are regulated by the pathway. These results were 
obtained in isogenic HME cell lines and we wanted to extend our analysis to NSCLC 
cell lines with multiple mutations. We have utilized a NSCLC cell line panel 
consisting of nine cell lines with various mutations in the MAPK/ERK cascade 
(Table 3) and examined whether they were sensitive to cystine deprivation.  
 
Table 3 
NSCLC cell lines 
 Mutations in the MAPK/ERK cascade  or PI3K 
A549 KRAS G12S 
Calu 6 KRAS Q61K  
NCI-NH1650 EGFR delE746-A750, L858R, T790M 
H1975 EGFR L858R, T790M 
H727 KRAS G12V  
H460 KRAS, PIK3CA 
143 
 
 
H322 WT 
H3255 EGFR L858R 
PC 9   EGFR delE746-A750 
 
The MAPK/ERK activity of these cells was analyzed by western blot using the level 
of phosphorylated EGFR (pEGFR) and ERK (ppERK) as an indicator of activation, 
and cell viability was measured following cystine deprivation for 72 hours (Figure 
55A and B). Although these nine cell lines possessed various activities in the 
MAPK/ERK signalling, as indicated by the levels of phosphorylated EGFR and 
ERK (Figure 55A), three cell lines NCI-NH1650 (EGFR delE746-A750), H3255 
(EGFR L858R) and Calu-6 (KRAS Q61K) exhibited high sensitivity to cystine 
deprivation, as demonstrated by the significant loss of viability following cystine 
deprivation (Figure 55B). In accordance with this, cystine deprivation has induced 
massive cell death in those cells, and most cells displayed balloon-like membrane 
extensions, a morphological feature of the ferroptotic event (Figure 55C). Therefore, 
cystine deprivation seems to be a vulnerability specific to NSCLC cell lines NCI-
NH1650 (EGFR delE746-A750), H3255 (EGFR L858R) and Calu-6 (KRAS Q61K). 
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Figure 55. Cystine deprivation induces cell death in three NSCLC cell lines.  
A. Immunoblots of lysates from WT and EGFR (delE746-A750) HME cells and the 
nine NSCLC cell lines, probed with antibodies detecting pEGFR, ppERK, GPX4, 
total EGFR and ERK1/2. B. CellTiter-Glo viability assay of EGFR (delE746-A750) 
HME cells and the nine NSCLC cell lines cultured for 72 hours in normal (light bars) 
or cystine-free (dark bars) media. Histograms represent the average values ± SEM of 
three biological replicates and the viability in normal medium was assigned the value 
of 1 for each cell line. C. Phase-contrast micrographs of Calu-6, NCI-NH1650 and 
H3255 cells cultured in normal or cystine-free (-Cys) media for 72 hours. 
Micrographs were captured using a 10X microscope objective. Arrowheads indicate 
membrane extrusions. Experiments shown in this figure were performed by Ioannis 
Poursaitidis (Panels B and C) and me (Panel A). 
 
Western blot analysis of GPX4 expression level in the nine NSCLC cell lines panel 
has demonstrated extremely variable expression patterns under both media 
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conditions (Figures 54A and 55A). GPX4, however, was highly expressed in NCI-
NH1650 and H3255 cell lines, both of which have exhibited high levels of the 
MAPK/ERK signalling activity and been highly sensitive to cystine deprivation. The 
nine NSCLC cell lines generally have expressed high levels of NOX4 (Figure 56B), 
whereas only three cell lines exhibited high levels of the MAPK/ERK activity and 
sensitivity to cystine deprivation (Figure 55). Overall, it might not be reliable to 
determine the association of GPX4 and NOX4 to cystine deprivation-induced cell 
death in the NSCLC cell lines due to their complex genetic contexts.  
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Figure 56. Analysis of GPX4 and NOX4 expression in a panel of NSCLC cell 
lines. 
Immunoblots of lysates from HME and the nine NSCLC cell lines cultured in normal 
(Normal) or cystine-free (-Cys) media for 24 hours were probed with antibodies 
detecting GPX4 (A), NOX4 (B) and total ERK1/2.  
 
3.3.7 Pharmacological depletion of intracellular cystine inhibits the growth of 
NCI-NHI1650 cells engrafted tumour 
Of the three NSCLC cell lines that were sensitive to cystine deprivation (Figure 55), 
NCI-NHI1650 cell line was of particular interest, because this cell line expresses the 
same mutation EGFR delE746-A750 that was also present in EGFR mutant HME 
cell line. We thus examined whether NCI-NHI1650 cells might be responsive to 
pharmacological depletion of cystine and cysteine pools, potentially offering new 
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therapeutic opportunities. NCI-NHI1650 cells were treated with an engineered 
human cysteine/cystine-degrading enzyme, AECase [213], and cell proliferation was 
analyzed by CellTiter-Glo viability assay and microscopy. As expected, AECase 
treatment resulted in a significant loss of cell viability in both NCI-NHI1650 and 
EGFR mutant HME cells, to similar extents as upon cystine deprivation, and 
moreover cell viability was restored by the ferroptosis inhibitor (Fer-1) treatment 
(Figure 57A). Likewise, widespread cell death was observed in cells treated with 
AECase, and the morphological alterations were similar to those in cells deprived of 
cystine (Figure 57B). In addition, cyclooxygenase-2 (COX2), a prostaglandin-
endoperoxide synthase that is upregulated during inflammation and development of 
certain types of cancer such as breast, pancreatic and lung cancers [214], has been 
recently identified as a marker for ferroptotic cell death [183]. As shown in Figure 
57C, COX2 has been induced following AECase treatment in NCI-NHI1650 cells 
for 8 hours. Taken together, these data suggest that AECase is able to induce cell 
death in NCI-NHI1650 NSCLC cells and the cell death likely occurs via ferroptosis.  
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Figure 57. Cystine/cysteine-degrading enzyme AECase induces cell death in 
NCI-NHI1650 NSCLC cells.  
A. CellTiter-Glo viability assay of EGFR mutant HME (dark bars) and NCI-NH1650 
NSCLC (light bars) cells cultured for 48 hours in normal (N) or cystine-free (-Cys) 
media, in the presence or absence of 125nM AECase or heat-inactivated AECase 
(AECase∗) alone, or together with the ferroptosis inhibitor (Fer-1). The viability 
measurement of each cell line in the normal medium (N) was assigned the value of 1. 
The AECase enzyme activity was eliminated by heating at 65°C for 5min, and was 
used as a control [213]. B. Phase-contrast micrographs of EGFR mutant HME (upper 
panel) and NCI-NH1650 NSCLC (lower panel) cells cultured for 48 hours in normal 
(Untreated), cystine-free (-Cys) media, normal media containing AECase or heat-
inactivated AECase. C. Immunoblots of lysates from NCI-NH1650 NSCLC cells 
treated with AECase or heat-inactivated AECase for 4 or 8 hours were probed with 
antibodies detecting COX2 and ERK1/2. Experiments shown in this figure were 
performed by Ioannis Poursaitidis (Panels A and B) and me (Panel C).  
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Since AECase treatment was shown to be effective in inducing cell death in NCI-
NHI1650 NSCLC cells under cell culture conditions, we wanted to examine whether 
AECase would have the same effect in vivo, on engrafted cells. Immuno-deficient 
mice were injected with NCI-NH1650 NSCLC cells to develop tumours, and then 
injected with 30 mg/kg or 100 mg/kg of AECase. Tumour growth and mice survival 
were then monitored. As shown in Figure 58A, the tumour volume was significantly 
reduced in AECase-treated mice compared with the vehicle (PBS)-treated control 
group (p = 0.0001, n=4). Similarly, AECase treatment prolonged mice survival by 
around 15 day in a dose-dependent manner. Moreover, the inhibition of tumour 
growth by AECase was likely due to the induction of ferroptosis, as determined by 
the upregulation of COX2 expression in tumour lysates from AECase-treated mice, 
relative to the control groups treated with heat-inactivated AECase (HI AECase) 
(Figure 58B and C). Taken together, these data indicate that enzymatic depletion of 
cystine can be potentially applied to inhibit the growth of tumours that are sensitive 
to cystine deprivation. 
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Figure 58. Cystine/cysteine-degrading enzyme AECase inhibits the growth of 
NCI-NHI1650 cells engrafted tumour.  
A. Upper panel, Tumour volume curve following intraperitoneal injection of PBS 
control (dark circles), 30 mg/kg (dark squares) or 100 mg/kg (light triangles) 
AECase, up to 50 days after inoculation of NCI-NH1650 NSCLC cells. Lower panel, 
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Median survival curve of NCI-NH1650 NSCLC cells engrafted mice following 
intraperitoneal injection of PBS, 30 mg/kg or 100 mg/kg AECase. B. Upper panel, 
Immunoblots of lysates from NCI-NH1650 cells engrafted tumour tissues probed 
with antibodies detecting COX2 (arrow) and ERK1/2. NCI-NH1650 cells engrafted 
mice were treated with 100 mg/kg heat-inactivated AECase (Control HI AECase, 1-
4) or AECase (5-8), n=4. Lower panel, Quantification of the relative COX2/ERK 
ratio (p=0.04, n=4) from the immunoblots shown in the upper panel using ImageJ. C. 
Images of immunohistochemical (IHC) staining of COX2 (brown) in control and 
AECase-treated tumours. Mice were treated with AECase for 4 days in A, B and C. 
Experiments shown in this figure were performed by Shira L. Cramer, Kenda 
Triplett, Everett Stone (Panels A and C) and me (Panel B). 
 
3.4 P53 is activated by amino acid deprivation  
Previously published studies suggest that activation of p53 can lead to inhibition of 
mTORC1 [215]. However, when mTORC1 activity was assessed using 
phosphorylated S6K1 T389 as an indicator, there was no increase in mTORC1 
activity in p53 null (p53 -/-) HCT116 cells, compared to isogenic p53 wild type 
HCT116 cells (Figure 59A). Likewise, induction of p53 expression by etoposide did 
not seem to cause obvious alteration in mTORC1 activity. In accordance with this, 
although the activity of mTORC1 was inhibited by amino acid deprivation, the 
presence of p53 did not decrease mTORC1 activity, relative to that in cells lacking 
p53 (Figure 59B). On the contrary, absence of p53 seemed to weaken mTORC1 
activation (Figure 59). One possible explanation for this might be that the inhibitory 
effect of p53 on mTORC1 activity is subtle and that it has been concealed by the 
high level of mTORC1 activity in p53 wild type cells cultured in the rich RPMI 1640 
medium (Figure 59A). The reduced mTORC1 activity in p53 null cells might be a 
result of the higher proliferation, due to lack of p53, which has consumed nutrients 
and lowered mTORC1 activity. This has become clearer when the cells were 
cultured in the same medium for 48 hours before the media shifts in Figure 59B. The 
difference in mTOR1 activity (pS6K1 T389, +AA) between p53 wild type and null 
cells became more obvious presumably due to the increased difference of cell 
numbers between the two cell lines during the 48 hours. In addition, if the inhibitory 
effect of p53 on mTORC1 was fundamental, mTORC1 would have become 
unresponsive and remained active during amino acid deprivation in the p53 null cells, 
which was contrary to the almost complete suppression of mTORC1 activity under 
the same condition as shown in Figure 59B. Therefore, p53 seems to have no effect 
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on mTORC1 signalling, or subtle effect if there is any. On the other hand, the 
decreased mTORC1 activation in Figure 59A might result from the decreased 
mTORC1 expression in the p53 null cells, although it is currently unclear whether 
p53 affects mTORC1 expression.  
 
 
Figure 59. P53 does not seem to inhibit mTORC1 activity in HCT116 cells.  
A. immunoblots of p53 wild type (p53 +/+) and null (p53 -/-) HCT116 cells treated 
with the vehicle control DMSO or 20µM etoposide for 24 hours. Immunoblots were 
probed with antibodies detecting p53, S6K1 T389 and ERK1/2 (a loading control), 
and re-probed for total S6K1. B. immunoblots of extracts from p53 wild type (p53 
+/+) and null (p53 -/-) HCT116 cells cultured in media containing amino acids (+), 
lacking amino acids (-) for 60min, or deprived and stimulated with MEM amino 
acids for 15min. Identical gels and samples were used for gel 1-2 analysis. 
Immunoblots were probed for p53, S6K1 T389, total S6K1 and actin (a loading 
control).  
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Surprisingly, p53 seemed to be activated, represented by increased levels of 
phosphorylated Ser15 (Ser15 p-P53), following amino acid deprivation for 60min (-
AA), and its activity might continue to increases during amino acid replenishment 
for 15min (-/+AA) (Figure 60). This alteration in p53 activation could potentially 
result from the shift from the relatively rich medium RPMI 1640 (the routine culture 
medium for HCT116 cells) to DMEM medium lacking AA as described in the 
Methods Chapter 2.1.10 and 2.2.4. Moreover, the continuous increase of p53 
activation following amino acid replenishment could be a prolonged effect of amino 
acid deprivation. To address these two issues, the media shift experiment was 
repeated using the DMEM medium and a time-course of amino acid deprivation was 
conducted.  
 
Figure 60. Amino acid deprivation seems to activate p53.  
Immunoblots of extracts from p53 wild type and null HCT116 cells. Cells were 
seeded in RPMI medium supplemented with 10% d.FBS, 48 hours after seeding, for 
each cell line, one well was remained in the original medium (+AA), two wells were 
washed with and incubated in DMEM medium lacking amino acid with 10% d.FBS 
for 60min (-AA), and one of them was replenished with MEM amino acids for 
15min (-/+AA). Immunoblots were probed for phosphorylated Ser15 of p53 (Ser15 
p-P53), total p53 and actin. Identical gels and samples were used for gel 1-2 analysis.  
 
As shown in Figure 61, the level of p53 phosphorylation seemed to increase 
similarly with both media shift treatments, the shift from normal DMEM to DMEM 
lacking amino acids and from RPMI to DMEM lacking amino acids. Thus, the 
activation of p53 did not seem to result from different types of media used. In 
addition, the level of phospho-Ser15 was barely detectable in cells seeded in DMEM 
medium, compared to that in RPMI medium, thus the media shift for the subsequent 
experiments followed the shift from normal RPMI to DMEM lacking amino acids. 
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As a positive control for p53 phosphorylation and activation, two wells of HCT116 
cells (p53 wild type) were exposed to 10Gy of γ-irradiation to induce DNA damage 
and incubated for 1 hour and 3 hour respectively. The level of phosphorylated Ser15 
of p53 was indeed massively increased following irradiation exposure.  
 
Figure 61. Activation of p53 in response to amino acid deprivation.  
Immunoblots of extracts from p53 wild type HCT116 cells. Cells were seeded in 
RPMI/DMEM media supplemented with 10% d.FBS, 48 hours after seeding, for 
each media shift, one well was remained in the original RPMI or DMEM media, two 
wells were washed with and incubated in DMEM medium lacking amino acid with 
10% d.FBS for 60min (DMEM –AA 1h), and one of them was replenished with 
MEM amino acids for 15min (DMEM –AA 1h --> +AA). Separately, two wells were 
exposed to 10Gy of γ-irradiation, and one was incubated for 1 hours and the other 3 
hours. Immunoblots were probed for Ser15 p-P53, total p53 and actin.  
 
To address the second issue, a time course experiment was performed in which cells 
were deprived of amino acids for different times up to 4 hours, or deprived for 1 
hour and stimulated with amino acids for different times up to 1 hour, and p53 
activation was analyzed by immunoblotting (Figure 62). The level of p53 expression 
and probably phosphorylated Ser15 indeed increased, although slightly, following 
amino acid deprivation for up to 4 hours (Figure 62A). In accordance with this, 
amino acid replenishment for up to 1 hour did not increase p53 expression or 
phosphorylation (Figure 62B). However, the changes in p53 expression and activity 
following amino acid deprivation were subtle and thus require further investigation.  
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Figure 62. A time-course of p53 activation following amino acid deprivation or 
replenishment in HCT116 cells. 
A. A time-course of amino acid deprivation. Immunoblots of extracts from cells 
cultured in normal medium (+AA), or medium lacking amino acids for 1h, 2h and 4h 
(-AA), or medium lacking amino acid for 1h followed by re-addition of MEM amino 
acids for 15min (-/+AA). B. a time-course of amino acid replenishment. 
Immunoblots of extracts from cells cultured in medium lacking amino acid for 1h 
followed by re-addition of MEM amino acids for 15min, 30min and 1h (-/+AA). 
Immunoblots were probed for Ser15 p-P53, pS6K1 T389, total p53 and S6K1, 
vinculin (A) and actin (B) as loading controls. Identical gels and samples were used 
for panel A and B respectively.  
 
Similarly and in accordance with the upregulation of p53 by amino acid deprivation, 
inhibition of mTORC1 activity by rapamycin seems to enhance p53 expression and 
phosphorylation, as displayed in Figure 63. This has raised the possibility that 
activated mTORC1 might inhibit p53 activation. Again, the alteration in p53 
activation observed was slight and requires further investigation.  
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Figure 63. Inhibition of mTORC1 by rapamycin induced an increase in p53 
overall levels and activity.  
Immunoblots of extracts from HCT116 cells cultured in normal medium in the 
presence of DMSO or 100nM rapamycin for 1h. Immunoblots were probed for Ser15 
p-P53, pS6K1 T389, total p53 and S6K1, and actin. Identical gels and samples were 
used for gel 1-3 analysis.  
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Chapter 4 
                                                Discussion                                                          
158 
 
 
Chapter 4-Discussion 
Cancer cells are capable of growing and proliferating constitutively and rapidly, 
primarily due to activation of oncogenes and inactivation of tumour suppressor genes 
[1, 216]. Many proteins encoded by these genes are critical components of signalling 
pathways that regulate cell survival, such as the p53, PI3K/Akt, MAPK/ERK and 
mTORC1 signalling pathways [47, 217, 218]. Dysregulation of these pathways has 
been implicated in a large number of cancer types, indicating the importance of these 
signalling pathways for cancer formation and/or maintenance. In addition, cancer 
cells exhibit extremely high demands for glucose and amino acids to sustain rapid 
proliferation and growth [219, 220]. Therefore, understanding of the mechanisms by 
which cells sense extracellular signals, stimulating the corresponding cellular 
responses that mediate metabolism and cell growth, is essential for developing a 
well-targeted chemotherapy.  
 
This study has centred on amino acid nutrients and their association with the 
oncogenic signalling pathways including PI3K/Akt, MAPK/ERK and mTORC1, as 
well as the tumour suppressor p53, all of which play a role in mediating metabolism 
and cell survival [47, 132, 217, 218]. The mTORC1 signalling pathway coordinates 
the availability of amino acid nutrients and growth factors with the biosynthesis of 
proteins, lipids and nucleotides required for cell proliferation and growth [46]. The 
MAPK/ERK signalling pathway is known to sense growth factors and promotes cell 
proliferation and survival, and members in this pathway are frequently mutated in 
cancer [5, 6, 38]. We have thereby particularly focused on understanding the 
mechanism of mTORC1 inactivation in response to amino acid deprivation in a 
variety of tissue-culture cells, and on understanding the role of MAPK/ERK in 
cellular response to deprivation of amino acid cystine in isogenic HME cells and 
further in a panel of NSCLC cell lines.  
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4.1 Mechanisms of mTORC1 inactivation following amino acid depletion 
 
4.1.1 GCN2 is a novel inhibitor of mTORC1 
Activation of mTORC1 requires the presence of growth factors and amino acids [67, 
112]. This is consistent with the notion that to be activated mTORC1 needs to be 
translocated to the lysosomes, a process regulated by amino acids through the Rag 
GTPase heterodimer [96, 97]. In addition, mTORC1 activation requires the presence 
of GTP-bound Rheb that is controlled by growth factors through TSC2, the master 
inhibitor of mTORC1 [46]. Previous studies have also suggested that TSC2 
undergoes lysosomal translocation by interacting with the Rag GTPase heterodimer 
in the absence of amino acids, a process that is required for mTORC1 inactivation 
[99]. However, the regulator/mechanism of the translocation remains elusive.  
 
In this study, we present a novel mechanism by which mTORC1 becomes inactive 
following amino acid deprivation. This mechanism links a known effect of amino 
acid depletion, accumulation of uncharged tRNAs, to cellular response regulated by 
the mTORC1 signalling pathway. Through a high-throughput quantitative cell 
imaging siRNA screen of around 975 protein kinases/phosphatases to identify 
mediators of TSC2 localization in Hela cells, GCN2, a kinase that senses amino acid 
deficiency and represses protein synthesis, has been identified as a novel regulator of 
TSC2 lysosomal localization (Figure 25). In accordance with this, GCN2 is required 
for mTORC1 inactivation in response to amino acid deprivation (Figure 27). Our 
finding that GCN2 inhibits mTORC1 is consistent with a very recent publication, 
suggesting that GCN2 contributes to mTORC1 inhibition through a mechanism that 
is independent of ATF4, one of the downstream effectors of eIF2α [111]. GCN2 is 
known to be activated by uncharged tRNAs and acts to suppress translation initiation 
via phosphorylation on Ser51 of its only known substrate eIF2α [118-120]. Using the 
two novel GCN2-specific inhibitors, we further determined that the kinase activity of 
GCN2 is required to promote TSC2 lysosomal translocation (Figure 28), however, 
eIF2α does not seem to be necessary for TSC2 subcellular localization (Figure 29), 
which is also consistent with previously mentioned publication [111].  
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It is unlikely that TSC2 itself is the substrate of GCN2, since no interaction has been 
detected between TSC2 and GCN2 (Figure 30). Therefore, future work will firstly 
involve identification and characterization of new substrates of GCN2 that 
potentially act as mediators to regulate TSC2 lysosomal translocation in response to 
amino acid deprivation, and secondly investigation of negative regulators of TSC2 
lysosomal localization. Our data suggest that GCN2 potentially inhibits mTORC1 at 
least in part through promoting the lysosomal translocation of TSC2 independently 
of eIF2α phosphorylation. In addition, GCN2 inhibitors are likely to prevent TSC2 
from associating with lysosomes, indicating the kinase activity of GCN2 is required 
to regulate TSC2 lysosomal translocation. However, a recent publication also 
suggests that the protein-protein interactions can be structurally destabilized by 
protein binding to compounds [221, 222]. Similarly, it might be possible that the 
dissociation of TSC2 from lysosomes is a result of structural alteration of inhibitor-
bound GCN2. Therefore, identification and characterization of critical residues 
within the kinase domain of GCN2 involved in its effect on TSC2-lysosome 
association will help to clarify this issue. Furthermore, it might be also interesting in 
the future to investigate the other candidates (apart from GCN2) from the imaging-
based high-throughput siRNA screen displayed in Figure 25, however, these kinases 
do not seem relevant to the mTORC1 pathway.  
 
4.1.2. Alternative model of mTORC1 regulation by TSC/Rheb axis  
It is well established that GTP-bound Rheb directly binds to mTORC1 and activates 
its catalytic activity in response to growth factors, and the master inhibitor TSC2 
inhibits mTORC1 by deactivating GTP-bound Rheb when growth factors are scarce 
(reviewed in reference [45]). However, whether the TSC/Rheb axis is associated 
with the lysosomal localization of mTORC1 and the Rag GTPases in response to 
amino acid conditions remained elusive. In addition to identifying GCN2 that 
inhibits mTORC1 potentially via regulating the lysosomal localization of TSC2, our 
studies also demonstrate that Rheb indirectly activates mTORC1 via promoting the 
lysosomal localization of mTOR and RagC, and it also contributes to mTORC1 
inactivation by stabilizing TSC2-lysosome association. Moreover, TSC2 is found to 
promote mTORC1 inactivation via stimulating the dissociation of RagA from 
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lysosomes. Therefore, our findings provide a more complete mechanistic framework 
for regulation of mTORC1 by the TSC2/Rheb axis in response to amino acid 
conditions.  
 
The lysosomal translocation of TSC2 seems to be mediated by the Rag GTPase 
heterodimer [99], and in accordance with this, RagA is required for TSC2 lysosomal 
translocation (Figure 30). In addition to the Rag GTPases, we have also identified 
Rheb, the substrate of TSC2 and a critical activator of mTORC1 [84], as a mediator 
that promotes the lysosomal translocation of both TSC2 and mTORC1 in response to 
amino acid deficiency and sufficiency respectively (Figures 30 and 33). Furthermore, 
Rheb is not only required for RagC to localize with lysosomes (Figure 33) but also 
for the association of RagA with the lysosomal protein Ragulator (Figure 34). 
Therefore, our findings suggest that Rheb is more important than it has been thought, 
and have positioned Rheb in the mTORC1 signalling pathway in response to amino 
acids due to the identified ability of Rheb to mediate the lysosomal localization of 
mTORC1, TSC2, RagC and RagA. However, whether Rheb interacts with the Rag 
GTPases requires further investigation.  
 
Consistent with previous findings [99], TSC2 was found to indeed interact with the 
RagA/RagC heterodimer and this interaction is enhanced by amino acid deprivation 
(Figure 31). However, TSC2 seems to interact preferentially with RagC (Figure 31), 
instead of RagA as has been suggested [99]. This discrepancy may have been caused 
by different experimental procedures including different plasmids that were used for 
the pull down assay, lysis and pull down conditions. The cell lines used might also 
be a concern although HEK293T and HEK293FT (a fast growing variant of 
HEK293T) cell lines were used in both our experiments and the cited article.  
 
Currently it is difficult to detect the subcellular distribution of endogenous RagA due 
to lack of antibody detecting endogenous RagA by immunofluorescence. However, 
TSC2 seems to prevent HA-tagged RagA from associating with lysosomes in 
response to amino acid deprivation, but it does not affect RagC co-localization with 
lysosomes under the same condition (Figure 35). This suggests an alternative model 
of mTORC1 inhibition by TSC2 in response to amino acid deficiency that lysosome-
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localized TSC2 likely inhibits mTORC1 indirectly by dissociating RagA from 
lysosomes. Endogenous RagC is found to localize on lysosomes regardless of amino 
acid conditions, which is consistent with the findings previously reported in 
reference [95]. It is worth noticing that HA-tagged RagA appears to dissociate from 
lysosomes upon amino acid deprivation, a finding different from suggestion that 
RagA localizes with lysosomes under the same condition that was proposed in the 
same publication. This statement was based on the results of IP experiments showing 
that RagA co-immunoprecipitates with RagC and that endogenous RagC localizes on 
lysosomes, regardless of amino acid conditions. An antibody that specifically detects 
endogenous RagA by immunofluorescence will certainly clarify whether the 
association of endogenous RagA with lysosomes is dependent on amino acids.  
 
It has been debated for many years whether Rheb is localized on the lysosomal 
membrane, due to lack of suitable reagents, including an antibody that can be used 
for detecting endogenous Rheb at that time [95, 101, 102]. By utilizing an antibody 
(recently established at Institute of Cancer Research) that specifically detects 
endogenous Rheb by immunofluorescence, it has been demonstrated in our studies 
that Rheb does not co-localize with lysosomes (Figure 32). Whether Rheb co-
localizes with mTORC1, as well as the compartment that retains Rheb need to be 
further investigated.  
 
Nevertheless, a very recent publication from 2018 suggests that endogenous Rheb 
localizes with Golgi apparatus in proximity to lysosomes in an amino acid-
independent manner [103], which is in accordance with our findings. On the other 
hand, another publication from 2015 suggests that endogenous Rheb localizes with 
lysosomes in the presence of amino acids [223]. It is interesting that in both of these 
studies a commercial antibody from Abnova has been used to detect Rheb. However, 
whether these two antibodies were from the same clone cannot be confirmed due to 
lack of information. In addition, the discrepancy might be caused by different cell 
lines were used in both studies, which are HEK293T and HCT116 cell lines. The 
differences between our findings and some of the published studies might be a result 
of a number of things. For example, the antibodies used for detection of endogenous 
Rheb by immunofluorescence in the published studies and the one used for 
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experiments described here were from different clones. In addition, Rheb might have 
differential expression and localization patterns in different cell lines or tissues. 
HCT116 cells [223] and HEK293T [103] cells used in the two studies were derived 
from colon cancer and human embryonic kidney respectively, whilst Hela cells used 
in our experiments were derived from cervical cancer and are also infected with 
HPV. Another reason might be different experimental procedures including culturing 
cells and media shift, and reagents used to culture or treat cells that might be from 
different companies or batches. Moreover, this discrepancy might result from the 
highly dynamic subcellular distribution of Rheb [102]. Overall, the subcellular 
localization of Rheb seems to be more complicated than what was initially proposed, 
and will require further investigation with approaches that allow the endogenous 
Rheb to be “tracked” in order to understand the dynamics of its subcellular 
trafficking.  
 
Our studies therefore support an alternative model by which mTORC1 is regulated 
by the TSC/Rheb axis in response to amino acid conditions (Figure 64). In the 
presence of amino acids, mTORC1 translocates onto lysosomal membrane via 
interacting with the RagA-RagC heterodimer, and this association is stabilized by 
Rheb via unknown mechanism(s). TSC is cytosolic and unable to inhibit Rheb. GTP-
bound Rheb then activates lysosome-localized mTORC1. Upon amino acid 
deprivation, GCN2 is activated and promotes the association of TSC with the RagA-
RagC heterodimer. TSC is then recruited onto lysosomal surface likely via 
interacting with RagC. Rheb stabilizes the association via unknown mechanism(s). 
Lysosome-localized TSC2 not only deactivates Rheb but also promotes RagA to 
dissociate from lysosomes, leading to release of mTORC1 from lysosomes and thus 
inactivation of mTORC1.  
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Figure 64. A suggested model of mTORC1 regulation by TSC/Rheb in response 
to amino acid deprivation 
Panel 1, in the presence of amino acids, mTORC1 is recruited to lysosomal 
membrane via interacting with the RagA/RagC heterodimer that binds to the 
lysosomal protein complex Ragulator. TSC, in contrast, residues in the cytosol and is 
unable to deactivates Rheb. GTP-bound Rheb, localized in proximity to lysosomes, 
not only activate the catalytic function of mTORC1 but also stabilizes the association 
of mTORC1 with the Rag heterodimer via an unknown mechanism. Activated 
mTORC1 stimulates a series of subcellular processes, ultimately promoting cell 
growth. Panel 2, upon amino acid deprivation, the kinase GCN2 is activated and 
promotes the lysosomal translocation of TSC via an unknown mechanism. TSC is 
recruited to lysosomal membrane by interacting with the RagA/RagC heterodimer, 
likely with RagC. Rheb stabilizes the lysosome-TSC association also via an 
unknown mechanism. Lysosome-localized TSC inhibits mTORC1 via inducing the 
GTP hydrolysis of Rheb. In addition, TSC seems to promote the dissociation of 
RagA from lysosomes, which destabilizes the interaction of mTORC1 with the 
RagA/RagC heterodimer and thus results in release of mTORC1 into cytosol. 
Inactive mTORC1 is unable to stimulate cell growth or repress autophagy. The 
processes indicated by arrows are novel findings compared to the proposed model in 
Figure 12. 
 
4.2. The MAPK/ERK cascade promotes cell death in response to cystine 
deprivation 
Anticancer therapies that affect cancer cells but spare normal cells are most 
beneficial for cancer patients. The concept of synthetic lethality opens opportunities 
to identify cancer-specific vulnerabilities that can be exploited to selectively 
eliminate cancer cells [224-227]. Instead of targeting a second gene which is the 
conventional way to identify synthetic lethality of cancer [224], we have focused on 
the reprogrammed metabolism of cancer cells, to identify metabolic vulnerabilities 
targeting the oncogenes in the MAPK/ERK cascade. Cancer cells universally exhibit 
reprogramming of glucose and amino acids metabolism [219, 220] to sustain their 
rapid cell division and growth. Many cancer types are found to strongly dependent 
on specific amino acids from either exogenous or endogenous sources [220, 228]. 
Amino acid deprivation therefore provides a potential approach to identify novel 
cancer-specific vulnerabilities.  
 
We have utilized isogenic breast cell lines (HME) that express a number of mutated 
oncogenic proteins (oncoproteins) resulting in activation of specific signalling 
pathways that have been established by Prof Alberto Bardelli [201]. Utilizing such 
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isogenic cell line confers an advantage of avoiding the highly heterogeneous context 
within cancer cells and allowing the oncogenic mutation-specific features to be 
characterized. These four mutations: EGFR delE746-A750, KRAS G13D, BRAF 
V600E, and PI3KCA H1047R, have been frequently implicated in a variety of 
cancer types, such as NSCLC, melanomas, pancreatic and breast cancer [27, 37, 38]. 
Particularly, EGFR delE746-A750 mutant is the most common EGFR mutation in 
NSCLCs [5].  
 
Through an amino acid dropout screen on HME cell lines containing isogenic knock-
in mutations, EGFR delE746-A750, KRAS G13D, BRAF V600E, and PI3KCA 
H1047R, we have identified amino acid cystine as a vulnerability specific to EGFR 
delE746-A750 HME cell line (Figure 45). Deprivation of cystine, but not of any 
other amino acids from the culture medium, has caused lethality in EGFR delE746-
A750 but not EGFR wild-type HME cells, and the induced cell death exhibits non-
apoptotic morphological features (Figure 45 and Appendix 6). Based on 
morphological characteristics observed, the cell death is likely to occurs via 
ferroptosis since we have also found that it is accompanied by elevated accumulation 
of lipid ROS and is strictly dependent on iron (Appendix 6). Furthermore, this 
cystine deprivation-induced cell death requires the activating MAPK/ERK cascade, 
since inhibition of this cascade using specific inhibitors prevents accumulation of 
lipid ROS and cell death (Figure 47). This suggests that cystine/GSH is likely to act 
as a synthetic lethal partner of the EGFR delE746-A750 mutant. It seems that 
deprivation of cystine has triggered a certain cellular stress, most likely oxidative 
stress, which is aggravated by the activating MAPK/ERK cascade as in the case of 
EGFR delE746-A750 HME cells, and results in severe loss of cell viability.  
 
Cancer cells experience higher oxidative stress from ROS than non-malignant cells 
due to genetic alterations and abnormal growth and as a result, maintenance of the 
antioxidant glutathione (GSH) is essential for their survival and proliferation [229-
231]. Wild-type HME cells might maintain the intracellular level of antioxidants, 
mainly cystine and GSH [229-231], to scavenge ROS and survive cystine 
deprivation. However, this does not seem to be the case since the intracellular levels 
of cystine and GSH decline to similar extends in wild-type and EGFR delE746-A750 
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cells (Figure 48). Another possibility is that EGFR delE746-A750 cells already 
produce high amounts of lipid ROS, but under the normal-nutrient condition the lipid 
ROS is scavenged by cellular antioxidants and thus the damage is eliminated. 
However, during deprivation of cystine, the cellular antioxidants are declined and 
incapable of scavenging the original high level of ROS, which results in dramatic 
damage to the cells. In accordance with this, inhibition of the MAPK/ERK cascade 
has lowered lipid ROS and thus protects these cells from cystine deprivation (Figure 
47).  
 
We further identified that the MAPK/ERK cascade promotes lipid ROS 
accumulation through regulating two enzymes, GPX4 and NOX4. These two 
enzymes act to remove and produce lipid ROS respectively, thereby tightly control 
the cellular level of lipid ROS [183, 232]. The activating MAPK/ERK cascade in the 
EGFR delE746-A750 HME cells downregulates the cellular level of GPX4 and 
upregulates that of NOX4 (Figures 50, 51 and 53), which render these cells rather 
susceptible to oxidative stress resulting from cystine deprivation. Therefore, a model 
of MAPK/ERK promoting cell death in response to cystine deprivation in the EGFR 
delE746-A750 HME cells has been proposed (Figure 65). The persistently active 
MAPK/ERK cascade, due to the EGFR delE746-A750 mutation, increases the 
production of lipid ROS by upregulating NOX4 and downregulating GPX4. Under 
normal-nutrient condition, this high level of lipid ROS is scavenged by cellular 
antioxidants mainly glutathione (GSH) that is synthesized from cysteine. In the 
absence of cystine, the cellular level of GSH has been depleted, resulting in 
excessive accumulation of lipid ROS and thus severe oxidative damages to the cell 
membrane and other compartments. These damages ultimately leads to cell death 
likely via ferroptosis. In addition, it is likely that cystine/cysteine is a synthetic lethal 
partner of the EGFR delE746-A750 mutation in HME cells, by targeting the 
intracellular cystine/cysteine pool using AECase, the EGFR mutant cells become 
vulnerable and inviable whereas the wild type HME cells survive (Figure 66).  
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Figure 65. MAPK/ERK cascade promotes cell death in response to cystine 
deprivation.  
In EGFR delE746-A750 HME cells, the MAPK/ERK cascade is continuously active, 
which upregulates the expression of NOX4 and downregulates that of GPX4 via 
unknown mechanisms. The lipid ROS is thus produced at a high level in these cells 
but they are scavenged by cellular antioxidants mainly GSH under the normal-
nutrient condition (Panel 1). During cystine deprivation, the GSH pool has been 
depleted due to lack of cysteine and cystine, and the lipid ROS is thus accumulated 
at high levels, which cause oxidative damages to the cells and ultimately leads to cell 
death likely via ferroptosis (Panel 2). The mechanism that the MAPK/ERK cascade 
promotes ferroptosis via downregulating GPX4 and upregulating NOX4 is a novel 
finding compared to the model in Figure 49.  
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Figure 66. Schematic representation of cystine/cysteine as a synthetic lethal 
target of EGFR delE746-A750 mutation. 
Depletion of cystine/cysteine pool by AECase causes cell death (likely ferroptosis) 
in EGFR delE746-A750 HME cells whereas wild type cells stay viable.  
 
Through the cystine deprivation experiments conducted using nine NSCLC cell lines 
obtained from Liverpool cell line repository, we identify that the NCI-NH1650 cell 
line is vulnerable to cystine depletion (Figure 55). This cell line contains the two 
most common EGFR mutations, delE746-A750 and L858R [5, 6], as well as the 
EGFR T790M mutation that is associated with resistance to EGFR inhibitor therapy 
[20]. Our in vitro work demonstrates that the NCI-NH1650 cells are susceptible to 
pharmacological depletion of cystine/cysteine pools by AECase, an engineered 
cysteine/cystine-degrading enzyme (Figure 57). Moreover, our study on a mouse 
tumour model engrafted with NCI-NH1650 NSCLC cells suggests that AECase and 
its analogues might be potentially used in preclinical studies and clinical application 
to inhibit the growth of tumours that are susceptible to cystine depletion. In addition, 
171 
 
 
our study has demonstrated an approach to screen for synthetic lethality of 
oncogenes based on amino acid metabolism reprogramming of cancer cells. This 
approach can be potentially used to screen for metabolic synthetic lethality of 
cancer-associated genes, which might contribute to novel cancer therapeutics.  
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Appendix - Supplementary Tables and Figures 
Appendix 1. Sites of point mutations in human MAP4K3 sequence. 
A. MAP4K3 opening reading frame (ORF, 2685bp) obtained from the website of 
GenScript. B. MAP4K3 amino acid sequence (894 amino acids) obtained from the 
website of UniProt. DNA and amino acid sequence of the nine MAP4K3 point 
mutations are highlighted in red in A and B.  
 
A 
 
5’      1 atgaaccccg gcttcgattt gtcccgccgg aacccgcagg aggacttcga gctgattcag 
       61 cgcatcggca gcggcaccta cggcgacgtc tacaaggcac ggaatgttaa cactggtgaa 
      121 ttagcagcaa ttaaagtaat aaaattggaa ccaggagaag actttgcagt tgtgcagcaa 
      181 gaaattatta tgatgaaaga ctgtaaacac ccaaatattg ttgcttattt tggaagctat 
      241 ctcaggcgag ataagctttg gatttgcatg gagttttgtg gaggtggttc tttacaggat 
      301 atttatcacg taactggacc tctgtcagaa ctgcaaattg catatgttag cagagaaaca 
      361 ctgcagggat tatattatct tcacagtaaa ggaaaaatgc acagagatat aaagggagct 
      421 aacattctat taacggataa tggtcatgtg aaattggctg attttggagt atctgcacag 
      481 ataacagcta caattgccaa acggaagtct ttcattggca caccatattg gatggctcca 
      541 gaagttgcag ctgttgagag gaaggggggt tacaatcaac tctgtgatct ctgggcagtg 
      601 ggaatcactg ccatagaact tgcagagctt cagcctccta tgtttgactt acacccaatg 
      661 agagcattat ttctaatgac aaaaagcaat tttcagcctc ctaaactaaa ggataaaatg 
      721 aaatggtcaa atagttttca tcactttgtg aaaatggcac ttaccaaaaa tccgaaaaaa 
      781 agacctactg ctgaaaaatt attacagcat ccttttgtaa cacaacattt gacacggtct 
      841 ttggcaatcg agctgttgga taaagtaaat aatccagatc attccactta ccatgatttc 
      901 gatgatgatg atcctgagcc tcttgttgct gtaccacata gaattcactc aacaagtaga 
      961 aacgtgagag aagaaaaaac acgctcagag ataacctttg gccaagtgaa atttgatcca 
     1021 cccttaagaa aggagacaga accacatcat gaacttcccg acagtgatgg ttttttggac 
     1081 agttcagaag aaatatacta cactgcaaga tctaatctgg atctgcaact ggaatatgga 
     1141 caaggacacc aaggtggtta ctttttaggt gcaaacaaga gtcttctcaa gtctgttgaa 
     1201 gaagaattgc atcagcgagg acacgtcgca catttagaag atgatgaagg agatgatgat 
     1261 gaatctaaac actcaactct gaaagcaaaa attccacctc ctttgccacc aaagcctaag 
     1321 tctatcttca taccacagga aatgcattct actgaggatg aaaatcaagg aacaatcaaG 
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     1381 agatgtccca tgtcagggag cccagcaaag ccatcccaag ttccacctag accaccacct 
     1441 cccagattac ccccacacaa acctgttgcc ttaggaaatg gaatgagctc cttccagtta 
     1501 aatggtgaac gagatggctc attatgtcaa caacagaatg aacatagagg cacaaacctt 
     1561 tcaagaaaag aaaagaaaga tgtaccaaag cctattagta atggtcttcc tccaacacct 
     1621 aaagtgcata tgggtgcatg tttttcaaaa gtttttaatg ggtgtccctt gaaaattcac 
     1681 tgtgcatcat catggataaa cccagataca agagatcagt acttgatatt tggtgccgaa 
     1741 gaagggattt ataccctcaa tcttaatgaa cttcatgaaa catcaatgga acagctattc 
     1801 cctcgaaggt gtacatggtt gtatgtaatg aacaattgct tgctatcaat atctggtaaa 
     1861 gcttctcagc tttattccca taatttacca gggctttttg attatgcaag acaaatgcaa 
     1921 aagttacctg ttgctattcc agcacacaaa ctccctgaca gaatactgcc aaggaaattt 
     1981 tctgtatcag caaaaatccc tgaaaccaaa tggtgccaga agtgttgtgt tgtaagaaat 
     2041 ccttacacgg gccataaata cctatgtgga gcacttcaga ctagcattgt tctattagaa 
     2101 tgggttgaac caatgcagaa atttatgtta attaagcaca tagattttcc tataccatgt 
     2161 ccacttagaa tgtttgaaat gctggtagtt cctgaacagg agtacccttt agtttgtgtt 
     2221 ggtgtcagta gaggtagaga cttcaaccaa gtggttcgat ttgagacggt caatccaaat 
     2281 tctacctctt catggtttac agaatcagat accccacaga caaatgttac tcatgtaacc 
     2341 caactggaga gagataccat ccttgtatgc ttggactgtt gtataaaaat agtaaatctc 
     2401 caaggaagat taaaatctag caggaaattg tcatcagaac tcacctttga tttccagatt 
     2461 gaatcaatag tgtgcctaca agacagtgtg ctagctttct ggaaacatgg aatgcaaggt 
     2521 agaagtttta gatctaatga ggtaacacaa gaaatttcag atagcacaag aattttcagg 
     2581 ctgcttggat ctgacagggt cgtggttttg gaaagtaggc caactgataa ccccacagca 
     2641 aatagcaatt tgtacatcct ggcgggtcat gaaaacagtt actga 3’ 
 
B 
        10         20         30         40         50 
MNPGFDLSRR NPQEDFELIQ RIGSGTYGDV YKARNVNTGE LAAIKVIKLE  
        60         70         80         90        100 
PGEDFAVVQQ EIIMMKDCKH PNIVAYFGSY LRRDKLWICM 
EFCGGGSLQD  
       110        120        130        140        150 
IYHVTGPLSE LQIAYVSRET LQGLYYLHSK GKMHRDIKGA NILLTDNGHV  
       160        170        180        190        200 
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KLADFGVSAQ ITATIAKRKS FIGTPYWMAP EVAAVERKGG 
YNQLCDLWAV  
       210        220        230        240        250 
GITAIELAEL QPPMFDLHPM RALFLMTKSN FQPPKLKDKM KWSNSFHHFV  
       260        270        280        290        300 
KMALTKNPKK RPTAEKLLQH PFVTQHLTRS LAIELLDKVN NPDHSTYHDF  
       310        320        330        340        350 
DDDDPEPLVA VPHRIHSTSR NVREEKTRSE ITFGQVKFDP PLRKETEPHH  
       360        370        380        390        400 
ELPDSDGFLD SSEEIYYTAR SNLDLQLEYG QGHQGGYFLG ANKSLLKSVE  
       410        420        430        440        450 
EELHQRGHVA HLEDDEGDDD ESKHSTLKAK IPPPLPPKPK SIFIPQEMHS  
       460        470        480        490        500 
TEDENQGTIK RCPMSGSPAK PSQVPPRPPP PRLPPHKPVA LGNGMSSFQL  
       510        520        530        540        550 
NGERDGSLCQ QQNEHRGTNL SRKEKKDVPK PISNGLPPTP KVHMGACFSK  
       560        570        580        590        600 
VFNGCPLKIH CASSWINPDT RDQYLIFGAE EGIYTLNLNE LHETSMEQLF  
       610        620        630        640        650 
PRRCTWLYVM NNCLLSISGK ASQLYSHNLP GLFDYARQMQ 
KLPVAIPAHK  
       660        670        680        690        700 
LPDRILPRKF SVSAKIPETK WCQKCCVVRN PYTGHKYLCG ALQTSIVLLE  
       710        720        730        740        750 
WVEPMQKFML IKHIDFPIPC PLRMFEMLVV PEQEYPLVCV GVSRGRDFNQ  
       760        770        780        790        800 
VVRFETVNPN STSSWFTESD TPQTNVTHVT QLERDTILVC LDCCIKIVNL  
       810        820        830        840        850 
QGRLKSSRKL SSELTFDFQI ESIVCLQDSV LAFWKHGMQG RSFRSNEVTQ  
       860        870        880        890  
EISDSTRIFR LLGSDRVVVL ESRPTDNPTA NSNLYILAGH ENSY 
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Appendix 2. Primers for MAP4K3 mutagenesis and sequencing 
 
 
 
 
 
 
 
  
Appendix 2-1 
Primers for mutagenesis 
Site  Forward (F) / 
Reverse (R) 
Sequence 5' to 3' 
D54N  (g160a) F ggaaccaggagaaaactttgcagttgtgc 
R gcacaactgcaaagttttctcctggttcc 
V182F (g544t) F ggatggctccagaatttgcagctgttgag 
R ctcaacagctgcaaattctggagccatcc 
E209G (a626g) F gccatagaacttgcagggcttcagcctcctatg 
R cataggaggctgaagccctgcaagttctatggc 
N290I (a869) F gctgttggataaagtaattaatccagatcattcc 
R ggaatgatctggattaattactttatccaacagc 
E351K (g1051a) F gacagaaccacatcataaacttcccgacagtg 
R caatgtcgggaagtttatgatgtggttctgtc 
Q473K (c1417a) F ccagcaaagccatccaaagttccacctagacc 
R ggtctaggtggaactttggatggctttgctgg 
T669A (a2005g) F gcaaaaatccctgaagccaaatggtgccag 
R ctggcaccatttggcttcagggatttttgc 
D715Y (g2143t) F gttaattaagcacatatattttcctataccatg 
R catggtataggaaaatatatgtgcttaattaac 
R753Q (g2258a) F caaccaagtggttcaatttgagacggtc 
R gaccgtctcaaattgaaccacttggttg 
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Appendix 2-2 
Primers for sequencing  
Site  Forward (F) / 
Reverse (R) 
Sequence 5' to 3' 
D54N  (g160a) F cggctacaattaatacataacc 
R cagccaatttcacatgacca 
V182F (g544t) F gtggaggtggttctttacagg 
R ctacttgttgagtgaattc 
E209G (a626g) F gtggaggtggttctttacagg 
R ctacttgttgagtgaattc 
N290I (a869) F ggcacttaccaaaaatccg 
R ctacttgttgagtgaattc 
E351K (g1051a) F ggcacttaccaaaaatccg 
R ctccctgacatgggacatctc 
Q473K (c1417a) F gaaggagatgatgatgaatct 
R ccctggtaaattatgggaat 
T669A (a2005g) F gccgaagaagggatttatacc 
R caacagtccaagcatacaagg 
D715Y (g2143t) F gccgaagaagggatttatacc 
R caacagtccaagcatacaagg 
R753Q (g2258a) F gaacaggagtaccctttagt 
R caacagtccaagcatacaagg 
 
  
177 
 
 
Appendix 3. PCR conditions for mutagenesis of human MAP4K3 
 
Appendix 3-1 
50µl PCR reaction setup 
10X reaction buffer  5µl 
QuikSolution reagent 3µl 
DNA template 10ng 
forward primer 125ng 
reverse primer 125ng 
10mM dNTP Mix 1µl 
DNA polymerase 2.5U 
ddH2O to a final volume of 50µl 
 
Appendix 3-2 
Thermol cycle for PCR reaction  
Step Cycles  Temperature Time 
1 1 95°C 1min 
2 18 
95°C 50s 
60°C 50s 
68°C 8.5min 
3 1 68°C   7min 
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Appendix 4. Rheb promotes the co-localization of mTOR and RagC with 
lysosomes. 
Confocal immunofluorescence micrographs of Hela cells stained with antibodies to 
mTOR (green in A) or RagC (green in B) and LAMP2 (red). Cells were treated with 
medium lacking amino acids for 60min (-AA) or deprived and stimulated with MEM 
amino acids for 15min (+AA) following transfection with control (Ctrl) and Rheb-
specific siRNAs.  
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Appendix 5. Inhibition of the MAPK/ERK cascade by the specific 
inhibitors.  
A. Schematic representation of MAPK/ERK cascade with the five inhibitors. B. 
Immunoblots of EGFR mutant cell lysates probed with antibodies detecting 
phosphorylated EGFR (pEGFR), ERK (ppERK), total EGFR and ERK1/2. Cells 
were cultured in normal medium in the presence of DMSO (vehicle control) and 
inhibitors for 30 hours.  
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Appendix 6. Publication 
See next page  
ReportOncogene-Selective Sensitivity to Synchronous Cell
Death following Modulation of the Amino Acid
Nutrient CystineGraphical AbstractHighlightsd A nutrient depletion screen revealed a selective role for
cystine in promoting viability
d Cystine was shown to promote viability by preventing
ferroptosis
d Sensitivity to depletion of cystine was related to activation of
MAPK
d Depletion of cystine inhibited tumor growth in a NSCLC
xenograft modelPoursaitidis et al., 2017, Cell Reports 18, 2547–2556
March 14, 2017 ª 2017 The Authors.
http://dx.doi.org/10.1016/j.celrep.2017.02.054Authors
Ioannis Poursaitidis, Xiaomeng Wang,
Thomas Crighton, ..., Scott W. Rowlinson,
Everett Stone, Richard F. Lamb
Correspondence
lambr@hope.ac.uk
In Brief
Poursaitidis et al. show that EGFR and
BRAF mutant cells are sensitive to
ferroptosis. Sensitivity was related to
activation of MAPK signaling and the
generation and release of hydrogen
peroxide. To show that this sensitivity can
be exploited therapeutically, growth of an
EGFR mutant NSCLC xenograft was
inhibited by a cyst(e)ine-degrading
enzyme.
Cell Reports
ReportOncogene-Selective Sensitivity to Synchronous
Cell Death following Modulation
of the Amino Acid Nutrient Cystine
Ioannis Poursaitidis,2,9 XiaomengWang,2,9 ThomasCrighton,2 Christiaan Labuschagne,3 DavidMason,4 Shira L. Cramer,5
Kendra Triplett,5 Rajat Roy,6 Olivier E. Pardo,6 Michael J. Seckl,6 Scott W. Rowlinson,7 Everett Stone,8
and Richard F. Lamb1,10,*
1School of Health Sciences, Liverpool Hope University, Hope Park Campus, Liverpool L16 9JD, UK
2Department of Molecular and Clinical Cancer Medicine, University of Liverpool NorthWest Cancer Research Centre, University of Liverpool,
200 London Road, Liverpool L69 7ZB, UK
3Cancer Research UK Beatson Institute, Switchback Road, Bearsden, Glasgow G61 1BD, UK
4Centre for Cell Imaging, Institute of Integrative Biology, University of Liverpool, Biosciences Building, Crown Street, Liverpool L69 7ZB, UK
5Department of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA
6Division of Cancer CRUK Laboratories, 1st Floor ICTEM Building, Hammersmith Hospital Campus of Imperial College London, Du Cane
Road, London W120NN, UK
7Aeglea BioTherapeutics, Austin, TX 78746, USA
8Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA
9Co-first author
10Lead Contact
*Correspondence: lambr@hope.ac.uk
http://dx.doi.org/10.1016/j.celrep.2017.02.054SUMMARY
Cancer cells reprogram their metabolism, altering
both uptake and utilization of extracellular nutrients.
We individually depleted amino acid nutrients from
isogenic cells expressing commonly activated onco-
genes to identify correspondences between nutrient
supply and viability. In HME (human mammary
epithelial) cells, deprivation of cystine led to
increased cell death in cells expressing an activated
epidermal growth factor receptor (EGFR) mutant.
Cell death occurred via synchronous ferroptosis,
with generation of reactive oxygen species (ROS).
Hydrogen peroxide promoted cell death, as both
catalase and inhibition of NADPH oxidase 4 (NOX4)
blocked ferroptosis. Blockade of EGFR or mitogen-
activated protein kinase (MAPK) signaling similarly
protected cells from ferroptosis, whereas treatment
of xenografts derived from EGFR mutant non-
small-cell lung cancer (NSCLC) with a cystine-
depleting enzyme inhibited tumor growth in mice.
Collectively, our results identify a potentially exploit-
able sensitization of some EGFR/MAPK-driven tu-
mors to ferroptosis following cystine depletion.INTRODUCTION
Synthetic lethal screens have led to the identification of specific
cancer cell vulnerabilities (Barbie et al., 2009; Possik et al., 2014;
Scholl et al., 2009). One such vulnerability has previously beenCell R
This is an open access article under the CC BY-Nexploited therapeutically in acute lymphoblastic leukemia
(ALL), where leukemic cells lacking asparagine synthase are
known to require the amino acid asparagine and apoptose
following administration of asparaginase (Holleman et al.,
2003; Tallal et al., 1970). Overall amino acid abundance itself
may be higher in cancerous tissue, suggesting an increased
need for amino acids in some tumors (Hirayama et al., 2009;
Kami et al., 2013). In pancreatic ductal adenocarcinoma
(PDAC), KRAS is thought to induce a genetic program that favors
metabolism of glutamine, rendering these cells particularly sen-
sitive to glutamine withdrawal (Son et al., 2013). Some tumor cell
lines (Scott et al., 2000) and primary tumors (Gonzalez and Byus,
1991) require exogenous arginine, indicating some selectivity in
amino acid requirements. Here, we have explored the extracel-
lular amino acid nutrient requirements of cells gene edited to
introduce common oncogenic mutations. We identify a selective
sensitivity to synchronous cell death by ferroptosis following
deprivation of the amino acid nutrient cystine. Sensitization
was found to be related to elevatedmitogen-activated protein ki-
nase (MAPK) signaling, with synchronous cell death involving
hydrogen peroxide generation and release. Finally, we show
that enzymatic cystine deprivation in vivo results in an inhibition
of tumor growth in an EGFR mutant NSCLC xenograft model,
suggesting that, by promoting ferroptosis, cystine depletion pro-
vides therapeutic benefit in some tumors.RESULTS
EGFR Mutant HME Cells Undergo Cell Death when
Deprived of the Amino Acid Nutrient Cystine
Human mammary epithelial (HME) cells were gene edited to
introduce common oncogenic driver mutations (epidermaleports 18, 2547–2556, March 14, 2017 ª 2017 The Authors. 2547
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Deprivation of Cystine Induces Selective Cell Death by Ferroptosis in EGFR Mutant HME Cells
(A) Cell viability screen of HME cell lines deprived of individual amino acids for 72 hr. Histograms represent the average viability ± SD of three biological replicates
relative to complete media assigned a value of 1 (+AA).
(B) Phase contrast micrographs of wild-type (WT) and EGFR (delE746-A750) HME cells deprived of cystine for 24 hr. Arrowheads indicate membrane
extrusions.
(C) Time-lapse phase contrast (left) and Sytox Green (right) micrographs of live EGFR (delE746-A750) cells deprived of cystine for various times up to 24 hr.
(legend continued on next page)
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growth factor receptor [EGFR] [delE746-A750], KRAS [G13D],
BRAF [V600E], and PIK3CA [H1047R]) in an otherwise diploid ge-
netic background (Di Nicolantonio et al., 2008). Following culture
in media deficient in specific amino acids, we measured cell
viability. All lines deprived of L-cystine (cystine) exhibited some
loss of viability ranging from 40% to >80%. However, EGFR
and BRAF mutant HME cells were especially sensitive, with
viability inhibited by >80% (Figure 1A). Cystine deprivation
induced a widespread loss of viability in EGFR mutant, but not
wild-type HME, cells, with the majority of cells exhibiting a
swollen or burst morphology (Figure 1B).
Next, we monitored EGFR mutant HME cells deprived of
cystine by video time-lapse microscopy and observed rapid
and synchronous cell swelling/bursting (Figure 1C; Movie S1).
Sytox Green, a cell-impermeant nuclear stain, synchronously
entered cells after cystine depletion (Figure 1C), indicating loss
of plasma membrane integrity at <2 mM cystine (Figure 1D).
Death was reversible upon re-supplementation of cystine for
up to 10 hr but declined progressively thereafter and was not
prevented by addition of D-cystine (Figure S1A).
Cell Death in Cystine-Deprived EGFR Mutant HME Cells
Exhibits Hallmarks of Ferroptosis
This type of death resembled ferroptosis, an iron-dependent
non-apoptotic cell death (Dixon et al., 2012). Because lipid
reactive oxygen species (ROS) accumulation characterizes fer-
roptosis (Dixon et al., 2012), we measured ROS. Fluorescence-
activated cell sorting (FACS) analysis indicated increased ROS
accumulation in EGFRmutant HME cells following cystine depri-
vation (Figure 1E). EGFR mutant HME cells treated with known
ferroptosis inhibitors inhibited lipid ROS generation (Figure 1F)
and protected EGFR mutant (and BRAF mutant; Figure S1B)
cells from cell death (Figure 1G), as did treatment with two other
antioxidants (Figure 1H). Finally, erastin, an inhibitor of the sys-
tem xc-cystine/glutamate antiporter (Dixon et al., 2012), also
induced selective loss of viability in EGFR mutant cells (Fig-
ure 1H). Collectively, these data indicate that cell death in
EGFR mutant cells occurs by ferroptosis.
MAPK Signaling Sensitizes EGFR Mutant Cells to Cell
Death following Cystine Deprivation
EGFR activation results in activation of downstream signaling
cascades (Pines et al., 2010). Ferroptosis had previously been
shown to require MAPK signaling (Yagoda et al., 2007; Dixon
et al., 2012). Treatment of EGFR mutant cells for >24 hr with(D) Cell viability following titration of cystine in WT and EGFR (delE746-A750) H
various concentrations of cystine ± EGF, relative to complete media (150 mM cy
(E) ROS in WT HME and EGFR (delE746-A750). (Upper panels) Total ROS measu
C11 BODIPY 581/591 (C11-BODIPY) is shown. Dark traces, cells cultured in norm
(F) Lipid ROS in WT and EGFR (delE746-A750) HME cells. Dark traces, cells cultu
ferrostatin (Fer-1; 2 mM) for 12 hr; light traces, cells cultured in media lacking cys
(G) Cell viability of EGFR (delE746-A750) HME cells. Histogram is average viabilit
arbitrary value of 1) or media lacking cystine for 24 hr (right four bars) in the pres
(H) Cell viability (bottom histogram) and phase-contrast microscopy (upper pane
three biological replicates cultured in normal media (assigned an arbitrary value
scavengers idebenone and a-tocopherol.
(I) Cell viability of WT (gray bars) and EGFR (delE746-A750; black bars) HME cells.
or media lacking cystine for 24 hr in the presence or absence of erastin and Fer-EGFR or MAPK (MEK and ERK1/2) inhibitors inhibited EGFR
and MAPK signaling (Figures 2A and S2A), restored normal
adherens junction formation and gap junctional intercellular
communication (GJIC) (Figures 2B and 2C), and rescued cell
viability following cystine withdrawal (Figures 2D and S2B). Like-
wise, EGFR and MAPK inhibition in EGFR mutant cells inhibited
ROS generation (Figures 2E, S2C, and S2D).
Cystine Promotes Viability in EGFR Mutant HME Cells
via a Glutathione-Independent Mechanism
HME cells might resist ferroptosis by maintaining intracellular
levels either of cystine or glutathione, the major cystine-derived
antioxidant. To address the former possibility, we deprived cells
of cystine and measured activation of GCN2, a sensor of amino
acid depletion (Hinnebusch, 2005). However, in both wild-type
and EGFR mutant HME cells, GCN2 was equivalently activated
following cystine deprivation (Figure 3A). Basal cystine levels
were also equivalent and declined similarly in wild-type and
EGFR mutant cells following extracellular cystine depletion (Fig-
ure S3A). Recent data have suggested a role for glutaminolysis in
promoting ferroptosis (Gao et al., 2015). However, both wild-
type and EGFRmutant HME cells contained similar steady-state
intracellular levels of glutamine that were largely unaltered by
deprivation of cystine (Figure S3A). Similarly, total levels of gluta-
thione declined equivalently in wild-type and EGFR mutant
HME cells following cystine deprivation (Figure 3B). However,
Iressa-treated EGFR mutant cells accumulated more oxidized
glutathione (GSSG) in comparison to untreated EGFR mutant
HME cells following deprivation of cystine, suggesting that
EGFR inhibition increased ROS detoxification (Figure 3C). Sur-
prisingly, an inhibitor of glutathione synthesis (buthionine sulfox-
imine [BSO]), although also depleting glutathione levels, did not
induce cell death (Figure 3D) nor increase ROS in EGFR mutant
HME cells, unlike deprivation of cystine (Figure S3B). We there-
fore asked whether short-term deprivation of cystine, or inhibi-
tion of cystine import, acted synergistically with glutathione
depletion to induce cell death. Indeed, short-term deprivation
of cystine or treatment with inhibitors of the system xc-antiporter
induced significantly increased cell death when combined with
glutathione depletion (Figure 3E). Treatment with auranofin, an
inhibitor of the thioredoxin reductase/thioredoxin (TRX) system
(Gromer et al., 1998) implicated in reduction of cystine to
cysteine (Mandal et al., 2010; Pader et al., 2014), also synergized
with glutathione depletion to promote loss of viability and lipid
ROS induction (Figures S3B and S3C). Thus, EGFR mutant cellsME cells. Histogram represents the average viability ± SD of cells cultured in
stine; assigned an arbitrary value of 1).
red using CMDCFDA (DCF) is shown; (lower panels) lipid ROS measured using
al media for 12 hr; light traces, cells cultured in media lacking cystine for 12 hr.
red in media lacking cystine in the presence of deferoxamine (DFO; 100 mM) or
tine for 12 hr.
y ± SD cells cultured in normal media (left four bars, untreated [] assigned an
ence or absence of DFO, Fer-1, and z-VAD-fMK.
ls) of EGFR (delE746-A750) HME cells. Histogram is average viability ± SD of
of 1) or media lacking cystine for 24 hr in the presence or absence of ROS
Histogram represents the average viability ± SD cells cultured in normal media
1.
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AC
D
E
B Figure 2. Active MAPK Signaling Promotes
Sensitivity to Cystine Deprivation
(A) Immunoblots of EGFR (delE746-A750) HME
cell lysates probed to detect phosphorylated
EGFR, ERK, and AKT from cells cultured in normal
media (normal) or media lacking cystine for 12 hr
(Cys) in the presence or absence of inhibitors
added for a total of 30 hr.
(B) Confocal micrographs of adherens junctions
stained with b-catenin antibody of WT or EGFR
(delE746-A750) HME cells treated with vehicle
(EGFR) or following treatment with inhibitors
for 30 hr. Arrows indicate linear staining for
b-catenin at intercellular junctions; arrowheads
indicate presence of discontinuous adherens
junctions.
(C) (Left panels) Fluorescence micrographs of
GJIC measured by lucifer yellow infiltration in
WT, EGFR (delE746-A750), Iressa-treated EGFR
(delE746-A750; EGFR/Iressa), and selumetinib-
treated EGFR (delE746-A750; EGFR/MEKi) in the
presence or absence of carbenoxolone (CBX).
(Right histogram) Quantification of GJIC is shown.
Each condition was analyzed in six random 203
fields in three biological replicates with the values
shown representing the mean and SEM and ex-
pressed relative to GJIC in WT HME cells as-
signed an arbitrary value of 1. Light bars represent
GJIC in the presence of CBX.
(D) Cell viability (left histogram) and phase-
contrast micrographs (right panels) of EGFR
(delE746-A750) HME cells treated with inhibitors.
Histogram is viability ± SD of cells cultured in
normal media (dark bars) or media lacking cystine
for 16 hr (light bars) in the presence or absence of
inhibitors. Results were expressed for each con-
dition separately, with viability in normal media
assigned the arbitrary value of 1.
(E) FACS analyses of lipid ROS in EGFR (delE746-
A750) cells following treatment with inhibitors.
Dark traces, cells cultured in normal media; light
traces, cells cultured in media lacking cystine
for 12 hr.oxidize less glutathione during cystine deprivation, contributing
to ROS accumulation, whereas intracellular cysteine appears
to play an additional role, aside from glutathione synthesis, in
counteracting ROS and ferroptosis.
GPX4 Is Downregulated in EGFR Mutant HME Cells via
MAPK Signaling and Modulates Sensitivity to Cell Death
upon Cystine Deprivation
Glutathione peroxidases (GPXs) are good candidates for medi-
ating sensitivity to ferroptosis. GPX4 has previously been impli-
cated in ferroptosis (Friedmann Angeli et al., 2014; Yang et al.,
2014), whereas GPX4 is induced following treatment with a
BRAF inhibitor (Parmenter et al., 2014). By immunoblotting,
GPX4, but not GPX1, expression was upregulated following
either EGFR or MAPK (MEK and ERK; Figure S3D) inhibition,
whereas GPX2 was not expressed in these cells (Figure 3E)
and GPX3 is a secreted GPX expressed in the kidney (Maser2550 Cell Reports 18, 2547–2556, March 14, 2017et al., 1994). Suppression of GPX4 strongly promoted cell
death in both wild-type (Figure 3G) and Iressa-treated EGFR
mutant cells (Figure 3H). Lipid ROS similarly increased after
suppression of GPX4 (Figure 3I). Thus, downregulation of
GPX4 in EGFR mutant HME cells conferred increased sensitivity
to ferroptosis following cystine deprivation. To determine
whether loss of viability was related to low levels of GPX4, we
expressed Flag-GPX4 in EGFR mutant cells. Indeed, ectopic
expression of GPX4 significantly increased viability following
deprivation of cystine (Figure 3J). Thus, downregulation of
GPX4 plays a key role in sensitizing EGFR mutant HME cells to
ferroptosis.
Synchronous Cell Death in EGFR Mutant HME Cells
Involves Generation and Release of Hydrogen Peroxide
Hydrogen peroxide is implicated in synchronous ferroptosis
in kidney tubule epithelia (Linkermann et al., 2014). Media
A B C
D E F
G
K L M
I J
H
Figure 3. Involvement of Intracellular Cysteine, GPX4, and Hydrogen Peroxide in Sensitivity to Ferroptosis
(A) Immunoblots of cell lysates probed with an antibody to active GCN2 (T899-P). Cells were cultured in normal media for 24 hr (normal) or media lacking cystine
for various times.
(B) Histogram of total glutathione levels in WT and EGFR (delE746-A750) cells cultured in normal media for 12 hr (N) or media lacking cystine for 8 or 12 hr. As a
positive control, BSO was added to cells for 12 hr to deplete the glutathione pool by inhibiting glutathione synthesis.
(C) Timecourseof glutathione oxidation (GSSG/total) in EGFR (delE746-A750) treatedwith vehicle (EGFR/DMSO) or Iressa for 30hr (EGFR/Iressa). Cellswere cultured
in media lacking cystine for 4 or 8 hr. Chart displays the average ratio of oxidized glutathione (GSSG) to total glutathione (GSH+GSSG) of three biological replicates.
(legend continued on next page)
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containing soluble catalase similarly rescued viability of EGFR
mutant HME cells (Figure 3K). Hydrogen peroxide is produced
by NADPH oxidase 4 (NOX4) (Takac et al., 2011). A NOX4 inhib-
itor (GKT136901; Laleu et al., 2010) also rescued viability, to the
same degree as addition of catalase (Figure 3K), and inhibited
lipid ROS generation (Figure 3L). NOX4 expression was also
increased in EGFR mutant HME cells and downregulated by
both EGFR and MAPK inhibition (Figure S3E). Finally, increased
accumulation of hydrogen peroxide was detected following
deprivation of cystine in EGFR mutant cells (Dickinson et al.,
2010; Figure 3M). Thus, hydrogen peroxide contributes to loss
of viability of EGFR mutant HME cells deprived of cystine.
NSCLC Tumor Cell Lines Exhibit a Targetable Sensitivity
to Ferroptosis
Mutations in the EGF receptor are found in non-small-cell lung
cancers (NSCLCs) (Pao et al., 2004) that are sensitive to tyrosine
kinase inhibitors (TKIs) (Paez et al., 2004). We removed cystine
from NSCLC cell lines and measured viability and MAPK activa-
tion. Of nine NSCLC cell lines tested, three with the highest
MAPK signaling (Figure S4A) demonstrated significant loss of
viability following withdrawal of cystine (Figures 4A and S4B).
In H3255 cells (EGFR L858R mutant), sensitivity was reversed
by either EGFR or MAPK inhibition, whereas in Calu-6 cells
(KRAS Q61K mutant), sensitivity was reversed by MAPK, but
not EGFR, inhibition (Figure S4C). Thus, in NSCLC cell lines,
the magnitude of MAPK activation is an important determinant
in sensitization to ferroptosis, rather than the nature of the
specific oncogenic driver that promotes MAPK signaling. In
NCI-NH1650 cells (EGFR delE746-A750), viability was restored
by addition of either a-tocopherol, the ferroptosis inhibitor
Fer-1 (Figure 4B), or Iressa (data not shown) following cystine
depletion, indicating that ferroptosis and EGFR signaling were
responsible for loss of viability. Surprisingly, however, MEK inhi-(D) Cell viability of WT (light bars) or EGFR (delE746-A750; dark bars) HME cells
normal media (N), normal media containing 200 mM BSO (N/BSO), or media lack
(E) Cell viability of EGFR (delE746-A750) pre-treated for 18 hr with DMSO vehicl
containing erastin (N/Erastin), or S4PG (N/S4PG) for 12 hr or following removal of
cultured in normal media (assigned a value of 1).
(F) Immunoblots of WT and EGFR (delE746-A750) cell lysates probed for GPX4, G
ERKwas calculated using ImageJ from scanned autoradiographs of three biologic
(G) (Left panels) Immunoblots of WT HME lysates probed for GPX4, GPX1, and E
(light bars) or media lacking cystine (dark bars) for 24 hr. Histogram represents the
for each condition separately, with viability in normal media assigned a value of
(H) (Left panels) Phase-contrast micrographs of EGFR (delE746-A750) HME cells f
(siGPX4) and treated with Iressa for 30 hr followed by culture in normal media
knockdown ofGPX1–4 in Iressa-treated EGFR (delE746-A750) cells. Viability of ce
determined. Results were expressed for each condition separately, with viability
(I) FACS analyses of lipid ROS inWT HME cells following knockdown of GPX1 and
media lacking cystine for 12 hr.
(J) Histogram is shown representing the average viability ± SD following overe
Viability of WT HME cells or vector- or GPX4-transfected EGFR (delE746-A750) ce
16 hr is shown. Results were expressed for each condition separately, with viab
(K) (Top panels) Phase-contrast micrographs of EGFR (delE746-A750) HME cells
GKT136901. (Bottom) Histogram representing the average viability ± SD of EGFR
a value of 1) or media lacking cystine alone (Cys) or with BSA, catalase, supero
(L) FACS analyses of lipid ROS in EGFR (delE746-A750) HME cells following treat
lacking cystine; light traces, cells cultured in normal media.
(M) Live images of hydrogen peroxide detected with PO1. (Left) Phase-contrast im
incubated with PO1 (right panels) are shown.
2552 Cell Reports 18, 2547–2556, March 14, 2017bition in these cells did not rescue viability following cystine
depletion (data not shown). Thus, MAPK activation may not
invariably promote sensitivity to ferroptosis, and other unknown
EGFR-dependent signaling pathway(s) can substitute.
Survival after treatment with TKIs in NSCLC is typically less
than 1 year, with patients developing secondary EGFR muta-
tions (Stewart et al., 2015). We therefore sought to determine
whether EGFR mutant NSCLC cells might be responsive to
low levels of cystine, potentially offering additional therapeutic
options utilizing a novel cystine/cysteine-degrading enzyme
(cyst(e)inase; AECase) engineered from cystathionine-g-lyase
(Cramer et al., 2017). Addition of AECase reduced viability in
both HME delE746-A750 EGFR or NCI-NH1650 cells (Figures
4C and 4D) and induced widespread uptake of Sytox Green
(Figure 4D; Movie S2). Finally, we injected mice bearing estab-
lished NCI-NH1650 xenografts with AECase. Mirroring the
in vitro results, tumor growth was significantly retarded in
AECase-treated groups (p = 0.0001; Figure 4E). AECase-
treated mice were also found to upregulate expression of
COX2 (Figure 4F), indicating that they had experienced cystine
depletion and initiated ferroptosis within the tumor (Yang et al.,
2014). Thus, inhibition of tumor growth can be achieved in
tumors sensitive to ferroptosis by enzymatic degradation of
cystine/cysteine in vivo.
DISCUSSION
Cell death by ferroptosis has been implicated in diverse pro-
cesses (Yang and Stockwell, 2016). Previous data indicated
that ferroptosis could be induced preferentially in cells overex-
pressing mutant RAS oncoproteins (Dixon et al., 2012; Dolma
et al., 2003; Yang and Stockwell, 2008) and in some sensitive
cell lines could be blocked by MAPK inhibition (Yagoda et al.,
2007).. Histogram represents the average viability ± SD of cells cultured for 24 hr in
ing cystine (Cys).
e (light bars) or 200 mM BSO (dark bars) in normal media (N), in normal media
cystine for 36 or 12 hr. Histogram represents the average viability ± SD of cells
PX1, GPX2, and ERK in the presence or absence of inhibitors. Relative GPX4/
al replicates, with the ratio in EGFR (delE746-A750) cells assigned a value of 1.
RK1/2. (Right) Histogram of cell viability of HME cells cultured in normal media
average viability ± SD following knockdown GPX1–4. Results were expressed
1.
ollowing transfection with control (siC) or GPX4 small interfering RNAs (siRNAs)
or media lacking cystine for 24 hr. (Right) Histogram is viability ± SD after
lls cultured in normal media (light bars) ormedia lacking cystine (dark bars) were
in normal media assigned the arbitrary value of 1.
GPX4. Dark traces, cells cultured in normal media; light traces, cells cultured in
xpression of Flag-GPX4 (Mannes et al., 2011) in EGFR (delE746-A750) cells.
lls cultured in normal media (light bars) or media lacking cystine (dark bars) for
ility in normal media assigned a value of 1.
in normal media or media deprived of cystine alone or containing catalase or
(delE746-A750) HME cells cultured for 24 hr in normal media (normal; assigned
xide dismutase (SOD), Trolox, or GKT136901 added is shown.
ment with the NOX4 inhibitor GKT136901. Dark traces, cells cultured in media
ages of WT and EGFR (delE746-A750) cells deprived of cystine for 24 hr and
A B
C
E
F G
D
Figure 4. Ferroptosis Is Induced in Some NSCLC Cell Lines and Inhibits Tumor Growth
(A) Histogram of viability ± SD of EGFR (delE746-A750) HME and NSCLC cell lines cultured for 72 hr in normal media (light bars) or media lacking cystine (dark
bars). Results were expressed for each cell line separately, with viability in normal media assigned a value of 1.
(B) Histogram representing the average viability ± SD of EGFR (delE746-A750) HME (dark bars) or NCI-NH1650 (light bars) cultured for 72 hr in normal media (N),
normal media containing ferrostatin (N/Fer-1), media lacking cystine (Cys), or media lacking cystine in the presence of a-tocopherol or Fer-1. Results were
expressed for each cell line separately, with viability in normal media assigned a value of 1.
(legend continued on next page)
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We identify here a selective cell death of EGFR mutant cells
deprived of the amino acid cystine. Death was associated with
synchronous loss of plasma membrane integrity. By a variety
of criteria, this mode of cell death is ferroptosis. In our model
(Figure 4G), active MAPK signaling downstream of active
EGFR can sensitize cells to ferroptosis upon cystine depletion.
Sensitization involves both impaired detoxification of lipid perox-
ides, due to reduced expression of GPX4, and generation of
hydrogen peroxide, via NOX4. A major consequence of lipid per-
oxidation is loss of impermeability to water (Lis et al., 2011;
Wong-Ekkabut et al., 2007), providing an explanation for the
characteristic cell swelling and rupture we observe.
Sensitivity to induction of ferroptosis or cystine deprivation is
likely to be modulated by additional, and possibly MAPK-inde-
pendent, mechanisms, such as the utilization of the sulfur-con-
taining amino acid methionine via the transsulfuration pathway
(Hayano et al., 2016). Our results suggest, however, the possibil-
ity of exploiting ferroptosis sensitivity in a translational manner.
Tumors with sustained MAPK activation, as found in NSCLC,
are likely to respond to cystine depletion in vivo by inducing
ferroptosis. Our results indicate that an enzymatic approach
(Cramer et al., 2017) may be effective in reducing cystine levels
in vivo, inducing ferroptosis. Collectively, our work indicates
that it might therefore be possible both to identify tumors exhib-
iting increased sensitivity to ferroptosis and to treat them via
cycles of cystine depletion.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatments
The hTERT-HME cell lines were a kind gift from Prof. Alberto Bardelli (Institute
for Cancer Research and Treatment, IRCC). Cells were grown in DMEMmedia
as described (Di Nicolantonio et al., 2008). To deprive individual amino acids,
cells were washed once in DMEM media lacking all amino acids (AA) and
switched to specific amino-acid-free media. DMEM media used for depriva-
tion were made from powdered AA-free DMEM (US Biological), with 10% dia-
lyzed fetal bovine serum (FBS) and additives (Di Nicolantonio et al., 2008).
Amino acids (Sigma) at 503 concentrations in water were added at 13 con-
centration. All amino acids were added for complete media (+AA), with individ-
ual DMEMamino acids omitted to generate single amino-acid-deficientmedia.
For the initial screen, 30,000 cells were plated per well in a 96-well plate and(C) (Left) Histogram of viability ± SD of EGFR (delE746-A750) HME (dark b
(N) (assigned a value of 1), media lacking cystine (Cys), normal media con
(N/AECase/Fer-1), or normal media containing 125 nM heat-inactivated AECa
contrast micrographs of EGFR (delE746-A750) HME cells in normal media,
(N/AECase) for 48 hr are shown.
(D) Phase contrast (left), and Sytox Green (right) micrographs of H1650 cells dep
treated with heat-inactivated AECase (right panels) for various times up to 20 hr.
(E) Cyst(e)inase (AECase) administration inhibits tumor growth in a NCI-NH1650
administration of PBS control (dark circles) or 30 mg/kg (dark squares) or 100 mg
shown. (Right panel) Kaplan-Meier plots of median survival of PBS- or AECase-t
(F) (Top panels) Immunoblots of lysates from control (lanes 1–4) or AECase-treat
head). (Middle histogram) Quantification of relative COX2/ERK in control or AECa
COX2 staining in control and AECase-treated tumors are shown.
(G) Model depicting role of activated EGFR in determining sensitivity to fe
expression of GPX4 and inducing expression of NOX4. GPX4 utilizes reduce
cystine-glutamate exchanger to detoxify membrane lipid peroxides (red), g
reducing equivalents derived from NADPH (dashed line). Cystine can be red
have additional functions (e.g., Briggs et al., 2016). Lipid peroxides are gene
producing hydroxyl radicals that initiate lipid peroxidation. Lipid peroxidation
and rupture.
2554 Cell Reports 18, 2547–2556, March 14, 2017switched after 24 hr to depleted amino acid media for 72 hr. Viability was as-
sessed in the initial screen usingCalcein AM (Molecular Probes; ThermoFisher)
at 1 mM for 2 hr and cells fixed for 15 min with 4% paraformaldehyde prior to
analysis on a Genios plate reader and in all other experiments using the
CellTiter-Glo luminescence assay (Promega).
FACS Analysis
To detect ROS, 200,000 cells were plated in 6-well plates and switched to
cystine-deprived media for 12 hr prior to FACS analysis. CMDCFDA and
C11-BODIPY581/591 (Molecular Probes; Thermo Fisher) were used to detect
total and lipidROS, respectively. Following deprivation of cystine for 12 hr, cells
were washed with PBS, loaded with either CMDCFDA (10 mM) or C11 BODIPY
(2 mM) in DPBS for 30min, trypsinized with 0.25% Trypsin-EDTA, resuspended
inPBSwith 1%FBS, andanalyzedusing anAttuneNxTflowcytometer (Thermo
Fisher). Dyes were excited using a blue 488-nm laser, and emission was re-
corded on BL1 (530/30) for a minimum of 5,000 cells per sample.
Xenograft Tumor Model
2.53 105 NCI-H1650 cells were inoculated 1:1 in Matrigel: PBS (100 mL) by
subcutaneous injection into eight non-obese diabetic (NOD) severe combined
immunodeficiency (SCID) gamma male mice. Tumors were allowed to engraft
and grow for 30 days (tumor volume averaged200mm3) andmice treated by
intraperitoneal (i.p.) injection with 100 mg/kg cyst(e)inase or 100 mg/kg heat-
inactivated cyst(e)inase (n = 4 ea.) on day 30, with a second dose given on
day 33. Mice were necropsied 24 hr after the second dose. For analyses of
COX2, control and treated tumors were excised and one-half preserved in
10%neutral buffered formalin for immunohistochemistry (IHC) and the remain-
ing half frozen in liquid nitrogen for protein extraction. For IHC, anti-COX2 from
Abcam (ab15191) was used with DAB detection.
Statistical Analyses
Data were analyzed using Microsoft Excel or GraphPad Prism software
(GraphPad) and are presented as mean values ± SEM. All viability data repre-
sent the mean of three biological replicates/condition. Statistical analyses
were performed using two-sided Student’s t test. For Kaplan-Meier plots, sta-
tistical significance was analyzed by the log rank (Mantel-Cox) test. Sample
variance was not significant between control and treatment groups prior to
study onset. Significance was set at p < 0.05. All data are representative of
at least two independent experiments.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2017.02.054.ars) or NCI-NH1650 (light bars) cells cultured for 48 hr in normal media
taining 125 nM cyst(e)inase (AECase) on its own (N/AECase) or with Fer-1
se on its own (N/AECase*) or with Fer-1 (N/AECase*/Fer-1). (Right) Phase-
media deprived of cysteine, or normal media containing 125 nM AECase
rived of cystine (left panels), treated with 125 nM AECase (middle panels), or
xenograft mouse model. (Left panel) Increase in tumor volume following i.p.
/kg (light triangles) AECase is shown. Start and end of treatment times are also
reated tumor-bearing mice are shown.
ed (lanes 5–8) NCI-NH1650 xenograft lysates probed to detect COX2 (arrow-
se-treated groups is shown. p = 0.04; n = 4. (Bottom micrographs) Images of
rroptosis. Activated EGFR (EGFR*) stimulates MAPK signaling, reducing
d glutathione (GSH) derived from cystine transported via the System xc-
enerating oxidized glutathione (GSSG). GSSG is recycled to GSH using
uced to generate cysteine that can independently detoxify ROS and may
rated from hydrogen peroxide (H2O2, derived from NOX4) and iron (Fe
2+),
leads to loss of membrane integrity, allowing uptake of water, cell swelling,
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Supplemental Figures and Legends, Tables, Experimental Procedures, and References 
 
Figure S1 (related to Figure 1).  
 
A, Left, cell viability following deprivation of cystine, followed by cystine resupplmentation, in wild type (WT) 
and EGFR (delE746-A750) HME cells. Histogram represents the average viability ± standard deviation (SD) of 
three biological replicates using CellTitre-Glo, relative to removal of cystine for 10 hours (assigned an arbitrary 
value of 1). Results are typical of experiments performed twice. Right, cell viability in normal media (N) or 
following deprivation of cystine (- L-Cys), followed by D-cystine addition (+ D-Cys, added at 150µM), in 
EGFR (delE746-A750) HME cells. Histogram represents the average viability ± standard deviation (SD) of 
three biological replicates using CellTitre-Glo with viability in normal media assigned an arbitrary value of 1. 
Results are typical of experiments performed twice. 
B, Cell viability in normal media or following deprivation of cystine in the presence or absence of Fer-1 (2µM), 
in wild type (WT), EGFR (delE746-A750) and BRAF-mutant HME cells. Histogram represents the average 
viability ± standard deviation (SD) of three biological replicates using CellTitre-Glo, relative to normal media 
(N, assigned an arbitrary value of 1). Results are typical of experiments performed twice. 
 
Figure S2 (related to Figure 2).  
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A, Immunoblots of EGFR (delE746-A750) HME cell lysates probed with antibodies detecting phosphorylated 
RSK (T359-P), and total RSK from cells cultured in normal media in the presence of vehicle (DMSO), Iressa, 
and the indicated MEK and ERK signalling inhibitors added for a total of 30 hours.  
B, Cell viability of EGFR (delE746-A750) HME cells. Histogram represents the average viability ± standard 
deviation (SD) of three biological replicates cultured in normal media (assigned an arbitrary value of 1), or 
media lacking cystine for 24 hours measured using CellTitre-Glo, in the presence or absence of Iressa, and the 
indicated MEK and ERK signalling inhibitors added for a total of 30 hours prior to cystine deprivation. Results 
were expressed for each inhibitor condition separately, with viability in normal media assigned the arbitrary 
value of 1. Results are typical of experiments performed twice. 
C, FACS analyses of total ROS in EGFR (delE746-A750) cells following treatment with MEK and ERK 
inhibitors. Dark traces, cells cultured in normal media; light traces, cells cultured in media lacking cystine for 12 
hours. Results are typical of experiments performed twice. 
D, FACS analyses of lipid ROS in EGFR (delE746-A750) cells following treatment with MEK and ERK 
inhibitors. Dark traces, cells cultured in normal media; light traces, cells cultured in media lacking cystine for 12 
hours. Results are typical of experiments performed twice. 
 
 
 
 
 
 
 
 
 
 
 3 
 
Figure S3 (related to Figure 3).  
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A, Amino acid analysis of steady-state levels of cystine, glutamine and glutamate measured by LC-MS in wild 
type and EGFR (delE746-A750) cells cultured in normal media (Normal, light bars) or media lacking cystine for 
for 8 hours. Histogram represents the average values ± standard deviation (SD) of three biological replicates 
with the level in normal media of wild type HME cells assigned the arbitrary value of 1. Results are typical of 
experiments performed twice. 
B, FACS analyses of lipid ROS in EGFR (delE746-A750) cells following treatment for 14 hours with BSO 
alone or with auranofin. Light traces, cells cultured in normal media or normal media containing auranofin for 
14 hours (N or N+AF); dark traces, cells treated for 14 hours with BSO alone (BSO), or cultured in media 
lacking cystine for 14 hours (-Cys) or treated with auranofin for 14h (N+AF) or treated  auranofin for 6 hours 
following pretreatment with BSO for 14h. Results are typical of experiments performed twice. 
C, Cell viability of EGFR (delE746-A750) HME cells. Viability of cells cultured for 18 hours in normal media 
containing DMSO vehicle (light bars), or containing 200µM BSO (BSO, dark bars), followed by deprivation of 
cystine, or treatment with auronofin for 24 hours, with viability measured using CellTitre-Glo. Histogram 
represents the average values ± standard deviation (SD) of three biological replicates with the level in normal 
media assigned the arbitrary value of 1. Results are typical of experiments performed twice. 
D, Immunoblots of EGFR (delE746-A750) HME cell lysates probed with antibodies detecting GPX4, and 
ERK1/2 from cells cultured in normal media in the presence of vehicle (DMSO), Iressa, and the indicated MEK 
and ERK signalling inhibitors added for a total of 30 hours. Relative GPX4 was calculated using ImageJ from 
scanned autoradiographs with the ratio in DMSO-treated EGFR (delE746-A750) HME cells assigned the 
arbitrary value of 1. 
E, Left, Immunoblots of wild type and EGFR (delE746-A750) HME cell lysates probed with antibodies 
detecting NOX4 and ERK1/2; right, from EGFR (delE746-A750) cells cultured in normal media in the presence 
of vehicle (DMSO), Iressa, or Selumetinib for a total of 30 hours. Relative NOX4 was calculated using ImageJ 
from scanned autoradiographs with the ratio in wild type or DMSO-treated EGFR (delE746-A750) HME cells 
assigned the arbitrary value of 1 in each case. 
 
Figure S4 (related to Figure 4). 
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A, Immunoblots of EGFR (delE746-A750) HME and various NSCLC cell lysates probed with antibodies 
detecting ppERK and ERK1/2 Relative ppERK was calculated using ImageJ from scanned autoradiographs with 
the ratio in A549 assigned the arbitrary value of 1. 
B, Left panels, phase contrast micrographs of Calu 6, NCI-NH1650 and H3255 cells followed by culture in 
normal media (left) or media lacking cystine for 72 hours (right). Arrowheads indicate balloon-like membrane 
extensions of cells that have undergone ferroptosis.  
C, Histogram representing the average viability ± standard deviation (SD) of three biological replicates of Calu 
6 and H3255 cells cultured for 30 hours in normal media containing DMSO, Iressa or PD0325901 (light bars) or 
media lacking cystine for 48 hours (dark bars). Results were expressed for each condition separately, with 
viability in normal media assigned the arbitrary value of 1. Results are typical of experiments performed twice. 
D, Pathological evaluation of COX2 immunostaining in mice treated with heat-inactivated AECase (Controls 1-
4) or AECase (5-8).  
 
Supplemental Movies S1, S2 
Movie S1 (related to Figure 1). 
Withdrawal of cystine leads to synchronous cell death. EGFR (delE746-A750) HME cells grown to confluency 
in normal media were switched to media lacking cystine from which point images were collected by time-lapse 
phase contrast microscopy. Frames were taken every 5 mins for 24 hrs and saved for playback at 100ms 
intervals. 
Movie S2 (related to Figure 4): 
Withdrawal of cystine leads to synchronous cell death in NSCLC cells. NCI-NH1650 cells grown to confluency 
in normal media were switched to media lacking cystine and containing Sytox Green, from which point images 
were collected. Individual frames were obtained every 5 minutes in phase contrast and green fluorescence 
channels with Sytox Green used at 0.5µM concentration (Molecular Probes, Thermofisher) for 24 hrs and saved 
for dual-channel playback at 100ms interval.  
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Supplemental Experimental Procedures 
 
siRNA knockdown and plasmid transfection 
 
Lipofectamine 2000 (Invitrogen, ThermoFisher) was used for siRNA transfection of HME cells. 500,000 cells 
were plated in 6-well plates and either mock-transfected or transfected with either siCtrl or siGenome Smartpool 
siRNAs (Dharmacon, GE Lifesciences) to GPX1, GPX2, GPX3 and GPX4 at a final concentration of 50nM. A 
day after transfection cells were trypsinized and split between a 12-well plate well, with 250,000 cells, and 6 96-
well plate wells, with 25,000 cells per well, for immunoblotting and viability assay respectively 3 days post 
transfection. For plasmid transfections, 5x105 EGFR-mutant cells were transfected in 3cm dishes with 5µg of 
Flag-GPX4 (p442-PL1 Flag-Strep-HA-GPX4, (Mannes et al., 2011)) or control vector using Lipofectamine 
2000 (Invitrogen, ThermoFisher). 48h after transfection wild type or transfected cells were trypsinised and 
replated in a 96 well plate at 20,000 cells per well and the viability experiment performed following 16h of 
cystine deprivation. 
 
 
Western Blotting 
Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 1mM EGTA, 1 mM EDTA, 1% Triton X-100, 1mM 
Na3VO4, 50 mM NaF, 50 mM β-glycerolphosphate, 0.27M sucrose, 0.1% beta-mercaptoethanol, Complete 
protease inhibitors (Roche). Protein concentration was determined using Bradford assay reagent (Biorad) and 25 
µg of total protein was loaded per sample.  
Commercial antibodies used were: pEGFR Y1068 (Cell Signalling Technologies) #3777, EGFR (Cell 
Signalling Technologies) #2232, pAKT S473 (Cell Signalling Technologies) #9271, AKT (Upstate, EMD 
Millipore) 07-416, ppERK (Cell Signalling Technologies) #4370, ERK1/2 (Santa Cruz Biotech) sc-94, GCN2-P 
T899 (Epitomics, Abcam) 2425-1, GCN2 (Cell Signalling Technologies) #3302, GPX1 (R&D systems, 
Biotechne) AF3798, GPX2 (R&D systems, Biotechne) MAB5470, GPX4 (Abcam) ab125066, COX2 (Cayman 
Chemicals) #160112, NOX4 (Abcam) #, RSK-P Thr 359-P and RSK (Cell Signaling Technologies) 133303 and 
b-catenin (Transduction Labs) C19220.  
 
GJIC scrape loading dye transfer assay  
Confluent EGFR-mutant cells growing in 24-well plates were incubated with 1µM Iressa, 1µM Wortmannin, 
5µM Selumetinib or 1µM DMSO (control) for 30h. Cells were then washed in Ca++-deficient PBS and 
transferred to PBS containing 0.5mg/mL Lucifer yellow (Sigma), 10mM glucose, 30mM HEPES buffer 
(Thermofisher), 0.1% BSA, 0.5 mg/mL rhodamine-dextran (Molecular Probes) and either vehicle (100mM 
DMSO) or 100mM carbenoxolone (Sigma). Wells were wounded via two perpendicular scratches to the 
monolayer and incubated for 15 minutes before being washed with PBS and fixed in 4% paraformaldehyde. 
Areas close to the wound margin were imaged for green fluorescence at 20X magnification using an AMG 
EVOS digital inverted microscope and the extent of Lucifer yellow infiltration into the monolayer was analysed 
using ImageJ software. 
Confocal immunofluorescence microscopy  
Confluent HME WT and EGFR-mutant cells growing on glass coverslips were incubated with 1µM Iressa, 1µM 
Wortmannin, 5µM Selumetinib or 1µM DMSO for 30h. Immunofluorescence labelling of β-catenin was 
undertaken as previously described (Menon et al.) and cells were imaged at 63X magnification with a confocal 
laser scanning microscope (Zeiss 3I LSM 800).  
 
Additional cell treatments and microscopy 
  The timelapse microscope used was a Nikon TE-300 [motorised with Sutter filter wheels and a Conix block 
changer] equipped with a 10X phase contrast [PC] objective, encased in a Perspex 37°C incubation chamber 
with an insert for multi-well plates flushed with humidified, 5% CO2 air. Green fluorescence was acquired 
through a Nikon B-2A block split into Sutter filter wheels and a Conix block changer. Images were collected 
using a Hamamatsu Orca AG camera, with MicroManager software (Edelstein et al., 2010), converting time 
series to an ImageJ readable format using in-house software. Cells were plated in a 6-well plate at 500,000 cells 
per well and grown for 3 days prior to media switch to cystine-deprived media. The plates were then transferred 
in the microscope stage maintained at 37°C with 5% CO2. Individual frames were obtained every 5 minutes in 
phase contrast and green fluorescence channels for detection of nonviable cells by Sytox Green nuclear staining 
used at 0.5µM concentration (Molecular Probes, Thermofisher). Apoptosis inhibitor z-VAD-fMK (Selleck) was 
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used at 50µM. ROS scavengers Idebenone and α-Tocopherol (Sigma) were used at 1µM and 30µM respectively. 
Induction of ferroptotic death by erastin (Cayman Chemical) was achieved at a concentration of 2.5µg/ml. Other 
inhibitors used were catalase used at 1000U/ml (Sigma), superoxide dismutase used at 100U/ml (Sigma), NOX4 
inhibitor GKT136901 (Aobious) at 20µM and the water-soluble vitamin E analogue Trolox at 5µM (Sigma). To 
determine ferroptotic cell death 10,000 EGFR HME cells were plated in a 96-well plate and allowed to grow for 
3 days prior to a media shift in the presence of inhibitors of ferroptotic or apoptotic death or scavengers of 
reactive oxygen species. Ferroptosis inhibitor Ferrostatin1 (Fer-1, Sigma) was used at 2µM and iron chelator 
deferroxamine (DFO, Sigma) was used at 100µM.  
   To image H2O2 confluent cells were transferred to cystine-deficient media for 24 hours. Cells were then 
incubated with 10µM Peroxy Orange 1 (PO1, Tocris Bioscience) for 60 minutes before being washed three 
times in dPBS and imaged immediately at 20X magnification using an AMG EVOS digital inverted microscope. 
To inhibit signal transduction downstream of EGFR cells were treated for 24h prior to media switch with EGFR 
inhibitor Iressa (Tocris) at 1µM, MEK inhibitor Selumetinib (Selleckchem) at 5µM, PI3K inhibitor Wortmannin 
(Sigma) at 1µM. DMSO (Sigma) was used as a vehicle control. Additional MEK and ERK inhibitors used were  
U0126  (Calbiochem, 10µM), PD184352 (Sigma, 10µM), PD0325901 (Selleckchem, 1µM), GDC-0994 (ERK 
inhibitor, Selleckchem, 5µM) and SCH772984 (ERK inhibitor, Cayman Chemicals, 5µM). Following pre-
treatment for 24h cells were switched to either complete or cysteine deficient media containing the same 
concentration of inhibitors for 12h prior to analysis. Wortmannin was re-added at the same concentration 1hour 
before collection. Auranofin and S4PG were from Santa Cruz and used at 1 and 100µM, respectively. NOX4 
inhibitor GKT136901 (Aobious) was used at 20µM. PEGylated AECase was used at a final concentration of 
125nM, heat inactivation was performed by incubation at 95 0C for 7 minutes, followed by brief centrifugation 
for 5 mins at 13,000 rpm.  
   For cystine titration cells were plated in triplicate cells at a final concentration of 30,000 per well in a 96-well 
plate (NUNC, Thermofisher) and the following day complete synthetic media containing or lacking EGF was 
serially diluted with DMEM lacking cystine to achieve a range of decreasing cystine concentrations. After 24h 
of treatment viability was determined using the CellTitre-Glo assay (Promega). An equal volume of CellTitre-
Glo reagent was added and the plate was vortexed at 1000 rpm for 2 minutes to allow cell lysis. The plates were 
then analysed on a Tecan Genios plate reader. 
GSH/GSSG quantification   
   For the quantification of cellular reduced (GSH) and oxidised (GSSG) glutathione the method described by 
Rahman et al (Rahman et al., 2006) was used, which utilises the reaction of GSH with 5,5′-Dithiobis (2-
nitrobenzoic acid) (DTNB) that leads to the production of the 5′-thio-2-nitrobenzoic acid (TNB) chromophore 
measured at 412nm (Tietze, 1969). 1x106 cells were plated in 6-well plates (Greiner) and the following day 
treated with 200µM of BSO or switched to cystine deficient media for 8h. Cells were then washed in cold PBS, 
trypsinised and resuspended in 0.2ml of ice-cold extraction buffer (0.1% Triton-X and 0.6% sulfosalicylic acid 
in 0.1 potassium phosphate buffer with 5 mM EDTA disodium salt, pH 7.5 (KPE)). Cells were then freeze-
thawed four times (liquid nitrogen - 37°C water bath) and lysates subsequently centrifuged at 3000g for 5 min at 
4 °C and supernatants collected.  Protein concentrations were measured using a Bradford assay in order to 
express GSH and GSSG levels as nM/mg of total protein. Total glutathione (Total [GSH] = [GSH] + 2 × 
[GSSG]) was measured via a kinetic assay based on the reaction of DTNB with GSH and the recycling reaction 
by the enzyme glutathione reductase (GR) (Sigma) which in the presence of β-Nicotinamide adenine 
dinucleotide 2′-phosphate (β-NAPDH, Sigma) can reduce GSSG to GSH (Guntherb.H and Rost, 1966). The rate 
of TNB formation was calculated by measuring 415nm absorbance in a plate reader every 30sec. GSH standards 
of known concentration were made from stock GSH (Sigma) and their rate of formation used to create a 
standard curve. For measurement of GSSG, 2-vinylpyridine (Aldrich) is added to cell lysates at 18.5 mM for 1h 
creating a covalent bond with GSH therefore allowing measurement only of GSSG. Excess 2-vinylpyridine was 
then neutralised with 75mM triethanolamine (Sigma) for 30 min (Griffith, 1980). Levels of GSSG were 
determined by applying the recycling assay and measuring rate of formation of TNB as described above but 
using GSSG standard samples (Sigma) to create a standard curve. Reduced glutathione (GSH) could be then 
determined by subtraction of oxidised (GSSG) from Total glutathione (Total [GSH] = [GSH] + 2 × [GSSG]). 
All measurements were done in triplicate. Glutathione synthesis inhibitor buthionine sulfoximine (BSO, Santa 
Cruz Biotechnologies) was used at 200µM. 
COX2 immunostaining 
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After immunostaining the slides were evaluated by a pathologist (Precision Pathology) for percentage of postive 
tumor cells in the sample and intensity of the staining after excluding all non-tumor cells and non-specific 
staining of any background stroma or other components.  Each sample was assessed using the Allred scoring 
matrix that generates a global score ranging from 0 to 8.  The global score was composed of stain intensity from 
1 to 3+ and a proportion score of 0 to 5 (5 being the highest) that was apportioned based on the raw percentge of 
positive target cells in the sample.  The percent of positive target cells is an average of at least 5 fields examined 
at 200X. The system was originally developed for scoring intensity and proportion of staining estimation of 
samples using a matrix of scores over a range of both intensity and proportion of positive cells in a given 
sample.  Scores range from 0 to 3 for intensity and from 0 to 5 for proportion with the global score being 
intensity + proportion.  Thus a sample where the staining is weak and is present in 15% of the target cells on the 
slide, the score would be 1 (intensity) + 1 (proportion) for a global score of 2.  Conversely, a sample that 
showed strong diffuse staining of 98% of target cells would have a score of 8 (3 intensity + 5 proportion).  
Amino acid anayses by Liquid Chromatography-Mass Spectrometry (LC-MS) 
Wild type and EGFR-mutant HME cells were seeded in seven dishes at 5x10 6/10cm dish for each cell line and 
the next day washed 3 times using DPBS. Three dishes of each cell line were then switched to –cys media, or 
normal media for 4h. The last dish was used to count cells from both cell lines to ensure similar cell number per 
volume of extraction buffer. Metabolites were extracted in a polar solvent (50% methanol, 30% acetonitrile, 
20% water) and centrifuged to precipitate and remove any proteins present, in preparation for LC-MS analysis. 
The volume of extraction solution was calculated from the cell count with 1-2 x 106 cells/ml. The cell 
metabolites were extracted from the samples by placing the cell culture plates on a rocking shaker at 0-4°C for 5 
minutes.  The extraction solution from each well was then pipetted into a microcentrifuge tube and shaken in the 
Thermomixer (Thermomixer comfort, Eppendorf AG, Hamburg, Germany) at high speed of 1400rpm at 0-4°C 
for 10 minutes. The microcentrifuge tubes were then centrifuged at 16,100 x g for 10 minutes at 0-4°C.  The 
supernatants are transferred to glass HPLC vials and kept at -75°C prior to LC-MS analysis. Hydrophilic 
Interaction Liquid Chromatography with a Sequant ZIC-pHILIC column (2.1 × 150 mm, 5 µm) (Merck) was 
used to separate amino acids before detection with high-resolution, accurate-mass (HR/AM) Mass Spectrometry 
using an Orbitrap Exactive in line with an Accela autosampler and an Accela 600 pump (Thermo Scientific). 
The elution buffers used to elute the analytes were Acetonitrile (ACN) for A and 20 mM (NH4)2CO3, 0.1% 
NH4OH in H2O for B. A linear gradient was programed starting from 80% A and ending at 20% A after 20 min 
at a flow rate of 200ul/min, followed by wash (20% A) and re-equilibration (80% A) steps at a flow rate of 400 
µl/min. An Electrospray Ionization (ESI) probe was used to achieve ionization and the mass spectrometer  
operated in full-scan and polar-switching mode with the positive voltage at 4.5 kV and negative voltage at 3.5 
kV. Metabolite identification and data analysis were done using TraceFinder TM software (Thermo Scientific). 
 
Supplemental References 
Edelstein, A., Amodaj, N., Hoover, K., Vale, R., and Stuurman, N. (2010). Computer control of microscopes 
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